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Advisory Professor: Dean Anthony Lee, M.D, Ph.D. 
 
 Natural Killer (NK) cells are cytotoxic lymphocytes, which play a critical role 
in the immune response against malignant cells and microbial infections, particularly 
viral. NK cells are equipped with germline encoded activating receptors, which 
upon detecting ligands expressed on stressed cells induce cytolytic activity of NK 
cells. Stimulation of NK cell proliferation and priming of NK cytolytic capability are 
accomplished by cytokines, which mediate their signals mainly through JAK-STAT 
signaling pathway. We found that K562 cells genetically modified to express 
membrane bound IL-21 (mbIL-21), which predominantly activates STAT3, induce 
robust expansion and activation of human NK cells. Further investigations in the 
lab, revealed role of STAT3 in the transcriptional regulation of NKG2D, a primary 
activating NK receptor. Based on these findings, I hypothesized that STAT3 
signaling plays a critical role in human cytolytic function and proliferation.  
 I analyzed NK cells from Job syndrome patients to test my hypothesis. Job 
syndrome caused by dominant negative STAT3 mutations is a naturally occurring 
STAT3 deficient genetic model. Assessment of cytolytic activity revealed impaired 
cytolytic function in Job Syndrome patients’ NK cells. Investigations into the 
probable underlying causes of impaired cytotoxicity showed deficient NKG2D 
receptor expression and impaired polarization of cytolytic granules to the immune 
synapse formed between Job syndrome patients’ NK cell and target cell. I validated 
these finding in STAT3 knock-down primary human NK cells, which also displayed 
impaired cytolytic function and impaired cytolytic granule polarization phenotype. 
 x 
 
Expansion of Job syndrome patients’ NK cells with mbIL21 stimulation restored 
NKG2D expression to normal levels, corrected impaired cytolytic granule 
polarization and enhanced cytolytic activity. As constitutively active STAT3 is 
oncogenic, STAT3 is major drug target in cancer therapeutics. To assess a 
probable side effect of pharmacological inhibition of STAT3, I assessed its effect  on 
human NK cell cytolytic function. Treatment of primary human NK cells with small 
molecule STAT3 inhibitor S3I-201 suppressed NK cytolytic function. 
 I employed pharmacological and genetic models of STAT3 deficiency to 
study the role of STAT3 in human NK cell proliferation. Treatment with STAT3 
inhibitor S3I-201 reduced expansion of human NK cells stimulated not only with 
mbIL21 that predominantly activates STAT3, but also the expansion stimulated with 
membrane bound IL-15 (mbIL15), which predominantly activates STAT5 and 
activates STAT3 only marginally. mbIL21 and mbIL15 induced expansion was also 
found to be deficient in Job syndrome patients’ NK cells. Thus, both 
pharmacological and genetic models complemented each other in underlying role 
of STAT3 signaling in human NK cell proliferation. Percentage of NK cells was also 
found to be lower in the peripheral blood of Job syndrome patients’ compared to 
normal donors. 
 Employing pharmacological and genetic approaches, I showed that STAT3 
deficiency in primary human NK cells causes impairment of cytolytic function and 
cytokine induced expansion. This is the first report to demonstrate the role of 
STAT3 in the transport of cytolytic granules in NK cell and NK cell functional 
deficiency in Job syndrome patients, which may provide an immunological basis for 
their proclivity to cancer. Restoration of NK cell function upon mbIL21 stimulation, 
 xi 
 
suggests adoptive NK cell therapy as a treatment option for Job syndrome patients. By 
assessing the effect of pharmacological STAT3 inhibition on NK cytotoxicity and 
proliferation, this study provides potential biomarkers for monitoring side effects of 
STAT3 inhibition, which is fast emerging as a therapeutic approach in cancer treatment. 
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CHAPTER 1 
BACKGROUND 
 
 
 1 
 
Background 
 Protection from the non-self and aberrant self is provided by the immune 
system. Non-self and aberrant self come in different forms and to counter them, the 
immune system has multiple tools in its arsenal. It is a complex organization of diverse 
types of cells, tissues and organs. Physical barriers such as skin and mucous 
membrane, mechanical processes including coughing and sneezing, biochemical 
defenses such as anti-microbial peptides, complement system, antibodies and 
cytokines, and cellular component comprising phagocytes and cytotoxic lymphocytes, 
all come under a big umbrella called the immune system. Some of these defense 
mechanisms such as physical barriers and anti-microbial compounds are common to 
all living organisms, while more evolved means of defense, such as phagocytic cells, 
are found in multi-cellular organisms, both vertebrates and invertebrates. Another 
component of cellular immunity, lymphocytes, which include cytolytic effector cells and 
antibody producing cells, are unique to vertebrates (1).  
The human immune system has all the aforementioned modes of defense at its 
disposal. The generic mechanisms, which are the first line of defense against the 
invading pathogens, belong to the innate or natural branch of the immune system, 
while the pathogen specific mechanisms that are deployed during the later phase of the 
infection belong to the adaptive or acquired branch of the immune system. Antigen 
specificity and immune memory formation are the characteristics that distinguish 
adaptive immunity from innate immunity. Dendritic cells, mast cells, macrophages and 
neutrophils, the cellular mediators of innate immunity do not possess these 
immunological features, while lymphocytes, T and B cells, which execute the functions 
of adaptive immunity, do. However, the third type of lymphocyte, which was till recently 
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considered to be a part of the innate immune system, has been shown to have the 
attributes of the adaptive immune system as well. This unique cell, which belongs to 
both, innate and adaptive, immune systems, is Natural killer (NK) cell (2).   
1.1 NK CELL 
 Observation of cell mediated cytotoxicity against tumor cells without prior 
sensitization to the tumor antigen in assays performed with human peripheral blood 
cells led to the discovery and coinage of the term natural killer cells (3). Since, the 
discovery in the early 70s the NK cell field has come a long way. In the beginning also 
monikered as null cells for having no T and B cell markers (3), NK cells now have an 
established identity as a subset of lymphocytes, defined by the expression of CD56, an 
isoform of neural cell adhesion molecule (4), and the absence T-cell co-receptor CD3  
(5). NK cells are granular lymphocytes found in bone marrow, blood, peripheral organs 
such as liver, lung, peritoneal cavity and placenta, and secondary lymphoid organs 
including lymph nodes, tonsils, thymus, and spleen (4, 6, 7). In the peripheral blood of 
humans, NK cells comprise 2-18% of the lymphocyte population (8). Like CD8 T cells, 
they are cytolytic effector lymphocytes. The primary cytolytic mechanism is through 
exocytosis of lytic granules, which contain a number of cytotoxic proteins such as 
perforin and granzymes. Even though, both, NK and CD8 T cells are cytolytic 
lymphocytes that primarily kill their targets through exocytosis of lytic granules, there is 
a clear distinction as to the mode of activation between the two. Like T cell receptor 
(TCR) on T cells, NK cells do not exclusively express receptors specific for a single 
antigen, but express a multitude of activating receptors, which provide a broader ability 
to detect target cells expressing diverse types of ligands. Also, like TCR, antigen 
recognition by NK cell receptors is not dependent on major histocompatibility complex 
 3 
 
(MHC) molecule dependent pathway of antigen presentation. NK cell receptors are 
germ-line encoded and like T cell receptor genes do not undergo somatic 
rearrangement and recombination (2, 9). As some of the activating ligands are 
expressed by normal cells, to differentiate normal self from abnormal cells, NK cells are 
also equipped with cell surface inhibitory receptors that recognize MHC class I classical 
and non-classical ligands on cells and mediate inhibitory signals to block cytolytic 
activity of NK cells. Thus, the cytolytic activity induced by NK cells is the net result of 
the balance between the strengths of activating and inhibitory signals (8). NK cells also 
kill target cells through ligands belonging to tumor necrosis factor (TNF) family. Three 
TNF-family ligands, viz. FAS ligand (FASL), TNF and TNF related apoptosis inducing 
ligand (TRAIL) either expressed on NK cells surface or secreted in the extracellular 
environment mediate apoptosis in target cells through the interaction with their 
respective receptors (6). 
Along with cytolytic capability, NK cells can exert their effect through secretion of 
cytokines and chemokines in response to stimulation by target cells and cytokines 
secreted by accessory cells (10). NK cell-generated cytokines include interferon (IFN)-
γ, TNF-α, granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte 
colony stimulating factor (G-CSF), interleukin (IL)-10 and IL-3, while chemokines such 
as CCL2, CCL3, CCL4, CCL5, XCL1 and CXCL8 are secreted by NK cells (2). 
1.1.1 NK Cell Receptors 
 
NK cells detect abnormal cells through the interactions of a large array of 
activating receptors expressed on NK cell surface with their corresponding ligands, 
whose expression is generally increased on the surface of stressed cells. Natural 
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cytotoxicity receptor (NCR) family, which includes NKp30, NKp44 and NKp46, is a 
major group of activating receptors. These receptors interact with pathogen-derived 
antigens such as viral hemagglutinins, cell wall core components of bacteria and 
malaria parasite, Plasmodium falciparum derived erythrocyte membrane protein-1. 
These receptors also interact with cellular ligands such as heparan sulphates and 
vimentin (11).  Another primary activating receptor is natural killer group 2D (NKG2D). 
Its ligands include MHC class-I-related chain (MIC) A and MICB and the UL-16 binding 
protein (ULBP) 1, 2, 3, or 4. Expression of these ligands is induced by cellular stress 
such as heat shock, DNA damage, transformation and viral and bacterial infections 
(12). Other activating receptors that play an important role in NK cell activation include 
DNAX accessory molecule-1 (DNAM-1), 2B4 and CD160 (13, 14). DNAM-1 interacts 
with poliovirus receptor and nectin-2, whose expression is up-regulated on some tumor 
cells (13). 2B4 recognizes CD48 (13), while CD160 binds human leukocyte antigen 
(HLA) C (14). In NK cells, cell adhesion receptors such as lymphocyte function-
associate antigen 1 (LFA-1) and CD2 mediate activating signals (13). In addition to 
antigen recognition receptors, NK cells express FcγRIIIA (CD16), a low affinity receptor 
for the Fc region of IgG, which enables NK cells to mediate antibody dependent cellular 
cytotoxicity (ADCC) (15). Most of these receptors (NCRs, NKG2D and CD16) associate 
with signaling adaptor proteins containing tyrosine-based activation motifs, which upon 
receptor engagement get phosphorylated by Src-family kinases. Phosphorylated 
tyrosines provide docking sites for more signaling proteins, which activate signaling 
pathways involving phosphatidyl- inositol-3-OH kinase (PI3K), phospholipase C and 
Vav. These signaling cascades affect exocytosis of lytic granules. Some of the 
activating receptor (2B4 and DNAM-1) do not couple with tyrosine-based activation 
motif containing adaptor protein, but possess such motifs in their own cytoplasmic 
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regions (13). 
 To recognize normal cells and thereby prevent their killing, NK cells are 
equipped with inhibitory receptors such as killer cell immunoglobulin-like receptors 
(KIRs) and CD94-NKG2A that recognize MHC class I classical and non-classical 
ligands on cells and mediate inhibitory signals to block cytolytic activity of NK cells. 
Inhibitory receptors do not associate with signaling adaptors, but contain tyrosine 
based motifs in their own cytoplasmic region. Instead of being activating, these motifs 
are inhibitory. These tyrosine residues are phosphorylated upon engagement of the 
inhibitory receptors and recruit tyrosine phosphatases SHP-1 and SHP-2, which in turn 
dephosphorylate tyrosine residues associated with activating receptor signaling 
complex thereby switching off the activation signals (13).  
Activating, adhesion and inhibitory receptors are listed in Table 1.  
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TABLE 1. NK CELL RECEPTORS 
 
 
 
Abbreviations: CD- Cluster of differentiation; HA- Hemagglutinin; HLA- Human 
leukocyte antigen; BAT3- HLA-B associated transcript 3; MICA and MICB- MHC Class I 
polypeptide-related sequence A and B; ULBP- UL16 binding protein; KIR-Killer-cell 
immunoglobulin-like receptor; LIR- Leukocyte immunoglobulin-like receptor; ICAM- 
Intercellular adhesion molecule; DNAM-1- DNAX accessory molecule-1; GlyCAM-
Glycosylation-dependent cell adhesion molecule  
* The Number in the parenthesis indicates reference. 
 
 
 
Type Receptors Ligands 
A
c
ti
v
a
ti
n
g
  
NKp30 Viral HA, pp65, BAT3, B7-H6, Heparin & heparan sulphates 
(11)* 
NKp44 Viral HA, Heparin & heparan sulphates (11)* 
NKp46 Viral HA, Heparin & heparan sulphates, Vimentin (11)* 
NKG2D MICA, MICB, ULBP (8)* 
DNAM-1  Poliovirus receptor, Nectin-2 (8)* 
2B4 CD48 (8)* 
CD16 Immunoglobulin G (8)* 
CD27 CD70 (8)* 
CD160 HLA-C (8)* 
CD94-NKG2C HLA-E (8)* 
CD94-NKG2E HLA-E (8)* 
A
d
h
e
s
io
n
 CD11a-CD18  ICAM-1 (8)* 
CD11b-CD18 ICAM-1 (8)* 
CD2 CD58 (16)* 
CD62L  GlyCAM-1(17)*   
In
h
ib
it
o
ry
 KIR HLA-A, B & C (8)* 
CD94-NKG2A HLA-E (18)* 
CD94-NKG2B HLA-E (18)* 
LIR-1 HLA Class I (8)* 
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1.1.2 NK Cell Differentiation 
 
NK cells are derived from hematopoietic stem cells (HSCs), primarily in the bone 
marrow, but evidence also points to their differentiation in secondary lymphoid tissues 
(SLTs) such as lymph nodes and tonsils (4). Based on the differentiation capability and 
commitment and gradual acquisition of NK specific phenotype, the human NK 
differentiation process is divided into 5 distinct stages. HSCs in response to cytokines 
such as Flt3 ligand, IL-6 and IL-7 differentiate into NK cell progenitors. Even though 
labeled NK progenitors for the ease of classification, these cells in reality are 
pluripotent as they are capable of differentiating into T cells and plasmacytoid dendritic 
cells. The stage 2 or precursor-NK (pre-NK) cell is marked by the acquisition of IL-15 
responsiveness. At this stage, cells express CD122, the β receptor required for IL-2 
and IL-15 signal mediation. The stage 2 cells are distinguished by their ability to 
differentiate into stage 3 in response to soluble IL-15 or IL-2 and in the absence of 
other cytokines and stroma. Even at this stage, the cells are not strictly committed to 
the NK cell lineage, but can also differentiate into T cells and dendritic cells. The other 
defining feature of this stage is the expression of CD56, which has come to define NK 
cells in the absence of T and B cell specific markers. The stage 3 is NK cell 
commitment stage. By differentiating into stage 3, the cells commit to NK cell lineage, 
as cells at this stage are incapable of differentiating into any other cell type. The stage 
3 cells express some NK associated antigens like CD2, 2B4 and NKp44, but not others 
such as NKG2D, NKp30, NKp46, CD16, CD94-NKG2 complexes and KIRs. Due to 
their inability to secrete IFN-γ and effect perforin mediated cytotoxicity, the functional 
attributes of mature NK cells, these cells are identified as immature NK cells. 
Transitioning into the 4th stage is marked by the expression of intracellular perforin, 
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IFN-γ, and surface expression of activating receptors NKG2D and NKp46. This stage is 
also characterized by the acquisition of the ability to mediate perforin and Fas ligand 
mediated cytotoxicity and IFN-γ secretion. Expression of CD94-NKG2A complex at this 
stage makes sure that attainment of functional capability is accompanied by the ability 
to be inhibited through MHC-I on the target cells. Due to the lack of CD16 expression, 
the NK cells at this stage are not capable of ADCC. The 5th and the terminal stage of 
differentiation is defined by the expression of CD16 and KIRs, equipping the cells with 
ADCC and MHC-I mediated licensing and inhibition (19).  
1.1.3 NK Cell Functions 
 
 Diverse types of activating receptors enable NK cells to recognize pathogen 
infected, stressed and transformed cells. NK cells are also endowed with inhibitory 
receptors to identify self-signals. Calibration of activating and inhibitory signals 
determines whether NK cell sees a target cell as a self or non-self. Expression of MHC 
class I molecules, the predominant self-signals recognized by NK cells, is usually 
down-regulated in diseased cells, particularly virally infected cells, and transformed 
cells. During NK cell contact with such cells, lack of or diminished inhibitory signals tilt 
the balance in favor of NK cell activation, resulting in the target killing. This mode of 
target detection is called missing self recognition (2). NK cells employ this mechanism 
in the immunosurveillance of virally infected cells and tumor cells. 
1.1.3.1 Anti-Cancer Activity of NK Cells 
 
Equipped with cell surface receptors that detect danger signals on malignant 
cells and activate cytolytic activity, the inherent function of NK cells is immune- 
surveillance of transformed cells (6). Tumor recognition and rejection by NK cells have 
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been demonstrated both in vitro and in vivo in mice and rats (20-22). In animal models, 
anti-tumor activity of several cytokines such as IL-2, IL-10, IL-12, IL-18 and IL-21 has 
been shown to be mediated in a NK cell-dependent manner (8, 23-26). Expression of 
ligands recognized by activating receptors, NKG2D and DNAM1, is often up-regulated 
on malignant cells and as a result these receptors play a major role in anti-cancer 
activity of NK cells (8, 13). Mice deficient in NKG2D and DNAM1 receptors have 
impaired tumor immunosurveillance by NK cells (27-29). In humans, the critical role 
played by NK anti-cancer activity was brought to light by an 11 year follow-up study, 
which showed an association of higher incidence of cancer with low NK cytotoxicity in 
peripheral blood (30). Also, high levels of tumor-infiltrating NK cells are associated with 
positive prognosis (31-33). In acute myeloid leukemia (AML) patients, receiving HLA 
haplotype mismatched hematopoietic transplantation, donor derived NK cells, with 
mismatched KIR for recipient’s HLA, have been shown to deliver graft-versus-leukemia 
effect (34). Anti-tumor effects of therapeutic monoclonal antibodies such as rituximab 
(anti-CD20) are also predominantly achieved through NK cell-mediated ADCC (35). 
Due to their anti-tumor activity, NK cells have emerged as candidate effector cells for 
immune therapy against cancer. Adoptive transfer of activated autologous or allogeneic 
NK cells has proven to be a safe and potentially efficacious immunotherapy for cancer 
(36, 37). NK cell therapy has been or being tested against multiple types of cancers 
(35). 
1.1.3.2 Anti-Viral Activity of NK Cells 
 
 Along with lysis of malignant cells, NK cells also detect and lyse virally-infected 
cells. NK cells are part of the first line of defense against viral infections. A large body 
of work in mouse and human has firmly established role of NK cells in the immune 
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response against viral infections, particularly herepesviridae infections (38). Studies 
with mouse model of mouse cytomegalovirus (MCMV) have been instrumental in 
expanding our knowledge of the dynamics of NK cell response to viral infections. NK 
cells are activated during the early phase of viral infection and are recruited to the site 
of infection. NK cells contain viral replication, before the adaptive immune response 
kicks in, by killing virally-infected cells (39). To evade recognition and killing by CD8+ 
cells, MCMV blocks MHC class I expression on the infected cell. But, reduction in MHC 
class I expression makes the cell susceptible to lysis by NK cell. To avoid NK cell 
mediated lysis, MCMV encodes MHC class I like proteins m157 and m144, which 
engage Ly49 receptors, the counterparts of human KIRs in mouse, to transmit 
inhibitory signals and thereby block NK cytolytic activity. Mouse NK cells counter this 
virus strategy by expressing an activating form of Ly49 receptor, Ly49H that couples 
with signaling adaptor protein DAP12 to transmit activating signals (39, 40). Ly49H+ NK 
cells are selectively expanded in the later phase of MCMV infection. This strategy and 
counterstrategy by the virus and NK cells underscore the selective evolutionary 
pressure; both, MCMV and NK cells are subjected to, and also highlight the critical role 
played by NK cells in the defense against MCMV (40). The importance of NK cells in 
anti-viral defense is also apparent from the viral strategy of reducing expression of 
ligands for NK activating receptors on the infected cell. Expression of ligands for the 
mouse NKG2D receptor, retinoic acid early inducible-1 (Rae-1) family of proteins, H60, 
and murine ULBP-like transcript 1 (MULT1), is down-regulated by MCMV encoded 
proteins (40). 
  The essentiality of NK cells in anti-viral defense in humans was first brought to 
light by the susceptibility to herpesviruses observed in a patient, who had normal T and 
B cells, but was devoid of any NK cells. This patient suffered from varicella zoster virus 
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(VZV), human cytomegalovirus (HCMV) and herpes simplex virus (HSV) infections 
(41). Like MCMV, HCMV employs similar survival strategies such as down-regulation of 
expression of human NKG2D receptor ligands, whose expression tend to be up-
regulated on stressed cells. Unlike in mouse NK cells, a receptor that recognizes 
HCMV encoded ligand has not been identified in human NK cells. However, CD94-
NKG2C, a heterodimeric receptor, which usually recognizes endogenous ligand HLA-E 
and transmits activating signals, is the likely candidate as CD94-NKG2C+ NK cells are 
preferentially expanded in HCMV infected patients. Viral ligands are also recognized by 
other NK cell receptors such as NCRs. NCRs, NKp46 and NKp44, bind viral 
hemagglutinins, while NKp30 binds HCMV encoded pp65 (40). Other than containing 
HCMV, VZV and HSV infections, NK cells have also been suggested to play a role in 
controlling infections by Epstein-Barr virus, human papilloma virus and human 
immunodeficiency virus due to the low NK cell activity observed in individuals 
susceptible to infections by these viruses (38, 42).  
1.1.3.3 NK Cells As Regulators of Innate And Adaptive Immunity 
 
 NK cell interactions with cells of innate and adaptive immune systems shape 
immune responses. NK cells secreted cytokines and direct cell-to-cell contact play a 
major role in the regulation of innate and adaptive immunity. Interactions of NK cells 
with dendritic cell (DC) are mutually beneficial. NK cells come in contact with DCs at 
the site of inflammation and in secondary lymphoid tissues. At the site of inflammation 
DCs are activated through their contact with microbes and microbial-infected cells. 
Activated DCs through cytokine secretion and direct contact with NK cells induce 
cytolytic capability, cytokine secretion, particularly IFN-γ and proliferation in NK cells. 
NK cells in return help DCs mature through IFN-γ and TNF-α secretion and also 
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through NK-DC contact in which NKp30 plays a critical role. Expression of antigen 
presenting molecules, MHC class I and class II, and co-stimulatory signals such as 
CD86 is up-regulated on mature DCs (43). NK cells also influence antigen presentation 
by DCs. Cell debris generated by NK mediated lysis of malignant and virally infected 
cells is internalized by DCs and then processed and presented on the cell surface 
bound to MHC molecules. Mature DCs migrate to secondary lymphoid organs such as 
lymph nodes where they present antigens to T cells leading to their activation. Thus, 
NK cell mediated maturation of DCs and NK cell influenced antigen presentation by 
DCs indirectly influence maturation and activation of T cells (8). In lymph nodes, mature 
DCs come in contact with NK cells in the parafollicular region of the T cell area. Here 
too, DC secreted cytokines induce proliferation, cytolytic capability and cytokine 
secretion in NK cells. Due to close proximity of DCs, NK and T cells in lymph nodes, 
the cells influence each other’s activation. DC induced secretion of IFN-γ by NK cells 
help CD4+ cells acquire Th1 phenotype, while DC activated secretion of IL-2 by CD4+ 
cells stimulate proliferation and cytolytic capability of NK cells (44, 45). NK cells are 
also known to activate IgM and IgG synthesis in B cells and activated B cells have 
been shown to enhance IFN- γ secretion by NK cells (46).  
 Along with promoting maturation and activation of innate and adaptive immune 
cells, NK cells can regulate immune responses by secreting immune suppressive 
cytokine IL-10 and by killing immature DCs and MHC deficient CD4+, CD8+ and B cells 
(8, 47). In turn, T regulatory cells are known to inhibit NK cell cytolytic activity through 
TGF-β mediated mechanism (48). Thus, NK cells acts as a bridge between innate and 
adaptive immunity through their contact with various cell types and have both positive 
and negative influence on immune responses. In return, NK cell mediated immune 
response is also shaped by other immune cells. 
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1.1.3.4 Role of NK Cells In Pregnancy  
 
 NK cells are the predominant leukocytes found at the maternal-fetus interface. 
NK cells comprise >70% of the leukocytes in the decidua. The cytokines and 
chemokines secreted by these decidual NK cells (dNK) have been suggested to play a 
role in successful trophoblast invasion. Decidual NK cell secreted vascular endothelial 
growth factors promote angiogenesis of the placenta. Due to the association of low 
number of dNK cells with spontaneous abortion, immunologic tolerance of the fetus has 
also been attributed to dNK cells. Along with protecting the fetus from immune assault, 
NK cells are also deemed to protect the fetus from the transmission of pathogens from 
mother such as HCMV (49). 
1.1.3.5 NK Cell Memory 
 
  Immune response mediated by clonally expanded cells armed with the 
same receptor that recognizes an identical antigen and the ability to mount a rapid and 
robust response upon exposure to the same antigen in the future due to the formation 
of long lasting memory cells during the initial exposure are the distinguishing 
characteristics of the adaptive immune system. The other defining feature of adaptive 
immune system is the mode of generating antigen receptor diversity. In T and B cells, 
recombination activating genes (RAGs) encoded enzymes mediated somatic non-
homologous recombination and rearrangement of variable (V), diversity (D) and joining 
(J) segments of T and B cell receptor genetic locus generate the immense antigen 
receptor diversity. NK cell shares some features with T and B cells such as 
differentiation from common lymphoid progenitor and like T cell it is a cytotoxic effector 
lymphocyte. While NK cells express a large repertoire of receptors with distinct antigen 
specificity, this receptor diversity emanates from germ-line encoded receptors, which 
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do not undergo somatic recombination and rearrangement. Due to the lack of RAG 
mediated recombination and the ability of NK cells to kill malignant and virally infected 
cells without prior sensitization to the antigen, NK cells are categorized as innate 
lymphocytes (50). However, recently NK cells have been shown to possess the 
distinctive attribute of the adaptive immune system, the formation of immunological 
memory. The initial evidence supporting memory NK cell formation was acquired in T 
and B cell lacking mice showing hapten induced contact hypersensitivity (51). A hapten 
is a small protein modifying chemical. Haptenated proteins elicit immune response. 
Initial sensitization with a hapten leads to generation of long living memory T and B 
cells, which mount a more potent response upon future challenge with the same 
hapten. Microscopic analysis of leukocyte accumulation at the hapten challenged tissue 
and NK cell depletion experiments indicated that in T and B cell lacking hapten 
sensitized mice, contact hypersensitivity to the subsequent exposure to the same 
hapten was mediated by NK cells (51). A recall response observed in these mice four 
weeks after initial sensitization demonstrated existence of long lasting memory NK 
cells. Contact hypersensitivity observed in naive mice adoptively transferred with NK 
cells from sensitized mice further confirmed the identity of these memory cells as NK 
cells. The researchers further showed that memory NK cells reside in the liver (51). 
Following this initial study, existence of memory NK cells was reported in MCMV 
infected mice (52). Like clonal T cell expansion, NK cells expressing Ly49H receptor, 
which recognizes MCMV encoded protein m157, are selectively expanded upon MCMV 
infection (53), but it was not known whether these cells bear any antigenic memory. 
Sun et al. (52) showed that Ly49H+ cells linger for a long time after infection and are far 
more effective than naïve cells in rendering protection upon adoptive transfer. Also, the 
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recall response was antigen specific. Thus, along with the attributes of an innate 
effector lymphocyte, NK cells also have the characteristics of adaptive immunity.       
1.1.4 Cytokine Signaling in NK Cells 
 
 Orchestrating the immune response is a complex task as it involves regulation 
and coordination of multiple cellular processes such as differentiation, proliferation, 
migration, activation and suppression in multiple cell types belonging to both, innate 
and adaptive, arms of the immune system. This task is accomplished by cytokine- 
mediated signaling. Cytokines are small extracellular proteins secreted by immune and 
non-immune cells. It is a large group of proteins with diverse structures and functions. 
NK cell development, homeostasis, and NK cell functions are regulated by cytokines 
secreted by immune and non-immune cells. 
1.1.4.1 Cytokines Involved in NK Development 
 
Many different cytokines such as Flt3 ligand (Flt3L), stem cell factor (SCF), IL-12 
and common cytokine receptor γ chain family of cytokines (IL-2, IL-4, IL-7, IL-15, and 
IL-21) are known to play a role at different stages of NK differentiation process (19, 54). 
Few of these cytokines, IL-2 and IL-15, have been shown to induce NK differentiation 
from HSCs in vitro in the absence of other cytokines, while the rest of the cytokines 
work in combination with IL-2 or IL-15 (19). NK cell generation, homeostasis and 
development is known to be IL-15 dependent as has been demonstrated by reduced 
NK cell numbers and impaired NK cell cytotoxicity in mice lacking IL-15 or IL-15 
receptor α chain (54-56). IL-15 responsiveness acquired during the NK precursor stage 
is considered a major step towards NK lineage commitment (19). IL-2 has also been 
reported to play a role in NK cell differentiation and activation (57), but the number of 
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mature NK cells is not affected in IL-2 deficient mice and humans, thereby ruling out 
any major role of IL-2 in NK cell development in vivo (54, 58). Even though, IL-4 and IL-
7 have been suggested to have a role in terminal differentiation and homeostasis of NK 
cells, studies in mice lacking IL-4 and IL-7, show that these cytokines are dispensable 
in NK cell generation and maturity (54). IL-21 has been demonstrated to play a 
synergizing role with IL-15 and Flt3L (59) and IL-15, Flt3L and SCF (60) in in vitro 
differentiation of NK cells from human HSCs. The evidence implicating IL-21 in human 
NK cell development in vivo is provided by NK cells from human subjects with loss of 
function mutations in IL-21 receptor gene (61). These patients had normal number of 
NK cells, but the IL-21 non-responsive NK cells showed diminished basal cytotoxicity, 
suggesting a flaw in functional maturation (61). In mouse too, IL-21, in combination with 
IL-2 or IL-15, has been shown to help in the functional maturation of NK cells in vitro 
and promote functional maturation in vivo (62). But this evidence in support of the role 
of IL-21 in NK differentiation is contrary to the finding of normal number of mature, 
functionally valid NK cells in IL-21 receptor knockout mice (63). This finding in mice is 
also contrary to the impaired NK cytotoxicity observed in IL-21 receptor deficient 
humans (61). The dissimilarity underscores the difference that may exist in the NK 
developmental process between mouse and human and serves as a caution while 
applying lessons learned from mouse to humans. 
1.1.4.2 Cytokines Involved in NK Homeostasis  
 
The homeostatic NK cell survival and proliferation are dependent on IL-15 
signaling in mice (64-66), but are independent of IL-15 in humans (67), again 
highlighting the difference in the physiology of NK cells between the two. However, NK 
cell proliferation in response to viral infections in both, mice and humans has been 
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shown to be dependent on IL-15 signaling (68, 69). IL-12 (70, 71) and IL-18 (70) have 
also been demonstrated to play a role in NK proliferation in response to MCMV 
infection in mice. In vitro studies have demonstrated that cytokines, which have not yet 
been shown to play a physiological role in NK cell proliferation in vivo, could also 
induce proliferation of NK cells. One of the potent activators of NK cell proliferation is 
IL-2 (72, 73). It is used to expand NK cells ex vivo for immunotherapy in cancer (74, 
75). Some cytokines do not induce proliferation acting alone, but in combination with 
other cytokines they do. For instance, IL-10, IL-12 and IL-18 stimulate proliferation of 
mice NK cells pre-activated with IL-2 (76). IL-18 also induces proliferation of mice NK 
cell in combination with other cytokines such as IL-12 and IL-15 (77-79). IL-21 too does 
not induce NK cell proliferation by itself, but does in combination with IL-2 in human NK 
cells (80). IL-21 also supports NK cell survival and enhances it further in combination 
with IL-2 (81). 
1.1.4.3 Cytokines Involved in NK Functions 
 
Unlike cytolytic T cells, NK cells do not need prior sensitization with target 
antigen before killing a target cell. Upon detecting stress signals through interactions of 
NK activating receptors with their cognate ligands on target cells, NK cells deliver their 
cytolytic function. This ready to kill approach makes it necessary for NK cells to be 
equipped with the detection tool, the activating receptors, and the effector tool, lytic 
granules containing perforin and granzymes, while on immunosurvelliance duty. 
Surface expression of activating receptors and pre-formation of lytic granules occur as 
a result of priming of NK cells by cytokines present in their microenvironment (8). Type 
1 interferons (IFNα and IFNβ), common γ-chain cytokines (IL-2, IL-15 and IL-21), IL-6, 
IL-12 and IL-18 are known to activate cytolytic capability of NK cells (82). These 
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cytokines induce expression of lytic effector proteins such as perforin (IFNα, IL-2, IL-6, 
IL-12, IL-15 and IL-21) and granzymes (Type I IFNs, IL-2, IL-15, IL-21) (81, 83-86). 
Along with the induction of expression of lytic molecules, cytokines also stimulate 
expression of NK receptors, whose interactions with their cognate ligands on the target 
cells are required for the degranulation of the lytic proteins. NKG2D expression on NK 
cells is up-regulated in response to IFN-α, IL-2, IL-15, IL-12 and IL-21 (81, 87-90). 
NCRs’ expression is induced by IL-2, IL-15, IL-12 and IL-21 (82), while DNAM-1 and 
2B4 expression is modulated by IL-2 and IL-21, respectively (91, 92).  
 NK cells also effect their functions through cytokine secretion. NK cells are one 
of the primary producers of IFN-γ, which is a modulator of innate and adaptive 
immunity. IFN-γ shapes innate immunity through activation of macrophage killing 
ability. IFN-γ influences adaptive immunity by stimulating antigen presentation through 
induction of expression of MHC class I and II proteins in antigen presenting cells and 
by promoting acquisition of Th1 phenotype by CD4+ T cells (4). It also exerts direct 
effect on virally-infected and malignant cells by inhibiting their proliferation and 
increasing their sensitivity to apoptosis (6). The major inducer of IFN- γ generation in 
NK cell is IL-12, secreted by activated DCs and macrophages (44, 93). Other cytokines 
such as IL-2, IL-15, IL-18 and IL-21 also stimulate expression of IFN- γ in NK cells (4).  
 The recently discovered feature of memory formation in NK cell has been shown 
to be regulated by cytokines. Adoptively transferred mouse NK cells, pre-stimulated 
with IL-12 in combination with IL-18 and IL-15, have been shown to retain priming 
memory. Stimulation with the same cytokines three weeks after initial stimulation elicits 
amplified IFN- γ secretion by these cells (94). A similar recall response has also been 
demonstrated in human NK cells (95). Viral antigen-specific memory in mouse NK cells 
is also dependent on IL-12 signaling (96).   
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 Some of the cytokines, which play a critical role in the regulation of NK cell 
functions, are depicted in Figure 1. 
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Figure 1.  Regulation of NK cell functions by cytokines. IL-2 and IL-21 
secreted by CD4+ helper T cells and dendritic cell (DC) and macrophage (MΦ) 
derived IL-15, IL-12, IL-18 and IFN-α/β prime NK cells for their functions by 
inducing expression of NK receptors, perforin, granzymes and cytokines.  
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1.2 JAK-STAT SIGNALING 
 
Cytokines mediate their signals by binding and activating their specific trans-
membrane receptors on the cell surface and thereby triggering a cascade of molecular 
events inside the cell. Down-stream of an activated cell surface receptor, signals are 
relayed in a sequential pathway through a chain of effector molecules. One such 
pathway is Janus kinase (JAK)-signal transducer and activator of transcription (STAT), 
which is shared by many cytokines with different structures, receptors and functions to 
mediate signals in multiple types of immune and non-immune cells. Cytokines 
transmitting signals through receptors belonging to type I and II cytokine receptor 
superfamily primarily mediate their signals through JAK-STAT pathway. This is a large 
group of cytokines, which includes interferons, most of the interleukins and colony 
stimulating factors. Type 1 (IFNα and IFNβ) and 2 (IFN-γ) interferons, common γ-chain 
cytokines (IL-2, IL-4, IL-7, IL-15 and IL-21), IL-6, IL-10, IL-12 and IL-18, the cytokines 
with indispensible roles in NK cell development, homeostasis, activation and function, 
mediate their signals pre-dominantly through JAK-STAT signaling system (97).  
The JAKs are a family of tyrosine kinases constitutively associated with 
cytoplasmic regions of the cytokine receptors. The family is comprised of four 
members, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). Cytokine-bound activated 
receptors activate JAKs’ kinase activity and activated JAKs in turn phosphorylate 
specific tyrosine residues in the cytoplasmic domain of the cytokine receptors. These 
phosphorylated tyrosine residues provide docking sites for latent cytoplasmic 
transcription factors STATs through the interaction of their Src homology 2 (SH2) 
domains. Conserved tyrosine residues on receptor-bound STATs are phosphorylated 
by JAKs. STAT molecules dimerize by reciprocal interactions of their SH2 domains and 
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phosphotyrosines. The dimerized STATs translocate to the nucleus, where they bind to 
specific DNA elements to regulate transcription of target genes. There are seven 
members in the STAT family, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and 
STAT6 (98). All STATs share a domain architecture comprising of amino terminal (N-
terminal), coiled-coil, DNA binding, linker, SH2 and transactivation domains from amino 
terminus to carboxy terminus (99).  
1.2.1 Regulation of JAK-STAT Signaling 
 
Regulation of JAK-STAT pathway occurs at multiple levels and by multiple 
mechanisms. JAKs are inhibited by suppressor of cytokine signaling (SOCS) family of 
proteins. Different SOCS use different mechanisms to block JAK activation. SOCS1 
through its SH2 domain binds directly to the phosphorylated tyrosine on the JAKs and 
thus directly inhibits the kinase, while SOCS3 inhibits JAKs indirectly by binding to the 
activated receptor. Transcription of SOCS is up-regulated by JAK-STAT signaling 
thereby providing a negative feedback loop to regulate its own signaling. 
Dephosphorylation of tyrosines on JAKs by protein tyrosine phosphatases (PTPs) such 
as SH2 domain containing PTPs SHP-1 and SHP-2 also terminates JAK activation. 
JAK-STAT signaling is also regulated through degradation of JAKs via ubiquitin-
proteasome pathway. Like JAKs, activated STATs are also dephosphorylated by PTPs 
such as SHP2 and T cell PTP (TCPTP). STATs are deactivated through 
dephosphorylation of tyrosine both in the cytoplasm and in the nucleus by SHP2, while 
TCPTP activity is restricted in the nucleus. Activated STATs are also disabled by 
protein inhibitors of activated STAT (PIAS) family of proteins, which bind to dimerized 
STATs in the nucleus (98). STAT family members can also regulate each other’s 
activation. STAT1 and STAT3 have reciprocal inhibitory effects either due to 
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competition for the same docking sites on the cytokine receptor and/or sequestration of 
each other due to STAT1:STAT3 heterodimerization. Deficiency in one of these STATs 
enhances temporal activation and signaling response by the other (100). STATs are 
also known to activate their own transcription as is evident from the increased STAT1 
protein expression in cells stimulated with STAT1 activating cytokines. Thus, there is a 
positive feedback mechanism that enhances signaling by a particular STAT (101).  
1.2.2 Functions of JAK-STAT Signaling 
 
 Immune disorders and disease phenotypes reported in patients carrying 
mutations in the individual components of JAK-STAT signaling pathway brought to light 
the central role played by JAK-STAT signaling in the differentiation and development of 
immune cells, homeostasis, and co-ordination of immune response. Loss of function 
and hypomorphic JAK3 mutations found in severe combined immune deficiency (SCID) 
patients, characterized by extreme susceptibility to microbial infections due to lack of or 
diminished number and function of T and NK cells, established role of JAK3 signaling 
downstream of common γ-chain cytokines in lymphocyte development (97, 102). 
Susceptibility to mycobacterial, salmonella, Staphylococcal and viral infections and 
unresponsive cells to IFN-α, IFN-β and IL-12 stimulation observed in patients with 
TYK2 loss of function mutations were instrumental in elucidating the function of TYK2 
signaling in anti-bacterial and anti-viral defense of above mentioned cytokines (102). A 
similar bacterial and viral infection and cell signaling phenotype detected in patients 
carrying loss of function and hypomorphic STAT1 mutations confirmed STAT1 as a 
signal relaying STAT downstream of TYK2 in response to IFN-α, IFN-β and IFN- γ 
signaling (102). Loss of function mutation in STAT2, another STAT activated by IFN-α 
and IFN-β signaling, results in susceptibility to vaccine-strain measles (103).  Though, 
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most of the JAK-STAT signaling family members have roles restricted to the immune 
system, some components such as STAT5 have non-immune functions along with a 
role in the immune system. Along with activation, downstream of common γ chain 
cytokines (IL-2, IL-7, IL-9, IL-15) (104), STAT5 is also activated in response to growth 
hormone receptor stimulation (97). As a result, patients carrying loss of function 
STAT5b mutations have non-immunological phenotypes such as growth retardation. 
These patients also display complex immune deficiency symptoms. They are 
vulnerable to microbial infections, a sign of immune deficiency, and are also prone to 
autoimmune disorders such as autoimmune thyroiditis, idiopathic thrombocytopenic 
purpura, lymphocytic interstitial pneumonitis, and severe eczema. This seemingly 
contradictory immune phenotype is explained by the role played by STAT5b signaling 
in the generation of T regulatory (Treg) cells as well as in T cell homeostasis. The 
requirement of STAT5b signaling downstream of IL-2 activation for induction of Foxp3, 
a transcription factor necessary for Treg differentiation, underlies the low number of 
Treg cells, accounting for autoimmune disorders observed in STAT5b deficient 
patients. STAT5b signaling is also required for T cell (CD4+ and CD8+) homeostasis 
and as a result STAT5b deficient patients suffer from T cell lymphopenia, which 
accounts for their susceptibility to microbial infections (102).  
Another constituent of JAK-STAT pathway with immune and non-immune 
functions is STAT3. Perhaps, STAT3 is the member of the JAK-STAT family with the 
most diverse functions that best exemplifies the reach and indispensability of JAK-
STAT pathway in systemic cell signaling.   
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1.2.3 STAT3 
 
 STAT3 was discovered as an activator of acute phase gene expression in 
hepatocytes in response to IL-6 stimulation and hence was initially named as acute 
phase response factor. Since its discovery, numerous in vitro and in vivo studies have 
revealed STAT3 as a transcription factor relaying signals downstream of diverse types 
of cellular signals in multitude of tissues (105). The functional diversity is a result of 
STAT3’s ability to be activated by different signaling mechanisms. STAT3 is activated 
not only by JAKs activated by cytokines, but also by receptor tyrosine kinases activated 
by growth factors (Epidermal and platelet-derived growth factor) and src tyrosine 
kinases (Src, Lck, Hck, Lyn, Fyn, and Fgr) either independently or downstream of 
activated receptor tyrosine kinases and G-protein coupled receptors (106). Despite its 
response to varied stimuli and signaling pathways, mode of STAT3 activation remains 
the same. The canonical STAT3 activation mechanism involves phosphorylation of 
tyrosine (Y) residue located at the interface of SH-2 and transactivation domains (Y705 
in human STAT3, which has 770 amino acids) by a tyrosine kinase (107, 108). In 
addition to the canonical pathway, STAT3 is activated by other mechanisms. 
Phosphorylation of a serine (S) residue located in the transactivation domain (S727 in 
human STAT3) unleashes maximal transcription activation potential of STAT3 (106). 
The serine can be phosphorylated by kinases such as ERK, CDK1, ATM and ATR 
independent of signal promoting tyrosine phosphorylation (109). Unphosphorylated 
STAT3 has been shown to form homodimers and translocate to the nucleus and 
regulates gene transcription either by itself or by interacting with other transcription 
factors such as NFκB (101). Along with homodimerized form, STAT3 regulates gene 
expression by forming heterodimers with STAT1 and STAT5 (110). Extranuclear 
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function of STAT3 has been reported recently, wherein STAT3 located in mitochondria 
was shown to be required for activation of electron transport chain and this function 
was dependent upon phosphorylation of S727 (111). Even though STAT3 can be 
activated in various ways and has a function outside of its role as a transcription 
activator, STAT3 pre-dominantly delivers its function as a transcription factor upon 
phosphorylation of its tyrosine residue (107). 
1.2.3.1 Functions of STAT3  
 
  STAT3 regulates expression of genes involved in fundamental cellular 
processes such as cell cycle, apoptosis, cell signaling, transcription, angiogenesis, lipid 
metabolism, remodeling of extracellular matrix and cell migration (112). STAT3 also 
plays a role in self-renewal of embryonic stem cells by blocking differentiation (105). 
Given STAT3’s pleiotropic role, it is not surprising that systemic deletion of STAT3 
results in embryonic lethality (113). Due to this limitation, researchers generated tissue 
specific deletion of STAT3 in mouse, which has been instrumental in our understanding 
of physiological role of STAT3. STAT3 has non-redundant functions in multiple organs 
ranging from skin to nervous system. In skin, STAT3 is required for wound healing and 
keratinocyte migration, while in thymic and memory epithelium and in sensory and 
motor neurons STAT3 is required for pro-survival signals. In liver, STAT3-activated 
gene expression promotes acute phase response (107).  
1.2.3.2 Role of STAT3 in Cancer 
 
   STAT3 is activated by mitogenic signals such as cytokines and growth factors 
and activates expression of genes promoting proliferation, survival, migration and 
angiogenesis; the processes when out of control give rise to cancers. Constitutive or 
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elevated activity and/or expression of STAT3 are associated with various types of 
cancers including leukemia, lymphomas, multiple myeloma, melanoma and cancers in 
breast, lung, liver, pancreas, prostate, ovary, and head and neck. In many of these 
cancers high STAT3 activity and expression are markers of poor prognosis (106). 
Oncogenic STAT3 activity could be a result of one or a combination of multiple 
processes. It could be secondary to deregulated upstream signaling pathway triggered 
by cytokines, growth factors and oncogenic Srcs. Loss of regulation in STAT3 signaling 
through repression or silencing of inhibitors of STAT3 signaling such as SOCS3, PTPs 
and PIAS3 have been shown to be responsible for over active STAT3. STAT3 by up-
regulating expression of itself and by activating expression of STAT3 activating 
cytokines such as IL-6 and IL-10 promotes its overexpression and sustained activation 
through positive feedback. Somatic mutations leading to constitutively active STAT3 
have also been reported in some cancers (108). STAT3 also drives oncogenesis by 
promoting inflammation in the tumor microenvironment. Persistent inflammation has 
been shown to be a cause of certain cancers such as gastric and liver and aids 
oncogenesis in others (114). STAT3 regulated IL-6 is one of the main drivers of 
inflammation in tumor microenvironment. IL-6, a pro-inflammatory cytokine not only 
mediates inflammatory conditions in the malignant cells, but also in the stromal and 
immune cells in the tumor microenvironment. IL-6 activates STAT3 in these cells, which 
activates expression of genes responsible for inflammation in a positive feedback loop 
(114). STAT3 also activates expression of IL-10, an immune suppressive cytokine. IL-
10 secreted by cancer cells and immune cells suppress anti-cancer response of 
immune cells in the tumor microenvironment. IL-10 also activates STAT3 thereby 
propagating immune suppression in a positive feedback loop (115).  
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1.2.3.3 Role of STAT3 in Immune System 
 
       STAT3 mediates signals down-stream of cytokines belonging to different 
families such as common γ-chain cytokines (IL-2, IL-7, IL-9, IL-15 and IL-21), gp130 
receptor utilizing cytokines (IL-6, IL-11, IL-27, IL-31, oncostatin M, leukemia inhibitory 
factor), Type I IFNs (IFNα and β), Type II IFN (IFNγ), IL-10 family (IL-10, IL-19, IL-20, 
IL-22, IL-24, IL-26), IL-12, IL-23, Flt3 ligand and colony stimulating factors (G-CSF and 
M-CSF). These cytokines play an important role in the differentiation, proliferation, 
survival and modulation of activation of myeloid and lymphoid cells (116). Like tissue 
specific deletion in non-immune tissues, STAT3 deletion in hematopoietic cells and 
specific types of immune cells in mouse have brought to light the critical role played by 
STAT3 signaling in immune function.  
 T cell specific deletion of STAT3 revealed its requirement in IL-6 and IL-2 
induced proliferation of T cells. In response to IL-2, STAT3 induces expression of 
CD25, the private IL-2 receptor, which is required for high affinity binding of IL-2 (107). 
STAT3 deficiency in CD4+ T cells impairs generation of Th17 cells. Th17 cells mediate 
anti-microbial immunity, mostly at the epithelial barriers, by secreting pro-inflammatory 
cytokines IL-17A, IL-17F, IL-21 and IL-22. These cytokines help recruit and activate 
neutrophils at the site of infection and also induce secretion of anti-microbial peptides 
from epithelial cells (116). Cytokines involved in Th17 differentiation, IL-6, IL-21 and IL-
23 mediate their signal through STAT3, which activates transcription of retinoic acid-
related orphan nuclear receptors (RORs) RORγt and RORα, the transcription factors 
that drive the genetic program for Th17 differentiation. The cytokines secreted by Th17 
cells, IL-17A, IL-17F and IL-21 are also STAT3 targets (117, 118). STAT3 deficiency in 
CD4+ helper cells also impairs their ability to secrete IL-10 in response to IL-6 and IL-
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27. Pro-inflammatory cytokines such IL-6 and IL-27 along with the induction of 
inflammation mediators also stimulate secretion of immune-suppressive cytokine IL-10 
from helper T cells, which prevents a protective inflammatory response from becoming 
a pathological one (119). Thus, in helper T cells, STAT3 is required for initiating an 
inflammatory response as well as for its regulation. CD8+ T cell specific STAT3 deletion 
helped elucidate role of STAT3 in memory T cell formation. Cytokines IL-10 and IL-21 
through STAT3 activation trigger the genetic program required for memory T cell 
differentiation (120). B cell specific STAT3 deletion impairs T cell dependent 
differentiation of B cells into plasma cells (121).  
Along with cells of lymphoid origin, STAT3 signaling is also critical for 
development and immune response of myeloid cells. STAT3 deficient macrophages 
and neutrophils lose their ability to respond to IL-10, which signals through STAT3 to 
rein in inflammation. Loss of STAT3 in these cells results in excessive secretion of pro-
inflammatory cytokines such TNF-α, IL-6 and IL-1, leading to inflammatory disorders 
(122). Employing bone marrow specific deletion, STAT3 has been shown to be 
required for neutrophil mobilization in response to G-CSF and chemokines (123). 
Hematopoietic cell specific STAT3 deletion results in decreased number of dendritic 
cells (DCs). Flt3 ligand, which mediates its signals through STAT3 activation, is a major 
regulator of DC development and as a result STAT3 deficiency leads to impaired 
development of DCs (124). 
Most of the knowledge about the role of STAT3 in immune function has been 
obtained from mouse experiments. Even though mouse is a preferred animal model 
due to the ease of handling, genetic maneuverability, and mainly because of the many 
similarities between mouse and human physiology, not everything learned from a 
mouse model can be extrapolated to humans due to the differences that exist between 
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these two species. Monogenic mutations, nature’s own experiment, found in humans 
offer an opportunity to study role of the protein coded by that gene in human 
physiology. STAT3 gain of function germline mutations were recently discovered in 
humans, which caused multiorgan autoimmunity and lymphoproliferation and in one 
patient, susceptibility to mycobacterial infections (125, 126). Even though all 
pathogenic mechanisms are not yet known, few insights into immune dysregulation 
caused by hypermorphic STAT3 have been obtained. The autoimmunity is due to the 
low number of Treg cells in these human subjects (125, 126) and Treg deficiency is 
likely caused by suppressed STAT5 activation in these patients (125). Suppression of 
STAT1 activation was also reported in these patients, but its implications, if any, are not 
known (125). Even though any mutation that affects normal function of the protein 
provides important information about the physiological role of that protein, more telling 
are the loss of function or hypomorphic mutations, which clearly highlight the necessity 
of the protein. 
There are naturally occurring, albeit rare, heterozygous dominant negative STAT3 
mutations in humans, which cause an immunodeficiency called Job syndrome. 
1.3 JOB SYNDROME 
 
 Job syndrome is a rare immune disorder, initially characterized by the triad of 
eczema and recurrent skin and lung infections (127). As boils due to recurrent skin 
infections is a cardinal feature of this immunodeficiency, the immune disorder was 
named after the biblical character Job, whose body was covered with boils. Later 
investigation also identified increased serum levels of IgE as a clinical symptom, which 
lent hyper IgE syndrome as an alternative name to the disorder (128). The skin and 
lung infections are primarily caused by Staphylococcus aureus. Lungs are also infected 
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with Streptococcus pneumoniae and Haemophilus species, albeit less frequently. Hard 
to treat secondary Pseudomonas aeruginosa and mycobacterial infections further 
exacerbate poor pulmonary conditions and are the main cause of mortality. Fungal 
infections such as mucocutaneous candidiasis and Aspergillus are also common (129). 
Job syndrome is also characterized by various non-immunological features such as 
facial asymmetry, scoliosis, osteopenia, minor trauma fractures, hyperextensibility, 
retention of primary teeth and aneurysm (129-131).  
 In 2007, two groups independently discovered dominant negative STAT3 
mutations as the causative factor for the Job syndrome (130, 131). The mutations are 
found to be sporadic as well as familial and are mostly restricted to the DNA binding 
and SH2 domains (132). Investigations into the pathogenesis of immunodeficiency of 
Job syndrome patients have delineated the role of STAT3 signaling in the generation 
and function of immune cells of lymphoid and myeloid origin (133). Cells from Job 
syndrome patients serve as a naturally occurring STAT3 deficient genetic model, which 
has helped decipher role of STAT3 in human physiology. 
1.4 GENESIS OF HYPOTHESIS AND SPECIFIC AIMS 
 
 NK cells play a crucial role in immune response to virally infected and malignant 
cells. Cytolytic activity of NK cells is a result of the balance between the activation of 
inhibitory and activating receptors expressed on NK cell surface. The innate ability of 
NK cells to use these receptors to recognize and destroy malignant cells has made 
them excellent candidate immune cells to be used in adoptive immunotherapy against 
cancer. Due to the limited number of NK cells in the peripheral blood, ex vivo 
expansion and activation of autologous or allogeneic NK cells before their transfer into 
the patient forms the basis of NK cell adoptive immunotherapy.  
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Research efforts in our lab are focused on developing NK cell adoptive 
immunotherapies against cancers. Activation and expansion of patient- or donor-
derived NK cells under laboratory conditions to a sufficiently large number is a pre-
requisite for the success of such a therapeutic approach. Understanding the signaling 
mechanisms involved in NK cell proliferation, survival and activation is a key to 
optimizing the ex vivo culture conditions of NK cells, which will translate to improved 
clinical applications of NK cell immunotherapy.  
We previously described robust ex vivo expansion and activation of human NK 
cells by co-cultivation with K562 (erythroleukemic cell line) based artificial antigen 
presenting cells (aAPC) genetically modified to express membrane-bound IL21 
(mbIL21). We found that mbIL21 results in greater proliferation, longer telomere length, 
and less senescence than NK cells expanded with aAPC expressing membrane-bound 
IL15 (mbIL15) (134). Within the STAT family, IL21 activates STAT3 most efficiently 
(135).  
 Investigations in our lab also revealed that STAT3 signaling activates 
expression of NKG2D (136), a primary activating receptor involved in the cytolytic 
immune response mediated by NK cells to infections and malignant cells (12). We 
showed that STAT3 regulates NKG2D expression at the transcriptional level (136).   
 Based on these findings, I hypothesized that STAT3 signaling is critical for 
human NK cell cytolytic function and proliferation.  
I proposed the following specific aims to investigate this hypothesis:  
Aim #1: To evaluate the role of STAT3 signaling in cytolytic function of NK cells  
Aim #2: To evaluate the role of STAT3 signaling in NK cell proliferation  
NK cells from Job syndrome patients carrying dominant negative STAT3 
mutations provided an opportunity to test my hypothesis in a naturally occurring genetic 
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model. Along with Job syndrome patients’ NK cells, I also validated my hypothesis in 
STAT3 knock-down primary human NK cells. Along with genetic models, I also 
employed pharmacological approach wherein STAT3 activation was blocked using 
small molecule STAT3 inhibitor.   
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ROLE OF STAT3 SIGNALING IN HUMAN NK CELL  
CYTOLYTIC FUNCTION 
 
 “This chapter is partly based on the already published results in the Journal Blood. 
Zhu S, Phatarpekar PV*, Denman CJ, Senyukov VV, Somanchi SS, Nguyen-Jackson 
HT, Mace EM, Freeman AF, Watowich SS, Orange JS, Holland SM, Lee DA. 
Transcription of the activating receptor NKG2D in natural killer cells is regulated by 
STAT3 tyrosine phosphorylation. Blood. 2014;124(3):403-411. © the American Society 
of Hematology." 
*Co-first Author 
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Role of STAT3 Signaling In Human NK Cell  
Cytolytic Function 
2.1 INTRODUCTION 
  
Cytokines, the central regulators of immunity, predominantly employ Janus 
kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway 
to mediate signals in immune cells. In canonical JAK-STAT signaling, signals are 
relayed from the extracellular environment to the nucleus to regulate gene expression 
in target cells. Upon binding of cytokines to their specific multimeric receptors, JAKs, 
tyrosine kinases, constitutively associated with cytoplasmic regions of cytokine 
receptors, are activated. Activated JAKs phosphorylate specific tyrosine residues in the 
cytoplasmic domain of the cytokine receptors to provide docking sites for latent 
cytoplasmic transcription factors STATs through the interaction of their Src homology 2 
(SH2) domains. Conserved tyrosine residues on receptor bound STATs are 
phosphorylated by JAKs. Phosphorylated STATs dissociate from receptors and 
dimerize by reciprocal interactions of their SH2 domains and phosphotyrosines. 
dimerized STATs translocate to the nucleus and bind to specific DNA elements to 
regulate transcription of target genes. Four JAKS, JAK1, JAK2, JAK3 and TYK2 
through seven STATS, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 
mediate signals from diverse types of cytokines in multiple types of immune cells (137). 
STATs are composed of multiple domains. The N-terminal domain facilitates 
binding of two adjacent DNA bound dimers, which stabilizes DNA-STAT interaction. 
The coiled-coil domain which succeeds the N-terminal domain is involved in 
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interactions with different proteins essential for forming transcription activation complex. 
C-terminus to the coiled-coil domain is the DNA binding domain and as the name 
indicates is at the core of the function of the protein (99). The linker domain, which 
bridges the DNA binding domain with the SH2 domain, is essential for the 
transcriptional activation (138). The SH2 domain serves two critical functions; initial 
binding of the latent STAT to the phosphorylated tyrosine on the cytoplasmic portion of 
the cytokine receptor that leads to the phosphorylation of its own tyrosine by JAKs and 
upon activation it enables dimer formation with other activated STAT through reciprocal 
interactions of SH2 domain and phosphotyrosine. The tyrosine residue, whose 
phosphorylation by JAKs activates the STATs, is located at the interface of SH2 
domain and the transcriptional activation domain (TAD). The TAD lies at the C-terminus 
of the protein and as the name suggests is critical for the transcriptional activation of 
target genes (139).  
Among STATs, STAT3 is the most pleotropic transcription factor regulating 
genes involved in fundamental cellular processes such as proliferation, apoptosis, 
differentiation and migration in multiple cell lineages downstream of a plethora of 
extracellular signals (107). Given its critical role in cellular processes, it is not surprising 
that germline STAT3 deletion is embryonically lethal in mouse (113). Targeted tissue 
specific deletion has revealed STAT3’s role in the development and function of multiple 
organs as diverse as skin and brain (107). STAT3 is activated by several families of 
cytokines that employ JAKs to mediate their signals (116). In addition to JAKs, receptor 
tyrosine kinases are known to activate STAT3 downstream of some extracellular 
ligands (EGF, M-CSF, PDGF and Flt3 ligand) and tyrosine kinases belonging to src 
family also activate STAT3 either directly or downstream of receptor tyrosine kinases or 
G-protein coupled receptors (105, 106). As STAT3 relays proliferative and anti-
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apoptotic signals initiated by different cytokines and growth factors in various cell types, 
dysregulation of these signaling pathways often leads to constitutive hyper-activation of 
STAT3 resulting in oncogenic transformation of various tissues. Increased expression 
and activation of STAT3 is associated with multiple types of cancers and besides 
mediating pro-proliferative and anti-apoptotic signals, STAT3 also promotes growth and 
spread of these cancers by activating expression of genes involved in angiogenesis 
and metastasis (106). Development of STAT3 inhibitors is a very active area of cancer 
therapeutics and many such drugs are at different stages of pre-clinical and clinical 
studies (140).  
Natural defense against cancer, the Immune system, whose failure to detect and 
destroy transformed cells manifests as the disease, is also under the influence of 
STAT3 signaling. Many cytokines responsible for initiating and modulating innate and 
adaptive immune responses by inducing differentiation and/or regulating activation of 
different types of immune cells mediate their signals through STAT3. Cytokine families 
critical for normal immune function such as common γ-chain cytokines (IL-2, IL-7, IL-15 
and IL-21), IL-6/gp130 (IL-6, IL-11, IL-27, IL-31, oncostatin M and leukemia inhibitory 
factor), IFNs (IFN-α, IFN-β and IFN-ϒ), IL-10 (IL-10, IL-19, IL-20, IL-22, IL-24 and IL-
26), IL-12, IL- 23, colony stimulating factors (G-CSF and M-CSF) and Flt3 ligand 
employ STAT3 down-stream of their receptors (116). These signaling molecules play 
an important role in the differentiation, proliferation, survival and modulation of 
activation of myeloid and lymphoid cells (116). Cell lineage specific STAT3 deletion in 
mice has revealed role of STAT3 signaling in differentiation and function of myeloid and 
lymphoid cells. STAT3 signaling plays a critical role in dendritic cell differentiation 
(124), neutrophil mobilization (123), and IL-10 mediated negative modulation of 
macrophage and neutrophil activity (122). In lymphoid cells, STAT3 signaling is 
 38 
 
required for the generation and maintenance of Th17 cells, a subset of T helper cells 
responsible for immune response against bacteria and fungi at epithelial surfaces (117, 
118) and T cell dependent differentiation of B cells into plasma cells (121).  
Dominant negative mutations in STAT3 cause a sporadic or autosomal dominant 
primary immunodeficiency called Job syndrome or Hyper IgE syndrome (HIES) 
characterized by immunological features such as eczema, recurrent bacterial and 
fungal skin and lung infections and elevated serum IgE as well as non-immunological 
manifestations such as facial asymmetry, scoliosis, osteopenia, minor trauma fractures, 
hyperextensibility, retention of primary teeth and aneurysms (129-131). Majority of the 
STAT3 mutations found in Job syndrome are one amino acid change causing missense 
mutations, while few have been found to cause in frame deletion of single amino acid 
(129, 132, 141). The mutations are mostly restricted to the DNA binding and SH2 
domains, with few in the transcriptional activation domain (142-146). A single mutation 
each has been reported in the coiled-coil (145) and linker domain (144). Though most 
of the mutations are in the exons, few intronic mutations causing exon-skipping leading 
to short in frame deletions have also been reported (142, 145, 146). Despite the large 
heterogeneity and their locations in different domains, the mutations have been shown 
to act in a dominant negative manner and give rise to the same immunological 
phenotype (142, 144, 146). The dominant negative mutations do not totally abolish 
STAT3 DNA binding activity in Job syndrome patients. As DNA binding and 
transcriptional activation is mediated by STAT3 dimers, the normal STAT3 allele 
enables dimer formation between wild type STAT3 and retains residual STAT3 activity, 
which is about 25% of the activity found in normal individuals (131). 
Since the discovery of deficient STAT3 signaling as a causative factor, 
investigations into the pathogenesis of immunological dysfunctions in Job syndrome 
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patients have revealed role of STAT3 in the development and function of multiple types 
of immune cells. Recurrent bacterial and fungal infections in Job syndrome patients 
prompted analysis of Th17 cells, which were found to be absent in these patients. 
Cellular and molecular evaluation delineated a direct role of STAT3 in the differentiation 
and function of these cells (147, 148). Similarly, inquiries into the molecular 
mechanisms underlying defective T cell dependent B cell activation and differentiation 
into plasma cells in Job syndrome patients established a fundamental role of STAT3 in 
the generation and function of T follicular helper cells (149), while investigations into 
the etiology of atopic dermatitis revealed requirement of STAT3 in IL-10 directed 
dendritic cell induced differentiation of T regulatory cells (150). Decreased number of 
central memory CD4+ and CD8+ cells in Job syndrome patients were pivotal in 
deciphering the requirement of STAT3 for the differentiation and proliferation of human 
central memory T cells and found to be the causative factor for vulnerability of Job 
syndrome patients to the varicella zoster virus and Epstein-Barr virus reactivation 
(151). Likewise, efforts to unravel the molecular mechanisms causing deficiency of 
memory B cells and antigen dependent antibody production in Job syndrome patients 
led to the establishment of role of IL-21 induced STAT3 signaling in the differentiation 
of human memory B cells and antigen specific plasma cells from naïve B cells (152, 
153). Along with the cells of lymphoid origin, immunological defects in Job syndrome 
patients also provided insights into the role of STAT3 in cells of myeloid origin. 
Investigations of cellular and molecular mechanisms causing atopic conditions in Job 
syndrome patients revealed requirement of STAT3 in IL-10 induced generation of 
tolerogenic dendritic cells (150) and in IgE mediated signaling in mast cells (154). 
Despite having reactivation of herpes virus infections and increased risk of 
malignancies as clinical symptoms (144, 151, 155, 156), surprisingly, the immune cell 
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that plays critical role in immune responses against these risks, namely the natural 
killer (NK) cell, hasn’t received any research attention in Job syndrome patients.  
NK cells, cytotoxic lymphocytes of the innate immune system, play a crucial role 
in immune response to viruses and tumors, destroying virally infected cells and 
neoplasms. NK cells detect abnormal cells through the interactions of activating 
receptors expressed on NK cell surface with their corresponding ligands, whose 
expression is generally increased on the surface of stressed cells. A large array of 
activating receptors such as natural cytotoxicity receptor (NCR) family (NKp30, NKp44, 
NKp46), NKG2D, DNAM1, 2B4, CD160, CD16, CD2, and CD94-NKG2C are expressed 
on NK cell surface providing broader ability to detect target cells expressing diverse 
types of ligands. Upon binding of activating receptors to their cognate ligands, signals 
are transmitted inside NK cells to trigger cytolytic activity. As some of these activating 
ligands are expressed by normal cells, to differentiate normal self from abnormal cells, 
NK cells are also equipped with cell surface inhibitory receptors such as killer cell 
immunoglobulin-like receptors (KIRs) and CD94-NKG2A that recognize major histo-
compatibility (MHC) class I classical and non-classical ligands on cells and mediate 
inhibitory signals to block cytolytic activity of NK cells. Thus, the cytolytic activity of NK 
cells is the net result of the balance between the strengths of activating and inhibitory 
signals (8). NK cells use multiple ways to kill the target cells. NK cells possess 
specialized lysosomal organelles called lytic granules containing cytotoxic molecules. 
The process of releasing the lytic content in the extracellular space through lytic 
granule exocytosis is called degranulation. The major cytolytic proteins in the lytic 
granules are perforin and granzymes. NK cells also express apoptosis inducing ligands 
belonging to the tumor necrosis factor (TNF) family viz. FAS ligand (FASL) and TNF 
related apoptosis inducing ligand (TRAIL) either in a membrane bound form and/or as a 
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part of lytic granules. Of the multiple mechanisms at NK cell’s disposal for target cell 
lysis, release of death inducing proteins, perforin and granzymes, into the cleft of the 
synapse formed between NK and target cell through the exocytosis of lytic granules, is 
the predominant one (6, 157). Upon release, perforin forms pores in the plasma 
membrane or in the endosomal membrane and facilitate entry of granzymes into the 
cytosol of target cells. Granzymes are serine proteases that induce apoptosis in 
caspase dependent and independent manner (157).  
The process of directed secretion of cytotoxic molecules at the interface of NK 
and target cell through degranulation is a well-regulated multistep process. The 
process is set in motion by the initial contact between NK cell and a potential target 
cell, which is likely mediated through tethering receptors like CD2 and receptors 
belonging to selectin family such as CD62L. Lymphocyte function associated antigen 1 
(LFA1; CD11:CD18) and macrophage receptor 1 (MAC1; CD11b:CD18), receptors 
expressed on NK cells belonging to integrin family, establish firm adhesion between NK 
and target cells through their interactions with intercellular adhesion molecule 1 
(ICAM1) expressed on target cells (158). Activating receptors such as NCRs, NKG2D, 
DNAM1 also contribute to NK adhesion through their interactions with their 
corresponding ligands on target cells and these receptors along with LFA1 transmit 
activating signals inside the NK cells to initiate immune synapse formation. The 
activating signals trigger F-actin reorganization, which is the first critical step required 
for the commitment to synapse formation (159). During the contact between NK and 
target cell, along with activating receptors, inhibitory receptors also engage their 
cognate ligands on target cells and mediate inhibitory signals. Integration of activating 
and inhibitory signals at this stage decides the fate of the immune synapse. Strong 
inhibitory signal blocks actin reorganization, clustering of activating receptors and 
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thereby prevents further activation of NK cells and synapse maturation, which results in 
NK detachment from the target (158). In the absence of overriding inhibitory signals, 
activating signals induce formation of polymerized filamentous actin (F-actin) from 
monomeric globular actin and accumulation of polymerized actin at the NK cell 
synapse. Accumulation of F-actin at the synapse is a pre-requisite for the clustering of 
activating receptors. Synergistic signals from the cluster of activating receptors 
stimulate polarization of cytolytic granules to the synapse. For directed secretion of 
perforin and granzymes into the synaptic cleft, cytolytic granules dispersed throughout 
the cell have to be congregated near the synapse. This is achieved first by movement 
of granules along microtubules to converge at microtubule organizing center (MTOC), a 
cellular structure where microtubule formation begins and from which microtubules 
radiate in all directions, and then by polarization of MTOC along with lytic granules to 
the synapse. Once near the synapse, the granules traverse the clearings created by F-
actin remodeling to reach the plasma membrane and secrete their lytic content into the 
synaptic cleft through exocytosis (158, 159). 
Unlike cytolytic T cells, NK cells do not need prior sensitization with target 
antigen before killing a target cell. Upon detecting stress signals through interactions of 
NK activating receptors with their cognate ligands on target cells, NK cells deliver their 
cytolytic function. This ready to kill approach makes it necessary for NK cells to be 
equipped with the detection tool, the activating receptors, and the effector tool, lytic 
granules containing perforin and granzymes, while on immunosurvelliance duty. 
Surface expression of activating receptors and pre-formation of lytic granules occur as 
a result of priming of NK cells by cytokines present in their microenvironment (8). Type 
1 interferons (IFNα and IFNβ), common γ-chain cytokines (IL-2, IL-15 and IL-21), IL-6, 
IL-12 and IL-18 are known to activate cytolytic capability of NK cells and that is mainly 
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achieved through STAT mediated signaling (82, 160). Cytokines induce perforin 
expression through STAT mediated signaling. IFNα and IL-6 stimulate perforin gene 
expression through STAT1 (83, 161), IL-2 and IL-15 through STAT5 (83, 84, 162), 
while IL-12 activates via STAT4 (84). Perforin gene has a STAT binding site in its 
enhancer region and cytokines have been shown to induce perforin expression through 
STAT mediated transcriptional activation (83, 84). Like perforin, granzyme B 
expression has also been demonstrated to be modulated through STAT signaling. 
During viral infection, type I IFNs stimulate granzyme B expression in NK cells via 
STAT1 signaling (86) and granzyme B production is significantly impaired in STAT1 
deficient NK cells in response to viral infection (163). Along with perforin and granzyme, 
cytokines also induce expression of activating receptors in NK cells. NKG2D 
expression on NK cells is up-regulated in response to IFN-α, IL-2, IL-15 and IL-12 (87-
90). IL-2 stimulation also increases expression of other activating receptors such as 
DNAM1, NKp44 and NKp30 (91). IL-21, which also modulates NK cell cytotoxicity, has 
been shown to up-regulate expression of activating receptors NKp30, NKp46, NKG2D 
and 2B4 (81, 92). Even though role of STATs in cytokine regulated expression of NK 
activating receptors has not been experimentally established yet, given that these 
cytokines predominantly signal through STAT family members (104, 116), their role in 
the regulation of expression of these receptors is very likely. The critical role played by 
STATs in cytokine mediated arming of NK cell for cytotoxicity is reflected in the 
impaired cytolytic activity of STAT deficient NK cells. NK cells from STAT1 deficient 
mouse and human had lower basal (164-166) as well as induced cytotoxicity, 
particularly during viral infections (68, 86, 163). Diminished basal and IL-2 and IL-15 
induced cytolytic activity was also observed in NK cells from STAT5b deficient mouse 
(162), while IL-12 failed to augment cytotoxicity of NK cells from STAT4 deficient 
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mouse (167, 168). Cytokines display signaling promiscuity by activating multiple 
STATs. Type 1 interferons (IFNα and IFNβ), common γ-chain cytokines (IL-2, IL-15 and 
IL-21), IL-12, IL-18 and IL-10, cytokines known to stimulate cytolytic capability of NK 
cells, in addition to other STATs also activate STAT3 in NK cells (80, 136, 161, 169-
173). Despite being activated by several cytokines critical for NK cytolytic function, very 
little research effort has gone into understanding the role of STAT3 signaling in NK 
cytotoxicity, particularly in human NK cells.  
Beyond serving just the academic interests, investigating the role of STAT3 in 
NK cytolytic function has far reaching clinical applications. Constitutively active STAT3 
is oncogenic (174). Constitutively active STAT3 drives development, maintenance and 
spread of multiple cancers by activating a transcriptional profile that promotes 
proliferation, survival, angiogenesis and metastasis (106). Besides malignant cell 
intrinsic effects, STAT3 signaling also influences tumor microenvironment. STAT3 
plays a critical role in tumor microenvironment to promote tumor growth and is 
generally considered to be a negative regulator of immunity against tumor. Tumor 
secreted factors such as VEGF, IL-6 and IL-10 activate STAT3 signaling in tumor cells, 
which helps them escape immune surveillance and activation of STAT3 by tumor 
associated factors in immune cells suppresses their activation and thereby the immune 
response (115). Thus, STAT3 plays a crucial role at the interface of tumor biology and 
immunity. STAT3 is a major drug target in cancer therapeutics and multiple approaches 
to block STAT3 signaling are at different stages of clinical development (106, 140, 
175). Equally promising therapeutic prospects against cancer are offered by NK cell 
immunotherapy. Equipped with cell surface receptors that detect danger signals on 
malignant cells and activate cytolytic activity, the inherent function of NK cells is 
immune- surveillance of transformed cells. This innate role of NK cells is evident due to 
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the fact that low NK cytotoxicity in peripheral blood is associated with higher incidence 
of cancer as was observed in an 11 year follow-up study (30). High levels of tumor 
infiltrating NK cells are associated with positive prognosis (31-33). Due to their anti-
tumor activity, NK cells have emerged as candidate effector cells for immune therapy 
against cancer. Tumor recognition and rejection by NK cells have been demonstrated 
both in vitro and in vivo in mice and rats (20-22). The anti-tumor activity of several 
cytokines such as IL-2, IL-12, IL-18 and IL-21 is mediated by NK cells (8, 26). Adoptive 
transfer of activated autologous or allogeneic NK cells has proven to be a safe and 
potentially efficacious immunotherapy for cancer (36, 37). NK cell therapy has been or 
being tested against multiple types of cancers (35). In the light of the role NK cells play 
in controlling malignancy, it becomes critical to understand the role of STAT3, which 
drives malignant growth and also regulates body’s immune response to it, in NK cell 
cytolytic function. It is all the more important when STAT3 inhibition and NK cell 
immunotherapy are emerging as treatment modalities for cancer.  
Due to the limited number of NK cells in the peripheral blood, expanding NK 
cells to a sufficiently large number is imperative to the success of NK cell 
immunotherapy. Expanding and activating NK cells ex vivo, before their transfer into 
the patients, forms the basis of NK immunotherapy. Research efforts in our lab are 
focused on developing an ex vivo NK cell expansion platform. We previously described 
robust ex vivo expansion and activation of NK cells by co-cultivation with K562 
(erythroleukemic cell line) based artificial antigen presenting cells (aAPC) genetically 
modified to express membrane-bound IL-21 (mbIL21) (134). Within the STAT family, 
IL-21 activates STAT3 most efficiently (104, 135). Intrigued by this initial finding, our 
further investigations revealed that STAT3 signaling activates expression of NKG2D 
(136), a primary activating receptor involved in the immune response mediated by NK 
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cells to infections and tumors (12). In this study the inquiries have been taken further to 
probe the role of STAT3 in NK cytolytic function. Job syndrome patients carrying 
dominant negative STAT3 mutations offer a naturally occurring genetic model of 
STAT3 deficiency. Employing NK cells from Job syndrome patients and siRNA 
mediated STAT3 knock-down in primary human NK cells, I studied role of STAT3 in NK 
cytolytic activity and the cellular processes involved in delivering the cytolytic function. 
The evidence presented in this study establishes a fundamental role of STAT3 in the 
cytotoxicity of human NK cells and the cellular processes underlying it.       
2.2 MATERIAL AND METHODS 
2.2.1 Cell and Cell Lines 
 
Anonymized normal donor buffy coats were obtained from the Gulf Coast 
Regional Blood Center (Houston, TX) under a protocol approved by the Institutional 
Review Board (IRB) of UT MD Anderson Cancer Center. Peripheral blood was 
obtained from STAT3 genotyped Job’s syndrome patients at National Institute of 
Allergy and Infectious Diseases and Children’s Hospital of Philadelphia under protocols 
approved by the IRB of each respective institution. IRB approval was obtained from UT 
MD Anderson Cancer Center to acquire Job’s syndrome samples from collaborators 
and to perform this research. The parental K562 cell line was obtained from the 
American Type Culture Collection (ATCC). This study was conducted in accordance 
with the Declaration of Helsinki. 
2.2.2 PBMC Isolation 
 
Peripheral blood mononuclear cells (PBMCs) from buffy coats and blood 
samples were obtained by buoyant density centrifugation on Ficoll-Paque following 
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previously described protocol (176). Briefly, buffy coats or blood samples mixed with 
phosphate buffer saline (PBS) were loaded on top of Ficoll-Paque in a 50 ml tube and 
centrifuged at 400g for 20 minutes without brake. The PBMCs settled at the interface of 
Ficoll-Paque and plasma were recovered and washed three times with PBS. The RBCs 
settled below Ficoll-Paque were used to isolate NK cells from PBMCs. 
2.2.3 NK Cell Purification 
 
NK cells were purified from PBMCs by enriching them to  90% purity 
(CD3−CD16/56+) with RosetteSep Human NK Cell Enrichment Cocktail (STEMCELL 
Technologies, Vancouver, BC, Canada) following manufacturer’s instructions. In brief, 
PBMCs were mixed at 1:100 ratio with red blood cells (RBCs) obtained from the same 
sample. To the PBMCs:RBCs mixture, Human NK Cell Enrichment Cocktail was added 
at 1 µl/106 PBMCs. The solution was mixed well and incubated at room temperature for 
20 minutes with gentle mixing every five minutes. After adding PBS with 2% fetal 
bovine serum (FBS) to the PBMCs:RBCs mix, the solution was layered on top of Ficoll-
Paque and centrifuged at 400g for 20 minutes. The NK cells were recovered from top 
of the Ficoll-Paque layer.  
2.2.4 Cell Culture Media 
 
The NK and K562 cells were cultured in RPMI 1640 (Cellgro/Mediatech, 
Manassas, VA) supplemented with 10% FBS (HyClone, Logan, UT), 2 mM l-glutamine 
(Gibco/Invitrogen, Carlsbad, CA), and 1% penicillin/streptomycin (Cellgro/Mediatech). 
This media is hereinafter referred to as NK cell media.  
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2.2.5 Antibodies 
 
 Fluorochrome conjugated mouse monoclonal antibodies (mAb) against human 
CD3, CD11b, CD16, CD25, CD27, CD56, CD57, CD62L, CD69, 2B4, DNAM1, NKG2D, 
NKp30, NKp44 and NKp46 were obtained from BD Biosciences (San Jose, CA). 
Fluorochrome conjugated mouse monoclonal antibodies against human KIR2DL1, 
KIR2DL2/3, KIR3DL1 were obtained from Miltenyi (San Diego, CA). Fluorochrome 
conjugated mouse monoclonal antibodies against human CD160 was obtained from 
BioLegend (San Diego, CA), while fluorochrome-conjugated mouse monoclonal 
antibodies against human NKG2A were obtained from R&D (Minneapolis, MN). Rabbit 
monoclonal antibodies against human β-actin and STAT3 were obtained from Cell 
Signaling Technology (Danvers, MA). 
2.2.6 CD3 Depletion 
 
NK cells expanded from PBMCs were depleted of T cells using magnetic 
separation system from Miltenyi Biotec (San Diego, CA) following manufacture’s 
protocol. Briefly, cells were stained with CliniMACS CD3 microbeads before loading 
them onto the MACS LD separation column. The CD3 microbead stained cells were 
separated from rest of the cells using QuadroMACS separator.   
2.2.7 Ex vivo Expansion of Human NK Cells 
 
NK cells were expanded as previously described with few modifications (176). 
Briefly, PBMCs were co-cultured with irradiated (100 cGy) K562 artificial antigen 
presenting cells (aAPCs), genetically modified to express membrane bound IL-21 
(mbIL-21), at 1:1 (PBMCs:aAPCs) ratio and 50 U/ml recombinant human IL-2 in a T-75 
flasks (Corning, Corning, NY) at 106 cells/ml. The K562s expressing mbIL-21 were 
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generated as previously described (134). Culture was refreshed with new media 
containing 50 U/ml IL-2 every three to four days. At the end of one week of expansion, 
PBMCs were re-stimulated with K562s expressing mbIL-21 and 50 U/ml IL-2. 
2.2.8 Cell Count and Cell Viability 
 
Cells were counted using hemocytometer. Cell viability was determined by 
Trypan blue exclusion method. Briefly, cells were stained with trypan blue and number 
of cells stained blue and total number of cells were counted using hemocytometer. 
Percentage viability was calculated using the formula [((Total number of cells-number 
of blue cells)/Total number of cells) *100].  
2.2.9 Cellular Cytotoxicity Assay  
 
NK cell cytolytic activity was determined using the Calcein-release assay as 
previously described (176). Briefly, NK cells treated with STAT3 inhibitor S3I-201 and 
NK cells electroporated STAT3 siRNA were co-incubated with the target cells (K562). 
Before co-incubation with effector cells, the target cells (K562) were labeled with 2 
µg/mL of calcein-AM (Sigma-Aldrich, St. Louis, MO) for 1 hour at 37 °C with occasional 
shaking. The target cells were dispensed in a 96 well round bottom microplate in such 
a way that each well contained 10000 cells. Effector and target cells were co-incubated 
at the indicated effector to target (E:T) ratios at 37 °C for 4 hours in a 96 well round 
bottom microplate. After incubation, 100 µL of the supernatant was collected and 
transferred to a new plate. Absorbance at 570 nm was determined using a SpectraMAX 
plus384 (Molecular Devices, Sunnyvale, CA). Percent specific lysis was calculated 
according to the formula [(experimental release-spontaneous release) / (maximum 
release – spontaneous release)] x 100.  
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2.2.10 Lytic Unit Calculation  
 
   To obtain a uniform measure to compare NK cytotoxicity assessed in assays 
performed at different times, lytic units were calculated. The number of NK cells 
required to kill a specified percentage of target cells was delineated as one lytic unit 
(177). To determine the lytic unit, a standard curve was plotted using percent specific 
lysis versus the log values of their corresponding E:T ratio for each sample. A specific 
percentage of target cell lysis was selected based on the criterion that the standard 
curves of all the samples in the relevant data set crossed the reference percentage 
exactly once (177). The E:T ratio corresponding to the reference percentage was 
interpolated from the standard curve. In the assays, where purified NK cells were used, 
the number of NK cells required to kill the specified percentage of target cells was 
calculated by multiplying the interpolated E:T ratio by 10000 (the number of target cells 
in each well). In the assays, where PBMCs were used, the number of NK cells were 
obtained using the formula [(E:T ratio x 10000 x % of NK cells in PBMCs)/100]. Lytic 
units per one million cells were obtained according to the formula (1,000,000/number of 
NK cells in one lytic unit) (177). 
2.2.11 siRNA Mediated Gene Silencing 
 
   Primary human NK cells isolated from PBMCs and cultured overnight in 
complete NK cell media with 50 U/ml IL-2 were nucleofected with siRNA using Amaxa 
human NK cell nucleofector kit from Lonza (Allendale, NJ, USA). Before 
electroporation, the cells were spun at 100 g for 10 minutes and washed once with NK 
media without serum and antibiotics. The cells were resuspended in human NK cell 
nucleofector solution at a density of 3-4 x 106 cells/100 µl. The cell suspension was 
mixed with the indicated concentration of On-Targetplus SMART pool siRNA for STAT3 
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or On-Targetplus non-targeting SMART pool siRNA for control from Dharmacon 
(Pittsburg, PA, USA) in a cuvette supplied with the nucleofector kit. The nucleofection 
was performed using program X-01 in an Amaxa Nucleofector from Lonza. Upon 
nucleofection, the cells were cultured for 2 hours in NK media without serum and 
antibiotics in a 12-well plate. After 2 hours, cells were resuspended in RPMI with 10% 
serum and 50 U/ml recombinant human IL-2 (Proleukin, Novartis Vaccines and 
Diagnostics, Inc.) at a density of 1x 106 cells/ml. The cells were cultured for 48 hours 
before use. 
2.2.12 Flow-Cytometry Analysis 
 
   Flow cytometry buffer, PBS with 2mM EDTA and 0.1% sodium azide, was 
used for blocking, staining, washing and resuspending the cells. Before staining with 
antibodies, the cells were blocked with 50% FBS for 30 minutes at 4C. Blocked cells 
were stained with appropriate fluorochrome conjugated antibodies for 30 minutes at 
4C, washed twice and resuspended in flow cytometry buffer. Data was acquired using 
a FACSCalibur cytometer (Becton Dickinson, Franklin Lakes, NJ), and was analyzed 
using FlowJo Version 9.2 software (FlowJo, Ashland, OR, USA).  
2.2.13 RT-PCR  
 
   RNA was isolated using RNeasy plus mini kit from Qiagen (Valencia, CA, 
USA) and its concentration was measured using NanoDrop spectrophotometer 
(Thermo Scientific, Wilmington, DE). Primers were designed using Primer-BLAST 
software (178) available at NCBI website (http://www.ncbi.nlm.nih.gov/tools/primer-
blast). Semi-quantitative reverse transcription PCR (RT-PCR) was performed using 
OneStep RT-PCR kit from Qiagen (Valencia, CA, USA) with primers listed in Table 2. 
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The reactions were run in PTC-200 peltier thermal cycler (GMI, Ramsey, MN). The RT-
PCR products were analyzed by electrophoresis through 1.2% agarose gel. Gel was 
imaged in Remi molecular imager using ChemiDoc XRS+ system (Bio-Rad, Hercules, 
CA). The RT-PCR bands were quantified using ImageJ software (179). 
For quantitative real-time PCR, cDNA was synthesized using SuperScript III first 
strand synthesis supermix (Invitrogen, Life technologies, Grand Island, NY). The real-
time PCR reaction was set up with cDNA and primers listed in Table 2 using IQ SYBR 
green supermix in iCycler real time PCR detection system (Bio-Rad, Hercules, CA). 
Relative gene expression was quantified using ΔCT method (180).      
2.2.14 Western-Blot Analysis 
 
  NK cells were lysed with RIPA buffer (Thermo Fisher Scientific, Grand Island, 
NY) supplemented with protease inhibitor cocktail and phosphatase inhibitor cocktail. 
The protein was quantified using BCA assay kit (Thermo Fisher Scientific, Grand 
Island, NY). Proteins were resolved using sodium dodecyl sulfate- Polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) 
membrane. The membrane was probed first with unconjugated primary and then with 
horseradish peroxidase conjugated secondary antibody. The protein on the membrane 
was detected using enhanced chemiluminescence (ECL) reagents following 
manufacture’s protocol (Amersham, GE Healthcare Life Sciences, Pittsburgh, PA). The 
protein bands were quantified using ImageJ software (179). 
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2.2.15 Pharmacological Inhibition of STAT3 in NK Cells 
 
   S3I-201 (Calbiochem, Gibbstown, NJ), a small molecule STAT3 inhibitor, 
reconstituted in DMSO was used to block STAT3 signaling. Purified NK cells were 
incubated overnight with or without S3I-201. The control cells were treated with DMSO. 
2.2.16 Single Cell Analysis 
 
  The single-cell cytotoxicity assay was performed using fabricated nanowell 
arrays as described previously (181, 182). Briefly, K562 tumor cells (targets) and 
STAT3 siRNA – or control siRNA- transfected NK cells (effectors) were labeled with 1 
µM of red PKH26 and green PKH67 respectively for 2 minutes (Sigma-Aldrich, St. 
Louis, MO). NK and K562 cells were loaded sequentially onto the nanowell array at a 
concentration of 106 cells/mL, let to settle for 3 minutes and the entire chip was 
immersed in phenol red free complete medium containing 1/60 (V/V) AnnexinV-
AlexaFluor-647 (Life Technologies, Carlsbad, CA). Images were acquired on an 
AxioObserver mounted with a 5% CO2, 37 
0C and 100% humidity incubator, piloted 
with Zen software (Carl Zeiss, Jena, Germany) and fitted with a Hamamatsu Orca 
Flash 4.0 sCMOS camera and a 20x 0.8 NA objective. Timelapse imaging microscopy 
in nanowell grids (TIMING) images were taken for 8 hours at intervals of 6 minutes and 
data were processed and analyzed as described previously (183).  
Data were post-processed using Excel and GraphPad Prism. Statistical testing 
was run using Fisher’s exact test when contingency numbers were compared. 
2.2.17 Analysis of Subcellular Cytolytic Processes  
 
   Analysis of synaptic strength, granule convergence to MTOC and MTOC 
polarization to the synapse were performed as previously described (184-186). Briefly, 
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NK and K562 cells were incubated together in suspension at 2:1 (PBMC:K562) ratio for 
15 minutes to form conjugates between the two. The cell suspension was then placed 
on poly-L-lysine coated glass slide (Sigma-Aldrich, St. Louis, MO) for 15 minutes to let 
the cells adhere to the slide. All the steps were carried out at 37oC. Cells attached to 
the slides were fixed and permeabilized with 4% formaldehyde, 0.1% saponin and 
0.1% triton X-100 in PBS for 15 minutes. Before staining with the antibodies, cells were 
blocked with 10% heat-inactivated mouse serum (Sigma-Aldrich, St. Louis, MO) for 30 
minutes. Blocked cells were first stained with biotinylated anti-tubulin mAb (Invitrogen, 
Waltham, MA) for 1 hour followed by rinsing and incubation with streptavidin-
conjugated Pacific blue 405 (Invitrogen, Waltham, MA). Slides were rinsed and 
incubated with Alexa Fluor 568-conjugated phalloidin (Invitrogen, Waltham, MA) and 
FITC-conjugated anti-perforin mAb (BD Biosciences, San Jose, CA) for 1 hr. After 
rinsing the slides, cells were covered with 0.15 mm glass coverslips (VWR Scientific, 
Radnor, PA) using Prolong Antifade reagent (Invitrogen, Waltham, MA) (185). 
Cell conjugates were imaged with a laser scanning confocal microscope 
(DMIRE2; Leica, Buffalo Grove, IL). The acquired images were analyzed using Volocity 
software (PerkinElmer, Waltham, MA). In an image, NK and K562 cells were 
distinguished on the basis of size difference (NK cell smaller compared to K562) and 
the presence of perforin (present in NK and absent in K562).  
To determine actin deposition at the interface of NK and K562, the entire 
interface was divided into squares, each measuring 1 μm x 1 μm. In each square, 
mean fluorescence intensity (MFI) of phalloidin, which stained F-actin, and the area 
occupied by phalloidin were quantified. Actin deposition in the square was estimated by 
the formula MFI of phalloidin x area occupied by phalloidin. The actin deposited at the 
NK-K562 interface, the immune synapse, was quantified by summing up actin 
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deposition in all the squares the interface was divided into. The quantified actin 
deposition at the interface included actin deposited by NK and K562. To estimate 
contribution of NK cell in actin deposition at the synapse, contribution of K562 to actin 
deposition and background actin deposition in unconjugated NK cells were subtracted 
from the quantified actin deposition at the interface. K562 contributed actin and 
background actin deposition in NK were estimated by quantifying actin deposited in 
equal number of squares in the cortex of unconjugated K562 cells and unconjugated 
NK cells, respectively (184).  
Microtubule organizing center (MTOC) was visualized by staining it with 
biotinylated anti-tubulin mAb and streptavidin-conjugated Pacific blue 405. During 
image analysis, MTOC was delineated as tubulin labeled region with a pixel size 
threshold that eliminated measurement of individual microtubules (185). MTOC 
polarization was defined as the distance between MTOC and immune synapse and 
was measured by drawing a line between MTOC and the center of immune synapse 
using Volocity software (185, 186).  
Lytic granules were identified by staining with FITC-conjugated anti-perforin 
mAb. Granule convergence to MTOC was defined as the shortest distance between 
each individual granule and MTOC in the NK cell in conjugation with K562. To measure 
the distance, x and y coordinates of the MTOC and all the lytic granules in the cell were 
obtained using Volocity software and the mean MTOC to granule distance (MGD) for 
the cell was measured using the following formula (186) 
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x and y denote coordinates for the MTOC;  xi and yi  denote coordinates of each 
individual granule; n denote number of granules in the cell (186). 
2.2.18  Statistical Analysis 
 
   Statistical analysis was performed for the indicated statistical tests using 
GraphPad Prism for Macintosh, version 5.0a. P values <.05 were considered 
significant. 
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TABLE 2. PRIMERS USED FOR RT-PCR AND REAL TIME PCR ANALYSIS 
Primer Sequence 5’ to 3’ Product 
length 
(base 
pairs) 
RT-PCR 
STAT1 Forward primer TCAGGCTCAGTCGGGGAATA 801 
STAT1 Reverse primer ATCACTTTTGTGTGCGTGCC 
STAT3 Forward primer GGAGCTGGCTGACTGGAAGAG 856 
STAT3 Reverse primer CTCGATGCTCAGTCCTCGCTTG 
STAT5a Forward primer GAGGATCAAGCGTGCTGACCGGC 670 
STAT5a Reverse primer TGGTTTCAGGTTCCACAGGTTGC 
STAT5b Forward primer CCGCAATGATTACAGTGGCG 828 
STAT5b Reverse primer TTCAAGTCTCCCAAGCGGTC 
Real Time PCR 
Arl8B Forward primer GACTGGTTCCGTTCGCTCTTCTGG 241 
Arl8B Reverse primer TGACTCCTCTGCAATACCGCTCCC 
CIP4 Forward primer TGGTGAAAAAATATCTGCCCAAGAGAC 293 
CIP4 Reverse primer CCGGCAGTCCCGCTCAAATT 
IQGAP1 Forward primer GGAGGCACTGGCTAAGACGGAAG 220 
IQGAP1 Reverse primer TCTCTGCATGGCTCTCTGATGTTCTG 
KIF5B Forward primer AAATAGGAATTGCTGTGGGAAATAATGATG 217 
KIF5B Reverse primer ATACGAAGCTGACATGCTGCTAACTCC 
SKIP Forward primer AGCTATTTTGCTGCATGTGAGGATGAG 276 
SKIP Reverse primer CTGGAACAACCGCAGGTAGCTCTC 
GAPDH Forward primer GGAGAAGGCTGGGGCTCATTTG 244 
GAPDH Reverse primer CTTCTGGGTGGCAGTGATGGC 
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2.3 RESULTS 
 
In our previous work, we showed that membrane bound IL-21, a STAT3 
activating cytokine, stimulates expression of activating receptors and cytolytic activity of 
human NK cells (134) and STAT3 activation plays a critical role in the transcriptional 
regulation of basal as well as induced expression of the primary activating receptor 
NKG2D in human NK cell (136). As cytolytic activity of NK cells is triggered by the 
signals transmitted by the activating receptors upon binding to their cognate ligands on 
target cells, our previous findings led me to hypothesize that STAT3 activation may 
play a role in the regulation of cytolytic function of NK cells. Availability of NK cells from 
Job syndrome patients carrying dominant negative STAT3 mutations (Table 3) offered 
me an opportunity to test my hypothesis in a physiologically relevant genetic model.  
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Table 3. STAT3 mutations in Job syndrome patients 
  Mutation  
Sample ID Source Nucleotide, cDNA location Amino acid Domain 
Job C001 NIAID/NIH 1027 G-T V343P DNA binding 
Job C002 NIAID/NIH 1144 C-T R382W DNA binding 
Job C003 NIAID/NIH 1144 C-T R382W DNA binding 
Job C004 NIAID/NIH 1970 A-G Y657C SH2 
Job C005 NIAID/NIH 1909 G-A V637M SH2 
Job C006 NIAID/NIH 2003 C-T S668F SH2 
Job C007 NIAID/NIH 1865 C-T T622I SH2 
Job C008 NIAID/NIH 1387-1389 delGTG V463del DNA binding 
Job C009 NIAID/NIH 1144 C-T R382W DNA binding 
Job C010 NIAID/NIH 2137 G-A V713M Transactivation 
Job C011 NIAID/NIH 1294 G-A V432M DNA binding 
Job C012 NIAID/NIH 1144 C-T R382W DNA binding 
Job C013 NIAID/NIH 1145 G-A R382Q DNA binding 
Job C014 NIAID/NIH 1145 R-A R382Q DNA binding 
NIAID: National Institute of Allergy and Infectious Diseases; NIH: National Institute    
            of Health 
Nucleotide Key: A- Adenine, G- Guanine, C- Cytosine, T- Thymine   
Amino acid key: C-Cysteine, F- Phenylalanine, I- Isoleucine, M- Methionine,  
                          P- Proline, Q- Glutamine, R- Arginine, S- Serine, T- Threonine, V-            
                          Valine, W- Tryptophan, Y- Tyrosine  
del: deletion 
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 2.3.1 NK Cells from Job Syndrome Patients 
2.3.1.1 Impaired Cytotoxicity of NK Cells in Job Syndrome Patients  
 
I assessed basal cytotoxicity of NK cells from Job syndrome patients against 
K562, an NK sensitive human erythroleukemic cell line (187), which is a standard target 
routinely used to measure NK cytolytic function using purified NK cells (188, 189) as 
well as PBMCs (190, 191). Due to limited availability of Job syndrome blood samples, 
instead of purified NK cells, PBMCs were used in the cytotoxicity assays. Due to 
varying percentage of NK cells in the PBMCs, assays were performed in pairs of 
PBMCs from one Job syndrome patient and PBMCs from a normal, healthy donor 
containing similar percentage of NK cells (Figure 2a). Number of PBMCs used in the 
paired assay was adjusted in order to get identical number of NK cells for both, Job 
syndrome and normal donor. Comparison between Job syndrome patient and its 
correspondingly matched normal donors showed diminished NK cytotoxicity in Job 
syndrome patients over a wide range of effector: target ratios (Figure 2a). As the 
assays were performed with PBMCs with varying number of NK cells, for bulk 
comparison between all the Job syndrome donors and normal donors, lytic unit, defined 
as the number of NK cells required to kill a specified percentage of target cells, was 
determined from the cytotoxicity curve of each individual sample. Job syndrome 
patients were found to have significantly reduced number of lytic units compared to 
normal donors (Figure 2b). These results showed that NK cells with dominant negative 
STAT3 mutations have impaired cytolytic function.    
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Figure 2. Deficient cytolytic function in NK cells from Job syndrome patients.  
(a) Cytotoxicity of NK cells was assessed against K562 using PBMCs employing 
calcein release assay at different effector to target ratios (E:T). Assay for each donor 
was performed in triplicates for each E:T ratio. Data is presented as mean ± standard 
deviation (SD) for each E:T ratio for each donor. Due to varying percentage of NK cells 
in the PBMCs, assays were performed in pairs of PBMCs from one Job syndrome 
patient and PBMCs from a normal, healthy donor containing similar percentage of NK 
cells. Number of PBMCs used in the paired assay was adjusted in order to get identical 
number of NK cells for both, Job syndrome and normal donor. Data is presented in a 
graphical form by plotting percentage specific lysis against its corresponding E:T ratio. 
The flow-cytometry graphs beside the cytotoxicity plots show the percentage of NK 
cells (CD3- CD56+) in PBMCs. (b) Significantly reduced number of lytic units in Job 
syndrome patients. Lytic unit, defined as the number of NK cells required to kill a 
specified percentage of target cells, was determined from the cytotoxicity curve of each 
individual sample obtained in the calcein assay. A specific percentage of target cell 
lysis was selected based on the criterion that the standard curves of all the samples in 
the relevant data set crossed the reference percentage exactly once. Based on this 
criterion, number of NK cells required to kill 5% of target cells were defined as one lytic 
unit for the comparison between normal donors and Job syndrome patients. The E:T 
ratio corresponding to the reference percentage was interpolated from the standard 
curve. The number of NK cells were obtained using the formula [(E:T ratio x 10000 x % 
of NK cells in PBMCs)/100]. Lytic units per one million NK cells were obtained 
according to the formula (1000,000/number of NK cells in one lytic unit). Lytic unit of 
each donor is shown along with the mean for the group. P value indicated is for two-
tailed Student’s t test. 
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2.3.1.2 Receptor Expression in NK Cells from Job Syndrome Patients  
            
Target cell lysis by NK cell is the culmination of a complex series of events 
mediated by various types of receptors expressed on NK cell surface. Initial tethering 
and later firm adhesion with target cell are mediated through adhesion receptors such 
as L-selectin (CD62L) and macrophage receptor 1 (CD11b) (158). The activating 
receptors upon binding to their ligands transmit signals to activate exocytosis of lytic 
granules. Signals relayed by a large array of activating receptors such as natural 
cytotoxicity receptor (NCR) family (NKp30, NKp44, NKp46), NKG2D, DNAM1, 2B4 and 
CD160, expressed on NK cells, have been shown to induce NK cytotoxicity (14, 15). 
Signals transmitted by inhibitory receptors belonging to killer cell immunoglobulin-like 
receptor (KIR) family (KIR2DL1, KIR2DL2/3, KIR3DL1) and CD94-NKG2A inhibit the 
cytolytic process (15, 192). The cytolytic activity of NK cells is the net result of the 
balance between the strengths of activating and inhibitory signals (8). Cytotoxic 
potential of mature NK cells is indicated by the expression of low affinity Fc receptor 
CD16 (193) and epitope CD57 (194) and the absence of TNF receptor family member 
CD27 (195). Priming of NK cells for cytotoxic action is denoted by the expression of 
CD69 and absence of CD25 (196). 
I assessed expression of the different receptors and maturation and activation 
markers in NK cells from Job syndrome patients by flow-cytometry to investigate 
whether the deficient cytotoxicity is due to the impaired receptor expression. The cells 
were found to have normal expression of all the surface molecules except the 
activating receptor NKG2D (Figure 3). Both, number of NK cells expressing NKG2D 
(Figure 3a) as well as receptor density per cell (Figure 3b) were found to be 
significantly reduced compared to NK cells from normal donors.  
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Figure 3. Significantly reduced expression of NKG2D receptor in Job syndrome 
patients’ NK cells. Basal expression of receptors showed no difference between NK 
cells from normal donors and Job syndrome patients, except NKG2D. Expression of 
NKG2D was significantly reduced in Job syndrome patients’ NK cells both in terms of 
number of NK cells expressing NKG2D, shown as percentage of NK cells expressing 
the receptor, as well as receptor density per cell, depicted as mean fluorescence 
intensity (MFI). PBMCs isolated from normal donors and Job syndrome patients were 
analyzed by flow-cytometry to assess baseline expression of different types of 
receptors on NK cells. In the flow-cytometric analysis of PBMCs, lymphocyte population 
was distinguished by their forward scatter and side scatter characteristics and from this 
gated population, NK cells were identified by gating CD56+ CD3- cells (a). Expression 
of different types of receptors; (a) activating, (c) adhesion (d) maturation markers (e) 
priming markers and (f) inhibitory was assessed and depicted as percentage of NK 
cells expressing the receptor. Each panel also shows representative flow charts 
comparing expression of the receptors in that particular category between a normal 
donor and Job syndrome patient. Panel b depicts receptor density per cell, shown as 
mean fluorescence intensity (MFI), of NKG2D.  
In each graph values for individual donor are shown along with the mean for the group. 
P value indicated is for two-tailed Student’s t test.  
“The percentage of NK cells expressing NKG2D receptor (Panel a) and NKG2D 
MFI (Panel b) shown in this figure were originally published in Blood. Zhu S, 
Phatarpekar PV*, Denman CJ, Senyukov VV, Somanchi SS, Nguyen-Jackson HT, Mace EM, 
Freeman AF, Watowich SS, Orange JS, Holland SM, Lee DA. Transcription of the activating 
receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood. 
2014;124(3):403-411. © the American Society of Hematology."                 *Co-first Author 
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2.3.1.3 Cellular Processes Involved in Cytolytic Function of Job Syndrome 
Patients’ NK Cells 
 
 Degranulation at the interface of NK and target cell leading to target cell lysis is 
the end result of a series of cellular processes. The process is set in motion by immune 
synapse formation between NK and target cells. Accumulation of F-actin at the syn-
apse leads to its maturation. Signals transmitted by activating receptors clustered at the 
mature synapse cause convergence of lytic granules dispersed throughout the cell to 
MTOC and subsequent polarization of MTOC to synapse for directed secretion of lytic 
granule contents into the synaptic cleft. Defect in all or any of these processes affects 
NK cytotoxicity (158). To investigate whether these cellular processes are intact in Job 
syndrome patients’ NK cells, I studied synaptic strength, granule convergence to 
MTOC and MTOC polarization to synapse in fixed conjugates of NK cells with K562 us-
ing confocal microscopy 
2.3.1.3.1 Synaptic Strength 
 
 F-actin accumulation at the interface of NK and target cell is the pivotal step in 
synapse formation, which enables clustering of activating receptors and subsequent 
integration of activating signals that mediate granule convergence to MTOC and later 
MTOC polarization to the synapse (159). As a result, amount of F-actin deposited at 
the NK: target interface reflects strength of the synapse and is used as a measure of it 
(184). To measure amount of F-actin, in fixed, permeabilized NK: K562 conjugates 
fluorescent phalloidin, an F-actin binding peptide (197), was used. The signal intensity 
of phalloidin fluorophore at the interface of NK and target and the area occupied by 
fluorescent phalloidin at the interface were measured in confocal micrographs. The F-
actin density at the synapse was estimated by multiplying signal intensity of fluorescent 
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phalloidin with the area occupied by F-actin (184). Synapse strength estimated by this 
method in >60 conjugates, pooled from four donors each, of Job syndrome patients’ 
and normal donors’ NK cells showed no difference between the two (Figure 4e). Thus, 
upon binding to the target formation of synapse appeared to be normal in Job 
syndrome patients’ NK cells.  
2.3.1.3.1 Granule Convergence 
 
 Directed secretion of perforin and granzyme into the synaptic cleft is initiated by 
recruitment of lytic granules dispersed throughout the cell to the MTOC, called as 
granule convergence (158). Granule convergence to MTOC was measured as the 
distance between a lytic granule, visualized by staining with fluorochrome conjugated 
perforin antibody, and the MTOC, visualized by staining with biotinylated conjugated 
anti-tubulin antibody and fluorochrome conjugated streptavidin, in a confocal 
micrograph of a fixed conjugate between NK and K562. Average of granule-MTOC 
distance for all the granules in a cell was denoted as the mean granule to MTOC 
distance for the cell. Granule convergence measured in >60 conjugates, pooled from 
four donors each, of Job syndrome patients and normal donors NK cells showed no 
difference between the two (Figure 4f).  
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Figure 4. Normal actin deposition at the synapse and granule convergence to 
microtubule organizing center (MTOC), but impaired MTOC polarization in Job 
syndrome patients’ NK cells.  PBMCs and K562 cells were incubated together to 
facilitate conjugate formation between the two. The cells were placed on poly-L-lysine 
coated glass slides. The cells attached to the slide were permeabilized and stained with 
fluorochrome conjugated phalloidin, fluorochrome conjugated anti-perforin antibody and 
biotinylated anti-tubulin antibody and fluorochrome-conjugated streptavidin. Phalloidin, 
anti-tubulin and anti-perforin were used to stain F-actin, MTOC and lytic granules, 
respectively. The conjugates were imaged using scanning confocal microscope. The 
images were analyzed using Volocity software. Representative brightfield image and its 
corresponding confocal image show conjugate formed between an NK cell from normal 
donor and K562 (a and b) and an NK cell from Job syndrome patient and K562 (c and 
d). In the image, NK cell was distinguished from K562 on the basis of cell size (NK 
smaller compared to K562) and the presence of perforin (present in NK and absent in 
K562). F-actin deposited at the interface of the conjugate, immune synapse, is stained 
with phalloidin (red). MTOC is stained with anti-tubulin (yellow) and lytic granules are 
stained with anti-perforin (green). (e) Synaptic strength was measured in terms of 
amount F-actin deposited at the interface of NK and K562. To quantify F-actin, signal 
intensity of phalloidin fluorophore at the interface of NK and target and the area 
occupied by fluorescent phalloidin at the interface were measured in confocal 
micrographs using Volocity software. The F-actin density at the synapse was estimated 
by multiplying signal intensity of fluorescent phalloidin with the area occupied by F-
actin. Synapse strength estimated by this method in conjugates, pooled from four 
donors each, of normal donors and Job syndrome patients is represented in graphical 
form. (f) Granule convergence to MTOC was defined as the shortest distance between 
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each individual granule and MTOC in the NK cell in conjugation with K562. Lytic 
granules were identified by staining with anti-perforin antibody and MTOC was 
recognized by staining with anti-tubulin antibody. The distance between MTOC and 
each lytic granule in a conjugated NK cell was measured using Volocity software. 
Average of granule-MTOC distance for all the granules in a cell was denoted as the 
mean granule to MTOC distance for the cell. Granule convergence measured in 
conjugates, pooled from four donors each, of normal donors and Job syndrome 
patients is represented in graphical form. Each data point represents mean granule to 
MTOC distance for an individual NK cell in conjugation with K562. (g) MTOC 
polarization was defined as the distance between the MTOC of an NK cell, visualized 
by staining with anti-tubulin antibody, and the immune synapse, demarcated as the 
contact area between the NK and K562 in a conjugate and stained with fluorochrome 
conjugated phalloidin.  The distance was measured by drawing a line between the 
MTOC and the center of immune synapse in a confocal image using Volocity software. 
MTOC polarization measured in conjugates, pooled from four donors each, of normal 
donors and Job syndrome patients is represented in graphical form.  
In each graph mean for the group is denoted. P value indicated is for two-tailed 
Student’s t test. 
   
 Confocal microscopic analysis of subcellular cytolytic processes and data 
processing were performed by my collaborator, Dr. Malini Mukherjee in Dr. 
Jordan Orange laboratory at the section of Immunology, Allergy, and 
Rheumatology, Baylor College of Medicine, Houston, Texas. 
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2.3.1.3.2 MTOC Polarization to the Synapse 
 
  Signals transmitted by activating receptors, clustered at the mature synapse, 
induce migration of MTOC in NK cell towards the synapse. MTOC along with it also 
brings the converged granules to the synapse. It is a critical step in the directed 
secretion of lytic content (185). MTOC polarization to the synapse was assessed by 
measuring the distance between the MTOC and the center of the synapse in confocal 
micrographs of NK cells conjugated with K562. MTOC polarization measured in >60 
conjugates, pooled from four donors each, of Job syndrome patients and normal 
donors NK cells showed MTOC to be at a significantly greater distance from the 
synapse in Job syndrome patients NK cells compared to normal donors (Figure 4g). 
The larger distance between the MTOC and synapse in Job syndrome patients’ NK 
cells indicated impaired polarization of MTOC and lytic granules. 
  Thus, even though the initial events of synapse formation and granule 
convergence occurred normally, transport of lytic cargo to the synapse was found to be 
defective in NK cells from Job syndrome patients. 
2.3.2 STAT3 Knock-Down in NK Cells 
 
To corroborate my finding of impaired cytotoxicity and cellular processes 
involved in cytolytic function in NK cells with dominant negative STAT3 mutations and 
to obtain unequivocal evidence for the role of STAT3 in the regulation of NK cytolytic 
function, I also evaluated cytolytic function in STAT3 knock-down (STAT3 KD) primary 
human NK cells.  
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2.3.2.1 siRNA Mediated Knock-Down of STAT3 
 
Purified human NK cells from normal donors maintained overnight with 50 U/ml 
IL-2 were electroporated with control and STAT3 siRNA and cultured thereafter with 50 
U/ml IL-2 for 48 hours before analysis. Calibration of STAT3 siRNA concentration 
showed incremental decrease in STAT3 mRNA expression in RT-PCR analysis. 
However, at concentration above 0.25 μm along with STAT3, GAPDH mRNA also 
started decreasing indicating non-specific effect (Figure 5a). As a result, 0.25 μm 
siRNA was used for rest of the studies. At 0.25 μm siRNA, STAT3 mRNA expression, 
quantified by ImageJ software and normalized to GAPDH, showed about 80% 
decrease compared to control siRNA (Figure 5a and 5b). STAT3 protein expression 
analyzed by western-blot also showed a corresponding decrease (Figure 5c).  RT-PCR 
analysis showed no effect of STAT3 siRNA on the expression of STAT1, STAT5a and 
STAT5b mRNA (Figure 5b), STAT family members closely related to STAT3 (198, 
199). Cell viability, analyzed by trypan blue exclusion method, was not affected by 
STAT3 knock-down 48 hr post electroporation (Figure 5d).    
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Figure 5. STAT3 siRNA mediated about 80% decrease in STAT3 mRNA and 
protein expression in primary human NK cells without any effect on the 
expression of other STATs and cell viability. Purified human NK cells from normal 
donors maintained overnight with 50 U/ml IL-2 were electroporated with control or 
STAT3 siRNA and cultured thereafter with 50 U/ml IL-2 for 48 hours before analysis. 
Knock-down of mRNA was assessed by semi-quantitative RT-PCR using gene specific 
primers. The RT-PCR products were analyzed by electrophoresis through 1.2% 
agarose gel. Gel was imaged and the RT-PCR bands were quantified using ImageJ 
software. Relative band intensities of target genes were normalized to GAPDH and 
converted to percentage expression by considering expression in control siRNA treated 
cells as 100%. (a) Calibration of STAT3 siRNA concentration showed incremental 
decrease in STAT3 mRNA as visualized in the gel image and its quantification plotted 
as percentage STAT3 expression. However, at concentration above 0.25 μm along 
with STAT3, GAPDH mRNA also started decreasing indicating non-specific effect. As a 
result, 0.25 μm siRNA concentration was used for rest of the studies (b) mRNA levels 
of STAT3, STAT1, STAT5a, STAT5b, and GAPDH in NK cells electroporated with 0.25 
μm siRNA were analyzed by semi-quantitative RT-PCR. The gels were imaged and the 
bands were quantified as described above. The gel image shown is a representative of 
multiple experiments. The graph beside the gel depicts quantification of RT-PCR bands 
normalized to GAPDH and represented as percentage expression. N denotes number 
of times the experiment was repeated (c) STAT3 knock down was also analyzed at the 
protein level by western-blot. Protein lysate, 15 μg/lane, resolved by SDS-PAGE and 
transferred to PVDF membrane, was probed with anti-STAT3 and anti-β-actin (loading 
control) antibodies. The bands were quantified by ImageJ software. Relative band 
intensities were normalized to β-actin and converted to percentage expression by 
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considering expression in control siRNA treated cells as 100%. The upper panel shows 
western gel image and lower panel depicts quantification in graphical form (d) Cell 
viability of siRNA treated cells was assessed by trypan blue exclusion method. N 
denotes number of times the experiment was repeated.     
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2.3.2.2 Impaired Cytotoxicity of STAT3 Knock-Down NK Cells 
 
Assessment of cytolytic activity by calcein release assay against K562 revealed 
small but consistent decrease in cytotoxicity of STAT3 knock-down NK cells compared 
to control cells over a wide range of E:T ratios (Figure 6a). Comparison between 
control cells and STAT3 knock-down cells also showed significantly diminished number 
of lytic units in the latter (Figure 6b). 
2.3.2.3 Single Cell Analysis of Cytotoxicity of STAT3 Knock-Down NK Cells 
 
In bulk electroporation, as was performed in the present study to knock-down 
STAT3 in primary human NK cells, all the cells may not be electroporated, leaving 
some cells without knock-down of the target mRNA. These cells, electroporated in bulk, 
if used in a bulk assay such as the calcein assay employed in the present study to 
assess the cytotoxicity of NK cells, then the cells with intact STAT3, even if few, could 
skew the output. The possibility of existence of cells with intact STAT3 in STAT3 knock-
down bulk population may explain the difference between the cytotoxicity of control 
cells and STAT3 knock-down cells being smaller as these cells with intact killing 
capacity through encounters with multiple target cells may compensate for the cytolytic 
deficiency of rest of the cells. Therefore, cytotoxicity of STAT3 knock-down NK cell at a 
single cell level was also analyzed. NK cell and K562 cell interactions were studied 
using the single cell assay, TIMING (Timelapse Imaging Microscopy in Nanowell 
Grids), as described previously (182) (Figure 7a). Among NK cells that established at 
least one contact with the target cell (K562) in nanowells containing exactly 1 NK cell 
and 1 K562 cell (number of nanowells=791 and 1010, respectively for conditions with 
STAT3 knock-down and control NK cells), STAT3 knock-down NK cells were able to 
perform lysis (detected using Annexin V staining) at a lower frequency (35%) compared 
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to control NK cells (43%) (Figure 7b). Serial killing ability of NK cells was also assessed 
by measuring killing frequency in nanowells containing exactly 1 NK cell and 2 K562 
cells and where NK cell made at least 2 contacts with the target cells (number of 
nanowells=463 and 388, respectively for conditions with STAT3 knock-down and 
control NK cells). STAT3 knock-down NK cells were able to perform lysis of both the 
target cells at a lower frequency (28.7%) compared to control NK cells (37.4%) (Figure 
7c). 
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Figure 6. Impaired cytolytic function in STAT3 knock-down NK cells.  
(a) Purified human NK cells from normal donors maintained overnight with 50 U/ml IL-2 
were electroporated with control or STAT3 siRNA and cultured thereafter with 50 U/ml 
IL-2 for 48 hours before assessment of their cytotoxicity against K562 using calcein 
assay. Assay for each donor was performed in triplicates for each E:T ratio. Data is 
presented as mean ± standard deviation (SD) for each E:T ratio for each donor. The 
experiment was repeated three times with three different donors. 
(b) Lytic unit, defined as the number of NK cells required to kill a specified percentage 
of target cells, was determined from the cytotoxicity curve of each individual sample 
obtained in the calcein assay. A specific percentage of target cell lysis was selected 
based on the criterion that the standard curves of all the samples in the relevant data 
set crossed the reference percentage exactly once. Based on this criterion, number of 
NK cells required to kill 75% of target cells were defined as one lytic unit for the 
comparison between control and STAT3 knock-down (STAT3 KD). The E:T ratio 
corresponding to the reference percentage was interpolated from the standard curve. 
The number of NK cells in the lytic unit were obtained by multiplying the interpolated 
E:T ratio by 10000 (the number of target cells in each well). Lytic units per one million 
NK cells were obtained according to the formula (1,000,000/number of NK cells in one 
lytic unit). Lytic unit of each donor is shown along with the mean for the group. P value 
indicated is for two-tailed paired Student’s t test.  
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Figure 7. Analysis of cytotoxicity at the single cell level demonstrated cytolytic 
function and serial killing ability of STAT3 knock-down NK cells to be impaired. 
The single-cell cytotoxicity assay was performed using fabricated nanowell arrays. 
STAT3 siRNA – or control siRNA- electroporated NK cells (effectors) and K562 cells 
(targets), labeled with green PKH67 and red PKH26, respectively, were loaded 
sequentially onto the nanowell array. The entire array chip was immersed in phenol red 
free complete medium containing AnnexinV-AlexaFluor-647. Timelapse imaging 
microscopy in nanowell grids (TIMING) images were taken for 8 hours at intervals of 6 
minutes  (a) Representative example of a nanowell containing a K562 cell (red, stained 
with PKH red) and a control NK cell (green, stained with PKHgreen). Scale bar 10 µm 
(b) Among NK cells that established at least one contact with the target cell in 
nanowells containing exactly 1 NK cell and 1 K562 cell (E:T -1:1), cytotoxicity of NK cell 
was assessed by detecting lysis of K562, identified using Annexin V staining, and by 
counting the number of wells in which the lysis occurred. The tabular presentation of 
the data shows the total number of wells, the number of wells in which the target was 
killed and not killed and the percentage of target cells killed for STAT3 knock-down 
(STAT3 KD) and control conditions. The charts beside the tables represent the same 
data in a graphical form (c) The serial killing ability of NK cells was assessed by 
measuring killing frequency in nanowells containing exactly 1 NK cell and 2 K562 cells 
(E:T-1:2) and where NK cell made at least 2 contacts with the target cells resulting in 
the death of both. The tabular presentation of the data shows the total number of wells, 
the number of wells in which the target was killed and not killed and the percentage of 
target cells killed for STAT3 knock-down (STAT3 KD) and control conditions. The 
charts beside the tables represent the same data in a graphical form. P values 
indicated are for Fisher’s exact test used for the analysis of contingency tables. 
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 The single cell cytotoxicity assay was performed by collaborators Drs. 
Gabrielle Romain and Navin Varadrajan at the Department of Chemical and 
Biomolecular Engineering, University of Houston, Houston, TX. 
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2.3.2.1 Receptor Expression in STAT3 Knock-Down NK Cells 
 
No difference in the expression of adhesion, activating and inhibitory receptors 
and maturation and activation markers was observed between STAT3 knock-down NK 
cells and control cells (Figure 8a-e). Unlike in Job syndrome patients’ NK cells, NKG2D 
was normally expressed in STAT3 knock-down NK cells (Figure 8a). 
2.3.2.2 Cellular Processes Involved in Cytolytic Function of STAT3 Knock-   
Down NK Cells 
Analysis of synapse strength, granule convergence and MTOC polarization in 
STAT3 knock-down NK cells showed recapitulation of cellular process phenotype that 
was observed in Job syndrome patients’ NK cells.  
Synapse strength measured in terms of actin density at the synapse was found 
to be no different between STAT3 knock-down NK cells and control cells conjugated 
with K562, indicating no effect of STAT3 deficiency on synapse strength (Figure 9e and 
h). 
Comparison of granule convergence estimated as the average of lytic granule to 
MTOC distance for all the granules in the cell was found to be greater in STAT3 knock-
down NK cells compared to control cells. However, the difference was statistically not 
significant (Figure 9f and I). 
 MTOC polarization to the synapse assessed by measuring the distance between 
the MTOC and the center of the synapse was found to be significantly greater in 
STAT3 knock-down NK cells compared to normal donors (Figure 9g and J). This 
finding corroborated impaired MTOC polarization observed in NK cells from Job 
syndrome patients and revealed requirement of STAT3 for this cellular process. 
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Figure 8. No difference in the expression of receptors between control and 
STAT3 knock-down (STAT3 KD) NK cells. Purified human NK cells from normal 
donors maintained overnight with 50 U/ml IL-2 were electroporated with control or 
STAT3 siRNA and cultured thereafter with 50 U/ml IL-2 for 48 hours before assessment 
of expression of different types of receptors by flow-cytometry. In the flow-cytometric 
analysis, lymphocyte population was distinguished by their forward scatter and side 
scatter characteristics and from this gated population, NK cells were identified by gating 
CD56+ CD3- cells (a). Expression of different types of receptors; (a) activating, (b) 
adhesion (c) maturation markers (d) priming markers and (e) inhibitory was assessed 
and depicted as percentage of NK cells expressing the receptor. Each panel also 
shows representative flow charts comparing expression of the receptors in that 
particular category between control and STAT3 knock-down (STAT3 KD) NK cells. In 
each graph values for individual donor are shown along with the mean for the group. 
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Figure 9. Normal actin deposition at the synapse and granule convergence, but 
impaired microtubule organizing center (MTOC) polarization in STAT3 knock-
down NK cells.  Purified human NK cells from normal donors maintained overnight 
with 50 U/ml IL-2 were electroporated with control or STAT3 siRNA and cultured 
thereafter with 50 U/ml IL-2 for 48 hours before assessment of cellular processes 
involved in cytolytic function. NK and K562 cells were incubated together to facilitate 
conjugate formation between the two. The cells were placed on poly-L-lysine coated 
glass slides. The cells attached to the slide were permeabilized and stained with 
fluorochrome conjugated phalloidin, fluorochrome conjugated anti-perforin antibody and 
biotinylated anti-tubulin antibody and fluorochrome conjugated streptavidin. Phalloidin, 
anti-tubulin and anti-perforin were used to stain F-actin, MTOC and lytic granules, 
respectively. The conjugates were imaged using scanning confocal microscope. The 
images were analyzed using Volocity software. The experiment was repeated two 
times with two different donors. Representative brightfield image and its corresponding 
confocal image show conjugate formed between a control NK cell and K562 (a and b) 
and a STAT3 knock-down NK cell and K562 (c and d). In the image, NK cell was 
distinguished from K562 on the basis of cell size (NK smaller compared to K562) and 
the presence of perforin (present in NK and absent in K562). F-actin deposited at the 
interface of the conjugate, immune synapse, is stained with phalloidin (red). MTOC is 
stained with anti-tubulin (yellow) and lytic granules are stained with anti-perforin 
(green). (e,h) Synaptic strength was measured in terms of amount F-actin deposited at 
the interface of NK and K562. To quantify F-actin, signal intensity of phalloidin 
fluorophore at the interface of NK and target and the area occupied by fluorescent 
phalloidin at the interface were measured in confocal micrographs using Volocity 
software. The F-actin density at the synapse was estimated by multiplying signal 
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intensity of fluorescent phalloidin with the area occupied by F-actin. Synapse strength 
estimated by this method in conjugates is represented in graphical form. (f,i) Granule 
convergence to MTOC was defined as the shortest distance between each individual 
granule and MTOC in the NK cell in conjugation with K562. Lytic granules were 
identified by staining with anti-perforin antibody and MTOC was recognized by staining 
with anti-tubulin antibody. The distance between MTOC and each lytic granule in a 
conjugated NK cell was measured using Volocity software. Average of granule-MTOC 
distance for all the granules in a cell was denoted as the mean granule to MTOC 
distance for the cell. Granule convergence measured in conjugates is represented in 
graphical form. Each data point represents mean granule to MTOC distance for an 
individual NK cell in conjugation with K562. (g,j) MTOC polarization was defined as the 
distance between the MTOC of an NK cell, visualized by staining with anti-tubulin 
antibody, and the immune synapse, demarcated as the contact area between the NK 
and K562 in a conjugate and stained with fluorochrome conjugated phalloidin.  The 
distance was measured by drawing a line between the MTOC and the center of 
immune synapse in a confocal image using Volocity software. MTOC polarization 
measured in conjugates is represented in graphical form.  
In each graph mean for the group is denoted. P value indicated is for two-tailed 
Student’s t test. 
Confocal microscopic analysis of subcellular cytolytic processes and data 
processing were performed by my collaborator, Dr. Malini Mukherjee in Dr. 
Jordan Orange laboratory at the section of Immunology, Allergy, and 
Rheumatology, Baylor College of Medicine, Houston, Texas. 
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2.3.3 Molecular Mechanism Underlying Impaired MTOC Polarization  
 
Upon converging to the MTOC, lytic granules along with MTOC start polarizing 
toward the immune synapse. The molecular players involved in this mobilization have 
been identified. CDC42 interacting protein 4 (CIP4), is one of the essential components 
of the molecular machinery driving MTOC polarization. Silencing of CIP4 expression in 
NK cells inhibits MTOC polarization (185). Lytic granules and MTOC polarize to 
immune synapse by moving along microtubules with the help of the motor protein 
kinesin family member 5B (KIF5B). A lytic granule associated small G-protein, ADP-
ribosylation factor like 8b (Arl8b), links the lytic granule to KIF5B. Silencing of Arl8b and 
KIF5B in NK cells impairs lytic granule and MTOC polarization to the immune synapse 
signifying their key role in the process (200).  Another member of the MTOC polarizing 
machinery is IQGAP1, a multi-domain scaffolding protein that interacts with both F-
actin and microtubules, whose silencing also inhibits MTOC polarization (201).  
To investigate the cause for impaired MTOC polarization in STAT3 knock-down 
NK cells, I analyzed gene expression of Arl8b, KIF5B, CIP4 and IQGAP1 by real-time 
PCR. Expression of Arl8b, KIF5B and IQGAP1 was similar in STAT3 knock-down and 
control cells (Figure 10a-c). But the expression of CIP4 was significantly lower in 
STAT3 knock-down cells (Figure 10d), suggesting it as a likely cause for impaired 
MTOC polarization in STAT3 knock-down NK cells.  
 I also assessed expression of CIP4 in Job syndrome patients’ NK cells. 
However, unlike STAT3 knock-down NK cells, CIP4 gene expression was found to be 
normal in Job syndrome patients’ NK cells (Figure 10e). This result indicated that a 
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different mechanism is responsible for impaired MTOC polarization in Job syndrome 
patients’ NK cells.     
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Figure 10. No difference in the gene expression of Arl8b, IQGAP1 and KIF5B, 
molecules involved in MTOC polarization, between control and STAT3 knock-
down (STAT3 KD) NK cells, except significantly reduced gene expression of 
CIP4, another molecule required for MTOC polarization, in STAT3 KD NK cells, 
but not in NK cells from Job syndrome patients. Purified human NK cells from 
normal donors maintained overnight with 50 U/ml IL-2 were electroporated with control 
or STAT3 siRNA and cultured thereafter with 50 U/ml IL-2 for 48 hours before 
assessment of gene expression by real-time PCR. For real-time PCR, cDNA was 
synthesized using SuperScript III first strand synthesis supermix. The real-time PCR 
reaction was set up with cDNA and primers listed in Table 2 using IQ SYBR green 
supermix in iCycler real time PCR detection system. Relative gene expression was 
quantified using ΔCT method with GAPDH as the housekeeping gene. Gene expression 
of (a) Arl8b (b) CIP4 (c) IQGAP1 and (d) KI5FB was measured. (e) CIP4 gene 
expression was also evaluated in NK cells from normal donors and Job syndrome 
patients.  
In each graph values for individual donor are shown along with the mean for the group. 
 
P value indicated is for two-tailed paired Student’s t test. 
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2.3.3.1 mbIL21 Expanded Job Syndrome Patients’ NK Cells 
 
Previous work in our lab demonstrated robust expansion of human NK cells 
stimulated with K562 genetically modified to present membrane bound IL-21 (mbIL21). 
These expanded cells had high expression of activating receptors and enhanced 
cytolytic activity (134). IL-21 predominantly activates STAT3 in NK cells (80, 136, 171) 
and as expected mbIL21 induced expansion and activation of NK cells is mediated 
through STAT3 signaling (202). Job syndrome patients have residual STAT3 activity, 
which is 25% of the normal (131). To explore whether stimulation of the residual STAT3 
activity by mbIL21 improves deficient NKG2D receptor expression, MTOC polarization 
and cytotoxicity of Job syndrome patients’ NK cells, I expanded NK cells from PBMCs 
of normal donors and Job syndrome patients, by stimulating them with mbIL21 over 
three weeks. After three weeks of expansion, T cells were depleted to obtain pure NK 
cell population.  
2.3.3.2   Receptor Expression in mbIL21 Expanded NK Cells 
 
 mbIL21 expanded NK cells showed increased expression of all the activating 
receptors analyzed except CD160 over basal expression. CD160 expression 
decreased after expansion. Deficient basal expression of NKG2D in Job syndrome 
patients’ NK cells was restored in mbIL21 expanded NK cells. Almost entire NK cell 
population was NKG2D positive and no difference in expression was observed 
between NK cells from Job syndrome patients and normal donors. Expression levels of 
other activating receptors were also found to be similar between NK cells from Job 
syndrome patients and normal donors, except NKp46 and CD160 (Figure 11a). NKp46 
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expression was significantly higher in Job syndrome patients’ NK cells, while CD160 
expression was significantly higher in NK cells from normal donors (Figure 11a-b). 
Compared to basal expression levels, expression of adhesion receptors, CD11b and 
CD62L, decreased in mbIL21 expanded NK cells. No difference in the expression of 
CD11b was found between NK cells from Job syndrome patients and normal donors, 
but CD62L expression was significantly higher in NK cells from normal donors (Figure 
11c-d). Among maturation markers, compared to basal expression levels, CD16 
expression showed increased, while CD27 and CD57 expression decreased in mbIL21  
expanded NK cells. No difference in expression was observed between NK cells from 
Job syndrome patients and normal donors (Figure 11e). Expression of activation 
marker CD25 did not change upon expansion, while CD69 expression increased over 
the basal levels. No difference in expression was observed between NK cells from Job 
syndrome patients and normal donors (Figure 11f). Expression of all the inhibitory 
receptors assessed increased in mbIL21 expanded NK cells and similar expression 
levels were observed in NK cells from Job syndrome patients and normal donors 
(Figure 11g). 
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Figure 11. Job syndrome NK cells expanded with mbIL21 stimulation had 
enhanced expression of NKG2D receptor, which was similar to the expression of 
NKG2D in mbIL21 expanded NK cells from normal donors. The level of 
expression of other receptors in mbIL21 expanded NK cells was also similar 
between Job syndrome and normal donors, except NKp46, whose expression 
was higher in the former and CD160 and CD62L, whose expression was higher in 
the latter. NK cells were expanded from PBMCs stimulated with K562s, genetically 
modified to present membrane bound IL-21 (mbIL21), over a three week period. 
Receptor expression was measured by flow-cytometry. In the flow-cytometric analysis, 
lymphocyte population was distinguished by their forward scatter and side scatter 
characteristics and from this gated population, NK cells were identified by gating CD56+ 
CD3- cells (a). Expression of different types of receptors; (a) activating, (c) adhesion (e) 
maturation markers (f) priming markers and (g) inhibitory was assessed and depicted 
as percentage of NK cells expressing the receptor. Each panel also shows 
representative flow charts comparing expression of the receptors in that particular 
category between a normal donor and Job syndrome patient. Panel b depicts receptor 
density per cell, shown as mean fluorescence intensity (MFI), of NKp46 and CD160. 
Panel d portrays MFI of CD62L.  
In each graph values for individual donor are shown along with the mean for the group. 
P values indicated are for two-tailed Student’s t test. 
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2.3.3.3     Cellular Processes Involved In Cytolytic Function of mbIL21 
Expanded NK Cells 
 
Comparison between mbIL21 expanded NK cells from Job syndrome patients 
and normal donors, pooled from three donors each, showed no difference in the 
synaptic strength and granule convergence (Figure 12e-f). Impaired MTOC polarization 
observed in un-stimulated Job syndrome patients’ NK cells were corrected in the 
mbIL21-expanded cells. The MTOC to synapse distance was similar in NK cells from 
Job syndrome patients and normal donors after mbIL21 expansion (Figure 12g). 
2.3.3.4      Cytotoxicity of mbIL21 Expanded NK Cells 
 
mbIL21 expanded NK cells from Job syndrome patients and normal donors 
showed enhanced cytotoxicity. The cytotoxicity of NK cells from normal donors was 
marginally higher than the NK cells from Job syndrome patients (Figure 13a). NK cells 
from normal donors had marginally higher number of lytic units than NK cell from Job 
syndrome patients, but the difference was statistically not significant (Figure 13b).  
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Figure 12. Impaired MTOC polarization observed in un-stimulated Job syndrome 
patients’ NK cells was corrected in the mbIL21 expanded cells. The MTOC to 
synapse distance was similar in NK cells from Job syndrome patients and 
normal donors after mbIL21 expansion. NK cells were expanded from PBMCs 
stimulated with K562s, genetically modified to present membrane bound IL-21 
(mbIL21), over a three week period. NK and K562 cells were incubated together to 
facilitate conjugate formation between the two. The cells were placed on poly-L-lysine 
coated glass slides. The cells attached to the slide were permeabilized and stained with 
fluorochrome conjugated phalloidin, fluorochrome conjugated anti-perforin antibody and 
biotinylated anti-tubulin antibody and fluorochrome conjugated streptavidin. Phalloidin, 
anti-tubulin and anti-perforin were used to stain F-actin, MTOC and lytic granules, 
respectively. The conjugates were imaged using scanning confocal microscope. The 
images were analyzed using Volocity software. Representative brightfield image and its 
corresponding confocal image show conjugate formed between an NK cell from normal 
donor and K562 (a and b) and an NK cell from Job syndrome patient and K562 (c and 
d). In the image, NK cell was distinguished from K562 on the basis of cell size (NK 
smaller compared to K562) and the presence of perforin (present in NK and absent in 
K562). F-actin deposited at the interface of the conjugate, immune synapse, is stained 
with phalloidin (red). MTOC is stained with anti-tubulin (yellow) and lytic granules are 
stained with anti-perforin (green). (e) Synaptic strength was measured in terms of 
amount F-actin deposited at the interface of NK and K562. To quantify F-actin, signal 
intensity of phalloidin fluorophore at the interface of NK and target and the area 
occupied by fluorescent phalloidin at the interface were measured in confocal 
micrographs using Volocity software. The F-actin density at the synapse was estimated 
by multiplying signal intensity of fluorescent phalloidin with the area occupied by F-
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actin. Synapse strength estimated by this method in conjugates, pooled from three 
donors each, of normal donors and Job syndrome patients is represented in graphical 
form. (f) Granule convergence to MTOC was defined as the shortest distance between 
each individual granule and MTOC in the NK cell in conjugation with K562. Lytic 
granules were identified by staining with anti-perforin antibody and MTOC was 
recognized by staining with anti-tubulin antibody. The distance between MTOC and 
each lytic granule in a conjugated NK cell was measured using Volocity software. 
Average of granule-MTOC distance for all the granules in a cell was denoted as the 
mean granule to MTOC distance for the cell. Granule convergence measured in 
conjugates, pooled from three donors each, of normal donors and Job syndrome 
patients is represented in graphical form. Each data point represents mean granule to 
MTOC distance for an individual NK cell in conjugation with K562. (g) MTOC 
polarization was defined as the distance between the MTOC of an NK cell, visualized 
by staining with anti-tubulin antibody, and the immune synapse, demarcated as the 
contact area between the NK and K562 in a conjugate and stained with fluorochrome 
conjugated phalloidin.  The distance was measured by drawing a line between the 
MTOC and the center of immune synapse in a confocal image using Volocity software. 
MTOC polarization measured in conjugates, pooled from three donors each, of normal 
donors and Job syndrome patients is represented in graphical form.  
 Confocal microscopic analysis of subcellular cytolytic processes and data 
processing were performed by my collaborator, Dr. Malini Mukherjee in Dr. 
Jordan Orange laboratory at the section of Immunology, Allergy, and 
Rheumatology, Baylor College of Medicine, Houston, Texas.
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Figure 13. Job syndrome NK cells expanded with mbIL21 stimulation had 
enhanced cytotoxicity, which was marginally lower than the cytotoxicity of 
mbIL21 expanded NK cells from normal donors (a) NK cells were expanded from 
PBMCs stimulated with K562s, genetically modified to present membrane bound IL-21 
(mbIL21), over a three week period. The expanded cells were CD3 depleted. 
Cytotoxicity was assessed using calcein assay. Assay for each donor was performed in 
triplicates for each E:T ratio. Data is presented as mean ± standard deviation (SD) for 
each E:T ratio for each donor. (b) Lytic unit, defined as the number of NK cells required 
to kill a specified percentage of target cells, was determined from the cytotoxicity curve 
of each individual sample obtained in the calcein assay. A specific percentage of target 
cell lysis was selected based on the criterion that the standard curves of all the 
samples in the relevant data set crossed the reference percentage exactly once. Based 
on this criterion, number of NK cells required to kill 75% of target cells were defined as 
one lytic unit for the comparison between control and STAT3 knock-down (STAT3 KD). 
The E:T ratio corresponding to the reference percentage was interpolated from the 
standard curve. The number of NK cells in the lytic unit were obtained by multiplying 
the interpolated E:T ratio by 10000 (the number of target cells in each well). Lytic units 
per one million NK cells were obtained according to the formula (1000,000/number of 
NK cells in one lytic unit). In the graph lytic unit of each donor is shown along with the 
mean for the group.  
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2.3.4 Pharmacological Inhibition of STAT3 Inhibits NK Cytotoxicity 
 
 Constitutively active STAT3 has been shown to be oncogenic in multiple cancers 
and as a result, STAT3 inhibitors have been tested in pre-clinical and clinical studies 
against various types of cancers (140). NK cells due to their inherent anti-cancer 
activity are also fast emerging as a candidate cell for immunotherapy against multiple 
types of cancer (35). The anti-tumor activity of several cytokines is also mediated by 
NK cells (8). As cancer treatment many a times involves combination of different 
treatment modalities, it is imperative to determine the compatibility of different modes of 
treatments with each other. To determine the effect of pharmacological STAT3 
inhibition on NK cytolytic function, I assessed cytotoxicity of NK cells treated with 
STAT3 inhibitor S3I-201. It binds SH2 domain of STAT3 to block dimerization and 
thereby inhibits DNA binding and transcriptional activity of STAT3 (203). It has been 
shown to inhibit tumor growth in pre-clinical studies (198, 203).   
I evaluated cytolytic activity of primary human NK cells from normal donors 
treated overnight with and without 10 μM S3I-201, a concentration shown not to affect 
viability of NK cells in a previous study from our lab (136). Along with the drug 
treatment, the cells were also activated overnight with 100 U/ml IL-2, a concentration 
commonly used to activate cytolytic function of NK cells (204-206). Comparison 
between S3I-201 treated and non- treated NK cells showed a substantial decrease in 
cytotoxicity in S3I-201 treated NK cells against K562 at all the E:T ratios tested (Figure 
14a). S3I-201 treated NK cells had reduced number of lytic units (Figure 14b). The 
results show that pharmacological inhibition STAT3 adversely affects NK cytolytic 
function.   
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Figure 14. Pharmacological inhibition of STAT3 reduces cytolytic function of 
human NK cells (a) Purified human NK cells from normal donors were treated 
overnight with IL-2 in the presence and absence of small molecule STAT3 inhibitor S3I-
201. Control cells were treated with the solvent for the drug DMSO. Cytotoxicity against 
K562 was assessed using calcein assay. Assay for each donor was performed in 
triplicates for each E:T ratio. Data is presented as mean ± standard deviation (SD) for 
each E:T ratio for each donor. The experiment was repeated three times with three 
different donors. (b) Lytic unit, defined as the number of NK cells required to kill a 
specified percentage of target cells, was determined from the cytotoxicity curve of each 
individual sample obtained in the calcein assay. A specific percentage of target cell 
lysis was selected based on the criterion that the standard curves of all the samples in 
the relevant data set crossed the reference percentage exactly once. Based on this 
criterion, number of NK cells required to kill 25% of target cells were defined as one 
lytic unit for the comparison between control and STAT3 knock-down (STAT3 KD). The 
E:T ratio corresponding to the reference percentage was interpolated from the standard 
curve. The number of NK cells in the lytic unit were obtained by multiplying the 
interpolated E:T ratio by 10000 (the number of target cells in each well). Lytic units per 
one million NK cells were obtained according to the formula (1000,000/number of NK 
cells in one lytic unit). In the graph lytic unit of each donor is shown along with the 
mean for the group. 
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2.4 DISCUSSION  
In this study, I showed that Job syndrome patients’ NK cells with dominant 
negative STAT3 mutations have impaired cytolytic function, NKG2D receptor 
expression, and MTOC polarization. I confirmed these findings in STAT3 knock-down 
primary human NK cell, which also showed deficient cytolytic function and MTOC 
polarization. I further showed that membrane bound IL-21 stimulation of Job syndrome 
patients’ NK cells with dominant negative STAT3 mutations enhances NK cytotoxicity, 
restores NKG2D receptor expression to normal levels and corrects defective MTOC 
polarization. Finally, I showed that pharmacological inhibition of STAT3 reduces NK 
cytolytic function. 
Cytokine signaling drives differentiation, homeostasis, and functional maturation 
of NK cells (207). As cytokine signals are pre-dominantly mediated through activation 
of members of STAT family, multiple STATs play a critical role in the regulation of basal 
as well as induced cytotoxicity of NK cells. IL-2 and IL-15, cytokines belonging to 
common γ chain family, are implicated in the differentiation, proliferation, survival and 
functional activation of NK cells (58). Both cytokines mainly activate STAT5 (104) and 
this signaling preference is reflected in the diminished basal as well as IL-2 and IL-15 
induced cytolytic activity of NK cells from STAT5b deficient mice (162) and loss of anti-
tumor activity in STAT5 deficient mice NK cells (208). The other STAT that has been 
shown to be important for NK cytolytic function is STAT1. Anti-viral response of NK 
cells is activated by IFN α/β (38, 86), which predominantly mediate their signals 
through STAT1 activation (173, 209). IFN α activates cytolytic activity of NK cells 
through STAT1 signaling (161, 165). The dependence on STAT1 signaling is 
manifested in the reduced NK cytotoxicity during viral infection in STAT1 deficient mice 
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(68, 163). STAT1 signaling also plays a role in NK cell development by enabling 
functional maturation (210). As a result, not only induced, but also basal NK cytotoxicity 
decreases in STAT1 deficient mice (164, 165). In humans too, STAT1 deficiency 
results in diminished basal as well as induced NK cytotoxicity (166). IL-12, a potent 
activator of NK cytolytic activity (211-214), predominantly stimulates STAT4 (173). 
Even though STAT4 is not known to influence basal NK cytolytic function, in STAT4 
deficient mouse, NK cells fail to augment cytotoxicity in response to IL-12 (167, 168). 
Compared to these STATs, very little is known about the function of STAT3 signaling in 
NK cytolytic activity, especially in human NK cells, and as a result its role is not well 
defined.   
Monogenic immune deficiencies have helped delineate the role of number of 
biomolecules in the immune system. Immune disorders caused by genetic deficiencies 
of different components of JAK-STAT signaling pathway are instrumental in expanding 
our understanding of the function of the individual members in the biology of multiple 
types of immune cells (97, 102, 137). Investigations into the pathogenesis of 
immunological dysfunctions in Job syndrome patients have revealed the role of STAT3 
in the development and function of immune cells of lymphoid origin, Th17, T follicular 
helper cells, T regulatory cells, central memory T cells, memory B cells, and antigen 
specific plasma cells (147-153), as well as of myeloid origin, tolerogenic dendritic cells 
and mast cells (150, 154). I took advantage of nature’s own genetic experiment to 
study the role of STAT3 in NK effector function. The cytolytic functional defect reported 
in this study is the first NK cell deficiency reported in this immune disorder carrying 
dominant negative STAT3 mutations.  Due to the paucity of PBMCs from Job syndrome 
patients, instead of using purified NK cells, the cytotoxicity assays in this study were 
performed with PBMCs. As other types of immune cells in the PBMCs could influence 
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cytotoxicity of NK cells, as has been demonstrated by the inhibition of NK cytotoxicity 
by T regulatory cells (215, 216), it was difficult to infer whether the diminished 
cytotoxicity is due to NK cell intrinsic STAT3 deficiency or indirect effect of STAT3 
deficiency in other immune cells. Thus, to confirm whether the effect is due to NK cell 
intrinsic STAT3 deficiency and to further validate the results obtained with Job 
syndrome patients’ NK cells, I evaluated cytotoxicity of STAT3 knock-down primary NK 
cells from normal human donors. The diminished cytolytic function observed in these 
cells unequivocally showed that NK cell intrinsic STAT3 deficiency impairs cytotoxicity. 
The degree of inhibition of cytotoxicity observed in STAT3 knock-down NK cells was 
not to the extent as was observed in Job syndrome patients’ NK cells. There could be 
two plausible reasons for the dissimilar decrease observed; the different types of 
STAT3 deficiencies in the two genetic models and different culture conditions. The 
presence of dominant negative STAT3 allele in Job syndrome patients’ NK cells 
renders these cells chronically deficient in STAT3 signaling, while siRNA mediated 
STAT3 knock-down creates an acute STAT3 deficiency. The ability to affect the 
cytolytic ability in a fundamental way such as impairment of functional maturity during 
development is possible in the former, but not in the latter case. The other reason could 
be the presence of 50 U/ml IL-2 in the culture medium of STAT3 knock-down NK cells. 
As nucleofection process puts cells under stress and decreases cell viability (Weaver, 
1993), to increase the chances of cell survival cytokine support was provided to the 
siRNA nucleofected cells 24 hrs before and 48 hrs after nucleofection i.e. throughout 
the culture period. The Job syndrome patients’ PBMCs on the other hand were not 
stimulated with any cytokine before the assessment of basal cytotoxicity. IL-2 is a 
potent activator of NK cells. Along with promoting cell survival and proliferation, it 
stimulates NK cytotoxicity (217-219). Though, IL-2 activates STAT3 in NK cells (80, 
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169, 173, 206, 220), the pre-dominant STAT activated by IL-2 is STAT5 (80, 173) and it 
activates NK cytotoxicity mainly through STAT5 signaling (162). As STAT5 expression 
is intact in STAT3 knock-down NK cells, IL-2 activated STAT5 may have alleviated the 
adverse effect of STAT3 deficiency on NK cytotoxicity.  
Yet another reason that could explain the smaller difference in cytotoxicity 
between STAT3 knock-down and control NK cells is the possibility of cells with intact 
STAT3 in STAT3 knock-down NK population. In bulk electroporation, as was performed 
in the present study to knock-down STAT3 in primary human NK cells, all the cells may 
not be electroporated, leaving some cells without knock-down of the target mRNA. 
These cells, electroporated in bulk, if used in a bulk assay such as the calcein assay, 
employed in the present study to assess the cytotoxicity of NK cells, then the cells with 
intact STAT3, even if few, could skew the output. The possibility of existence of cells 
with intact STAT3 in STAT3 knock-down bulk population may explain the difference 
between the cytotoxicity of control cells and STAT3 knock-down cells being smaller as 
these cells with intact killing capacity through encounters with multiple target cells may 
compensate for the cytolytic deficiency of rest of the cells. To overcome this limitation 
of calcein assay, cytolytic activity of STAT3 knock-down NK cells was assessed at the 
single cell level, which also revealed lower frequency of killing in STAT3 knock-down 
NK cells compared to control cells.  
This is the first study to report that STAT3 deficiency causes impaired 
cytotoxicity in primary human NK cells. Very few studies have investigated the role of 
STAT3 in the cytolytic function of human NK cells. Similar to my results, silencing of 
STAT3 expression in NK92 cells, a human NK cell line, using siRNA has been shown 
to reduce cytotoxicity, while silencing of suppressor of cytokine signaling 3 (SOCS3), a 
negative regulator of STAT3 signaling (221), increased NK92 cytotoxicity against K562 
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(222). Pharmacological inhibition of STAT3 in primary human NK cells has also been 
shown to decrease basal cytotoxicity (223). However, the evidence presented in this 
particular study is not very conclusive due to the type of STAT3 inhibitor used. Iannello 
et al. (223) used cucurbitacin or JSI-124 to block STAT3. Even though JSI-124 is used 
as a STAT3 specific inhibitor (224, 225), along with STAT3, it also inhibits activation of 
JAK2 and JAK3 and thus actually is a JAK-STAT inhibitor (226, 227). In fact, JSI-124 
blocks activation of STAT5 (228) at a concentration well below the one used by 
Iannello et al. (10 μM) (223). As STAT5 deficiency impairs basal NK cytotoxicity (162), 
the effect of JSI-124 could have been mediated through STAT5 inhibition. The only 
other study to implicate STAT3 in human NK cell cytotoxicity reported a decrease in IL-
2 induced STAT3 activation and a concurrent reduction in cytotoxicity of primary human 
NK cells treated with immunosuppressant FK506 (170). Though the evidence 
implicating STAT3 in NK cytotoxicity was not direct, the fact that only STAT3 activation 
was inhibited, while IL-2 induced STAT1 and STAT5 activation remained unaffected in 
FK506 treated NK cells suggested requirement of STAT3 activation in IL-2 induced 
human NK cell cytotoxicity (170). 
Contrary to human NK cells, STAT3 deficiency in mouse NK cells either 
enhances cytolytic function or does not have any effect. Ablation of STAT3 in 
hematopoietic cells of mice did not affect NK cell cytolytic activity in tumor free mice, 
but in tumor bearing mice, STAT3 ablation increased cytolytic activity compared to wild 
type (229). This observation suggests that STAT3 deficiency by itself may not impart 
any beneficiary effect on NK cell cytotoxicity, but in the context of tumor 
microenvironment, it does in mouse NK cells. STAT3 deficiency in mouse NK cells 
does not seem to have an uniform effect on the cytotoxicity, but is rather influenced by 
the type of target cells as it is apparent from a study in which NK cell specific deletion 
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of STAT3 did not show any effect on cytotoxicity assessed in vitro against different 
targets such RMA, RMA-Rae1, YAC-1 and v-abl cell lines, but increased cytotoxicity 
against a melanoma cell line B16F10 (230). This increase was due to the high 
expression level of ligands for DNAM-1 receptor on the target cell and enhanced 
expression of the receptor on STAT3 deficient NK cells (230). Interestingly, no 
difference was observed in the cytotoxicity of STAT3 deficient and wild type NK cells 
against v-abl cells in assays performed in vitro, but in vivo, STAT3 deficient cells 
displayed enhanced anti-tumor activity against the same cells (230). The different 
outcomes in in vitro and in vivo settings indicate that cell extrinsic factors play a critical 
role in determining the effect of STAT3 deficiency on mouse NK cytotoxicity. Even 
though STAT3 deficiency does not always equate to an increase in mouse NK 
cytotoxicity, it does so depending upon the target and the microenvironment in which 
NK interacts with the target, whereas in human NK cells, reported results so far 
associate STAT3 deficiency with impaired cytotoxicity. As there are similarities between 
mouse and human immune systems so are the differences (231). With respect to NK 
cells, the differences are highlighted by the structurally divergent families of inhibitory 
receptors, KIRs in human and Ly49s in mouse, different types of ligands for human and 
mouse NKG2D receptor (231), and difference in the function of 2B4 receptor, mainly 
activating in human and inhibitory in mouse, due to the coupling with divergent types of 
intracellular signaling molecules (232). Cytolytic activity of NK cells is a result of the 
balance between the activation of inhibitory and activating receptors expressed on NK 
cell surface (8) and as a result the tumor model used to assess cytolytic activity may 
play a major role in the outcome of NK cell activity, particularly with respect to the 
modulation of specific activating or inhibitory ligands. The difference in the structure, 
function, and ligands for some of the receptors between mouse and human NK cells 
 116 
 
underscores the caution that should be exercised while applying lessons learned from 
mouse to humans. It may also be possible that STAT3 deficiency may affect 
expression of receptors and intracellular signaling molecules differently in mouse and 
human NK cells. 
Cytolytic activity of NK cells is the net result of the balance between the 
strengths of signals mediated by activating and inhibitory receptors (8). To investigate 
the cause of impaired cytotoxicity in STAT3 deficient human NK cells, I assessed 
receptor expression. Out of all the activating, inhibitory, adhesion receptors and 
activation and maturation markers measured, expression of NKG2D receptor was 
found to be different between Job syndrome patients’ NK cells and normal donors’ NK 
cells. Previously, we reported transcriptional activation of NKG2D by STAT3 (136) and 
consistent with earlier finding NKG2D receptor expression was found to be impaired in 
NK cells carrying dominant negative STAT3 mutations. The decrease in Job syndrome 
patients’ NK cell cytolytic activity against K562 could be attributed to the impaired 
NKG2D expression as NK cells lyse K562 pre-dominantly in a NKG2D dependent 
manner (233, 234). Despite of STAT3 deficiency NKG2D receptor expression was 
found to be normal in STAT3 knock-down NK cells. The normal expression may be 
attributed to IL-2 present in the culture medium. IL-2 modulates NKG2D expression at 
post-transcriptional level by increasing transcription and translation of DAP10, the 
adaptor protein NKG2D associates with to mediate signal. Pairing with DAP10 is 
required for NKG2D receptor expression and IL-2 induces NKG2D expression by 
enhancing availability of DAP10 (89). The normal expression of NKG2D may also 
explain the smaller decrease in cytotoxicity observed in STAT3 knock-down NK cells 
compared to the drastic reduction observed in Job syndrome patients’ NK cells. The 
only other receptor that has been shown to be modulated by STAT3 is DNAM-1, which 
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showed up-regulated expression in STAT3 deficient mouse NK cells (230). No such 
change in the expression of DNAM-1 was observed in Job syndrome patients’ NK cells 
as well as in STAT3 knock-down human NK cells, again emphasizing the difference 
between mouse and human NK cells.  
Signaling cascades initiated by activating receptors enable synthesis and 
deposition of F-actin at the NK-target interface, convergence of lytic granules dispersed 
throughout the NK cell to MTOC and polarization of granules and MTOC towards the 
immune synapse. These are the critical cellular processes involved in NK lytic activity 
(158). Assessment of these cellular processes demonstrated normal deposition of F-
actin at the synapse in STAT3 deficient NK cells. Normal deposition of F-actin suggests 
that the signaling axis of activating receptor signals- Src family kinase- Vav 
phosphorylation- Rac1 activation- actin nucleators- actin polymerization is intact and 
functional in STAT3 deficient NK cells (13, 235-239). Normal convergence of lytic 
granules to MTOC indicates that STAT3 deficiency does not affect Src family kinase 
mediated dynein motor dependent transport of lytic granules along microtubules (186, 
240). Convergence of lytic granules to MTOC is the first step in the directed traffic of 
these lysosomal organelles towards immune synapse. Upon convergence, movement 
of MTOC along with the lytic granules in the direction of the synapse is called MTOC 
polarization. I observed impaired polarization of MTOC to synapse in both Job 
syndrome patients’ and STAT3 knock-down NK cells. During polarization to the 
immune synapse, the transport of MTOC and lytic granules along the microtubules is 
powered by plus-end motor protein kinesin-1 (KIF5B), which associates with MTOC 
and lytic granules through a small G-protein, Arl8b (200). The transport of MTOC and 
lytic granules along the microtubules towards the actin rich immune synapse is 
facilitated by proteins, which could associate with both microtubules and actin. CDC42 
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interacting protein 4 (CIP4) and IQGAP1 are two such proteins. CIP4 can interact with 
actin through Wiskott-Aldrich syndrome protein (WASp), an actin associated actin 
polymerization activating protein (236), and with MTOC through its binding with tubulin 
(185). Activation of NK cells by a target cell triggers localization of CIP4 at MTOC and 
its interaction with WASp (185). IQGAP1 is a multi-domain scaffolding protein that can 
also interact with F-actin and microtubules (201). Individual silencing of these proteins 
have been shown to impair MTOC and lytic granule polarization in NK cells (185, 200, 
201). To investigate whether the expression of these molecules is affected by STAT3 
deficiency, I quantified mRNA expression by Real-time PCR. Expression of Arl8b, 
KIF5B and IQGAP1 was found to be similar in STAT3 knock-down and control NK 
cells, but CIP4 expression was found to be significantly reduced in STAT3 knock-down 
NK cells, suggesting it as a likely cause for impaired MTOC polarization. However, 
CIP4 gene expression was found to be normal in Job syndrome patients’ NK cells 
indicating that a different mechanism is responsible for the impaired MTOC polarization 
observed in these cells. As discussed earlier, the two genetic models used in this study 
do not exactly mimic each other, which may result in differential regulation of 
expression of genes such CIP4. Signals mediated by NKG2D receptors trigger MTOC 
polarization (241, 242). However, the reduced expression of NKG2D observed in Job 
syndrome patients’ NK cells as a possible cause of MTOC impairment is unlikely as 
STAT3 knock-down NK cells with normal expression of NKG2D receptor also had 
impaired MTOC polarization. Thus, the causative factor responsible for impaired MTOC 
polarization in Job syndrome patients’ NK cells remains elusive.  
Despite of impaired MTOC and lytic granule polarization in STAT3 knock-down 
NK cells, the decrease in cytotoxicity was marginal. This could be attributed to the lytic 
granules which are known to exist near the immune synapse in NK cell and do not 
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require MTOC polarization for their delivery to the synapse (243-245). These granules 
are responsible for initial rapid release of lytic molecules in the synaptic cleft (245). As 
suggested in an earlier study (185), pre-activation of NK cells during the culture period 
such as IL-2 activation as was done in this study may have increased the number of 
pre-docked lytic granules in STAT3 knock-down NK cells. Even though it is not known 
how many lytic granules are required to kill K562, the target cell used in the present 
study, considering its sensitivity to NK cell mediated lysis, exocytosis of few lytic 
granules may be sufficient to do the job.  
One of the primary functions of NK cells is tumor immunosurveillance (6, 8, 246, 
247). This innate role of NK cells is reflected in the association of low NK cytotoxicity in 
the peripheral blood with higher incidence of cancer as was observed in an 11-year 
follow-up study (30). NK immunosurveillance of tumor cells is pre-dominantly mediated 
through NKG2D receptor (27). NKG2D is a primary activating receptor on NK cells. In 
humans, its ligands include MHC class-I-related chain (MIC) A and MICB and the UL-
16 binding proteins (ULBP). Expression of these ligands is induced by cellular stress 
such as heat shock, DNA damage, transformation, and viral and bacterial infection. Not 
surprisingly, NKG2D plays a critical role in the immune response mediated by NK to 
infections and tumors (12). As observed in the present study, Job syndrome patients 
with dominant negative STAT3 mutations have both the factors, impaired NKG2D 
receptor expression and NK cytotoxicity, that could cause a predisposition to cancer. In 
fact, autosomal dominant Job syndrome patients do carry higher risk of malignancy, 
particularly lymphoma (144, 155, 156, 248-251). Very few instances of other types of 
malignancies such as vulvar cancer (252) and pulmonary adenocarcinoma (253) have 
been reported. The possibility of deficient NK cytolytic function due to impaired NKG2D 
receptor expression as a putative cause of proclivity to lymphoma development in Job 
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syndrome patients is supported by the earlier reports of impaired NK cytotoxicity 
observed in lymphoma patients (254, 255) and a recent study linking the cytotoxic 
impairment to reduced NKG2D receptor expression on NK cells (256). The risk of 
lymphoma development is 259 fold higher in autosomal dominant Job syndrome 
patients compared to general population (155). Many cases of lymphoma in autosomal 
dominant Job syndrome patients were reported before the discovery of dominant 
negative STAT3 mutations as the causative factor of the syndrome, but confirmation of 
STAT3 mutations in subsequent cases has established a firm link between STAT3 
deficiency and occurrence of lymphoma (144, 156, 250, 251). STAT3 deficiency not 
only inhibits NK cytotoxicity through NK intrinsic effects, but tumor specific STAT3 
deletion also adversely affects NK infiltration and NK cytotoxicity as has been shown in 
a STAT3 deleted BCR/ABL induced lymphoma model (257). Thus, impaired cytotoxicity 
of STAT3 deficient NK cells and reduced NK immunosurveillance influenced by STAT3 
deficient lymphoma could be promoting lymphogenesis in Job syndrome patients.  
Even though Job syndrome patients carry dominant negative STAT3 mutations, 
they are not totally devoid of STAT3 activity. As STATs mediate their transcriptional 
activation function as dimers, the 25% probability of functional dimer formation, due to 
the one normal STAT3 allele present, retains residual STAT3 activity in Job syndrome 
patients’ cells, which is 25% of the wild type (131). I wanted to investigate whether 
stimulation of the residual functional STAT3 by IL-21 could improve deficient NKG2D 
receptor expression, MTOC polarization, and cytotoxicity of Job syndrome patients’ NK 
cells. IL-21, a cytokine belonging to common γ chain family, pre-dominantly activates 
STAT3 (80, 136, 171) and marginally activates STAT1, STAT4, and STAT5 in NK cells 
(80, 92, 136, 171, 258). IL-21 is a potent activator of NK cells. It induces expression of 
activating receptors, effector cytolytic proteins, granzymes and perforin, and cytolytic 
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activity of NK cells (80, 81, 92, 136, 223, 259). In vivo anti-tumor effects of IL-21 are 
mediated by NK cells (26) and these anti-tumor effects are NKG2D dependent (260). 
IL-21 induced expression of activating receptors and perforin, and activation of cytolytic 
function in NK cells is mediated through STAT3 activation (136, 223). Previous work in 
our lab demonstrated robust expansion of human NK cells stimulated with K562, 
genetically modified to present membrane bound IL-21 (mbIL21). These expanded 
cells had high expression of activating receptors and enhanced cytolytic activity (134). 
In the present study, NK cells, expanded from PBMCs stimulated with mbIL21 over a 
three-week period, were found to have similar expression of NKG2D receptor in Job 
syndrome patients and normal donors. MTOC polarization was also found to be normal 
in mbIL21 expanded Job syndrome patients’ NK cells. Thus, the deficient NKG2D 
receptor expression and MTOC polarization in resting Job syndrome patients’ NK can 
be corrected by mbIL21 stimulation. Consistent with these results, mbIL21 activation 
also enhanced cytolytic function of Job syndrome patients’ NK cells. Though the 
cytotoxicity of mbILl21 expanded Job syndrome patients’ NK cells was marginally lower 
than mbIL21 expanded NK cells from normal donors, there was no significant 
difference as was observed at basal level.  
As discussed earlier, deficient NK cytotoxicity caused by impaired NKG2D 
receptor expression is the likely reason for Job syndrome patients’ predisposition 
towards lymphoma development. The finding that mbIL21 activation restores NKG2D 
receptor expression to normal levels and enhances cytotoxicity of Job syndrome 
patients’ NK cells offers an adoptive NK cell immunotherapy approach to treat 
lymphoma in these patients. 
  Due to oncogenic properties of STAT3 signaling in multiple cancers, inhibition of 
STAT3 is emerging as a therapeutic approach in cancer treatment. Multiple 
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approaches to block STAT3 signaling are at different stages of clinical development 
(106, 140, 175). In the light of the finding of the present study that STAT3 deficiency 
inhibits NK cytolytic activity, it is critical to determine the effect of this therapeutic 
approach on the function of the immune cell whose primary function is tumor 
immunosurveillance. It is all the more important when equally promising treatment 
options against cancer are offered by NK cells. High levels of tumor infiltrating NK cells 
are associated with positive prognosis (31-33). The anti-tumor activity of several 
cytokines such as IL-2, IL-12, IL-18, and IL-21 is mediated by NK cells (8, 26). Adoptive 
transfer of activated autologous or allogeneic NK cells has proven to be a safe and 
potentially efficacious immunotherapy for cancer (36, 37) and has been or being tested 
against multiple types of cancers (35). As cancer treatment many a times involves 
combination of different treatment modalities, it is imperative to determine the 
compatibility of different modes of treatments with each other. Development of Small 
molecule inhibitors of STAT3 is one of the most actively researched areas in cancer 
therapeutics (140). S3I-201 is one such inhibitor, which binds SH2 domain of STAT3 to 
block its dimerization and thereby inhibits DNA binding and transcriptional activity 
(203). It has been shown to inhibit tumor growth in pre-clinical studies (198, 203). In a 
previous study, we reported suppression of NKG2D receptor expression in S3I-201 
treated primary human NK cells (136). Assessment of the effect of this drug on the 
cytotoxicity of human NK cells in the present study showed that S3I-201 reduces 
cytolytic activity of NK cells. Thus, pharmacological inhibition of STAT3 impairs NKG2D 
receptor expression and cytolytic function; the former could be the cause of the latter, 
thereby disarming NK cells. These results indicate that blocking STAT3 as a 
therapeutic approach in cancer treatment may have adverse effects on NK cell cytolytic 
function and caution needs to be exercised, while employing this mode of treatment.  
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2.5 CONCLUSION 
 
 The evidence presented in this report shows that STAT3 deficiency in human 
NK cells causes impairment of cytolytic function. I used two genetic models to study the 
role of STAT3 in NK cytolytic function; NK cells from Job syndrome patients carrying 
dominant negative STAT3 mutations, a naturally occurring genetic model of STAT3 
deficiency, and siRNA mediated knock-down of STAT3 in primary human NK cells. NK 
cells from Job syndrome patients displayed significantly reduced cytotoxicity compared 
to NK cells from normal donors. Investigations into the probable underlying causes of 
impaired cytolytic function of Job syndrome patients’ NK cells revealed reduced 
expression of NKG2D receptor, a primary activating receptor involved in activating 
cytotoxicity of NK cells. Among the subcellular cytolytic processes probed, synapse 
formation and granule convergence were found to be normal, while MTOC polarization 
to the synapse was defective. The cytolytic phenotypes of STAT3 deficient Job 
syndrome patients’ NK cells were recapitulated in STAT3 knock-down primary human 
NK cells. Assessment of cytolytic activity by conventional bulk assay as well as single 
cell analysis showed suppressed cytolytic function in STAT3 knock-down NK cells. 
Impaired MTOC polarization was also observed in these cells. Thus, two genetic 
models complemented each other in highlighting role of STAT3 in MTOC polarization 
and cytolytic function of human NK cells. Job syndrome patients are not totally devoid 
of STAT3 activity. One normal allele of STAT3 enables them to retain about 25% 
activity of the wild type. In this study, I showed that stimulation of Job syndrome NK 
cells with membrane bound form of STAT3 activating cytokine IL-21 restores NKG2D 
expression and MTOC polarization to normal levels and improves cytolytic function. 
Lastly, I studied the effect of pharmacological inhibition of STAT3 on NK cell cytolytic 
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function. Deregulated STAT3 activity is associated with different types of cancers and 
as a result, STAT3 is considered a promising therapeutic target. Various ways to block 
STAT3 are under clinical consideration and small molecule inhibitors are one of the 
important ones. One of the major functions of NK cells is immunosurveillance of 
malignant cells. In the light of the finding of the present study, I found it imperative to 
evaluate the effect of pharmacological inhibition of STAT3 on NK cytolytic function. 
Treatment of primary human NK cells with small molecule STAT3 inhibitor S3I-201 
suppressed NK cytolytic function, thereby showing a possible side effect of this 
therapeutic approach. 
 This is the first report to show that STAT3 deficiency in primary human NK cells 
causes impairment of MTOC polarization and cytolytic activity. This is also the first 
report of NK cell functional deficiency in Job syndrome patients. Reduced NKG2D 
expression and impaired NK cytolytic function, observed in this study, may provide an 
immunological basis for the proclivity of Job syndrome patients to lymphoma and 
restoration of NK cell function upon mbIL21 stimulation, as demonstrated in this study, 
suggests an adoptive NK cell therapy as a therapeutic approach to treat Job syndrome 
patients. By assessing the effect of small molecule STAT3 inhibitor on NK cytolytic 
function, this study provides a potential biomarker for monitoring side effects of STAT3 
inhibition. 
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Chapter 3 
ROLE OF STAT3 SIGNALING IN HUMAN NK CELL 
EXPANSION 
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Role of STAT3 Signaling In Human NK Cell Expansion 
3.1 INTRODUCTION 
 
NK cells, effector lymphocytes of the innate immune system, control microbial 
infections, particularly viral and are the first line of defense against cancer cells. Like T 
and B cells, NK cells do not require prior sensitization with antigen to execute their 
effector functions. NK cells are equipped with an array of germline encoded activating 
receptors to detect ligands expressed on stressed cells and inhibitory receptors to 
detect self-signals such as MHC class I molecules. The balance between the strength 
of signals mediated by the two types of receptors determines whether NK cells 
discharge their effector function upon contact with the target cell (8).  
Immune response entails availability of a pool of effector cells in normal 
conditions and further expansion of these cells during infections. Steady-state number 
of NK cells is maintained through homeostatic proliferation as has been shown in both 
mice (65, 261, 262) and humans (263, 264). The homeostatic NK cell survival and 
proliferation are dependent on IL-15 signaling in mice (64-66), but are independent of 
IL-15 in humans (67).  
In addition to proliferation during steady state, NK cells also proliferate in 
response to viral infections. NK proliferative responses to various types of viral 
infections in mice such as mouse cytomegalovirus (MCMV) (38, 53, 68, 265), 
lymphocytic choriomeningitis virus (LCMV) (266), and vaccinia virus (163) and a wide 
range of viral infection in humans such as human cytomegalovirus (HCMV) (267, 268), 
Epstein-Barr virus (EBV) (269), human immunodeficiency virus (HIV) (270), hepatitis C 
virus (271) and hantavirus (69) have been reported. In the early phase of viral infection, 
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NK cells proliferate in response to cytokine signaling. In MCMV and LCMV infections in 
mice this effect has been shown to be Type I interferon (IFNα/β) dependent (38, 272). 
Type I IFNs do not directly mediate pro-proliferative signals in NK cells, but promote 
proliferation by inducing generation of IL-15 (68). The role of IL-15 in NK proliferative 
response to viral infection has also been established in humans (69). IL-12 (70, 71) and 
IL-18 (70) have also been demonstrated to play a role in NK proliferation in response to 
MCMV infection in mice, but whether these cytokines directly act on NK cells or 
promote proliferation through an indirect mechanism remains to be determined. 
Cytokine induced NK cell proliferation in the early phase of viral infection is 
nonselective, while in the later phase NK cells expressing activating receptors that 
recognize virus induced ligands are selectively expanded (272). This is best 
exemplified by the well-studied preferential proliferation of Ly49H+ NK cells in response 
to MCMV infection in mice (52, 53, 265, 273, 274). Ly49H is an activating receptor 
expressed in mouse NK cells that recognizes MCMV encoded ligand m157 (272). 
Ly49H transmits signals in NK cells by coupling with signaling adaptor protein DAP12 
and these signals directly promote proliferation of NK cells (273). In humans too, 
selective expansion of NK cells such as KIR+ NK cells in response to HIV (275) and 
CD94/NKG2C+ in response to HCMV (267) infection have been reported, but evidence 
supporting direct involvement of these receptors’ signaling in NK proliferation is lacking.  
In vitro studies have demonstrated that cytokines and activating receptors, which 
have not yet been shown to play a physiological role in NK cell proliferation in vivo, 
could also induce proliferation of NK cells. One of the potent activators of NK cell 
proliferation is IL-2 (72, 73). It is used to expand NK cells ex vivo for immunotherapy in 
cancer (74, 75). Some cytokines do not induce proliferation acting alone but in 
combination with other cytokines they do. For instance, IL-10, IL-12, and IL-18 
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stimulate proliferation of mice NK cells pre-activated with IL-2 (76). IL-18 also induces 
proliferation of mice NK cell in combination with other cytokines such as IL-12 and IL-
15 (77-79). IL-21 too does not induce NK cell proliferation by itself, but does in 
combination with IL-2 in human NK cells (80). Stimulation of activating receptors also 
promotes NK cell proliferation. Individual stimulation of NKG2D, NKp30, and NKp46 
induces proliferation in human NK cells (276).  
Cytokines known to induce proliferation of NK cells mediate their signals 
employing JAK-STAT pathway. IL-15, established to be the major endogenous cytokine 
responsible for survival and proliferation of NK cells in vivo in mice and IL-2 which is 
routinely used to expand NK cells from mouse and human in vitro activate STAT 1, 3, 
4, and 5 in NK cells (171, 173, 277). Out of all the STATs, STAT5 is predominantly 
activated by IL-2 and IL-15 (171, 173). The importance of STAT5 signaling in NK cell 
proliferation is reflected in the reduced proliferative response of NK cells from STAT5 
knock-out mice to IL-2 and IL-15 (162). Out of the two members of the STAT5 group, 
STAT5a and STAT5b, these effects are more pronounced in STAT5b knock-out mice, 
thereby signifying its role in mouse NK cell proliferation (162). IL-2 and IL-15 also 
support NK cell survival (58) and signals promoting survival are also pre-dominantly 
mediated through STAT5 (208, 278). Apart from STAT5, the only other STAT that has 
been implicated in NK cell proliferation is STAT1. NK proliferative response to viral 
infection is dependent on type I IFN mediated STAT1 signaling. The pro-proliferative 
effects are not due to NK cell intrinsic STAT1 signaling, but due to the availability of IL-
15 that is generated as a result of Type I IFN mediated STAT1 signaling (68).  
The cytokines, IL-2, IL-15, IL-10, IL-12 and IL-18, which have been shown to 
induce proliferation of NK cells either in vivo or in vitro, activate STAT3 in NK cells (80, 
136, 169-173). STAT3 is considered to be a pro-proliferative and pro-survival 
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transcription factor. STAT3 target genes such as cyclin D1, D2, D3, cdc25A, and c-Myc  
(174, 279, 280) promote cell cycle progression, while Bcl-XL (281) and survivin (282) 
prevent apoptosis. However it is not known whether STAT3 signaling plays any role in 
NK cell proliferation and survival.  
Anti-cancer activity of NK cells has generated a great deal of interest in NK cell 
immunotherapy against cancer. Due to the limited number of NK cells in the peripheral 
blood, expanding NK cells to a sufficiently large number is imperative to the success of 
NK cell immunotherapy. Expanding and activating NK cells ex-vivo, before their 
transfer into the patients, forms the basis of NK immunotherapy. Research efforts in our 
lab are focused on developing an ex vivo NK cell expansion platform. We previously 
described robust ex vivo expansion of NK cells by co-cultivation with K562 
(erythroleukemic cell line) based artificial antigen presenting cells (aAPC) genetically 
modified to express membrane-bound cytokines (134). We observed significantly 
higher fold expansion of NK cells activated with membrane bound IL-21 (mbIL21) than 
those activated with membrane bound IL-15 (mbIL15) (134). As out of all the STATs, 
IL-21 activates STAT3 most efficiently (104, 135), I hypothesized that STAT3 may play 
a role in NK cell proliferation.  
In this investigation, I studied role of STAT3 in membrane bound cytokine 
activated primary human NK cell proliferation by blocking STAT3 employing 
pharmacological and genetic tools. In the pharmacological model, I blocked STAT3 
using a small molecule STAT3 inhibitor, while in the genetic model NK cells from Job 
syndrome patients carrying dominant negative STAT3 mutations were used. Both the 
approaches showed significant reduction in the proliferation of NK cells thereby 
underlining requirement of STAT3 in NK cell proliferation.  
 
 130 
 
3.2 MATERIAL AND METHODS 
3.2.1 Cell and cell lines 
 
Anonymized normal donor buffy coats were obtained from the Gulf Coast 
Regional Blood Center (Houston, TX) under a protocol approved by the Institutional 
Review Board (IRB) of UT MD Anderson Cancer Center. Peripheral blood was 
obtained from STAT3 genotyped Job’s syndrome patients at National Institute of 
Allergy and Infectious Diseases and Children’s Hospital of Philadelphia under protocols 
approved by the IRB of each respective institution. IRB approval was obtained from UT 
MD Anderson Cancer Center to acquire Job’s syndrome samples from collaborators 
and to perform this research. This study was conducted in accordance with the 
Declaration of Helsinki. 
3.2.2 PBMC Isolation 
 
Peripheral blood mononuclear cells (PBMCs) from buffy coats and blood 
samples were obtained by buoyant density centrifugation on Ficoll-Paque following 
previously described protocol (176). Briefly, buffy coats or blood samples mixed with 
phosphate buffer saline (PBS) were loaded on top of Ficoll-Paque in a 50 ml tube and 
centrifuged at 400g for 20 minutes without brake. The PBMCs settled at the interface of 
Ficoll-Paque and plasma were recovered and washed three times with PBS. The red 
blood cells (RBCs) settled below Ficoll-Paque were used to isolate NK cells from 
PBMCs. 
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3.2.3 NK Cell Purification 
 
NK cells were purified from PBMCs by enriching them to  95% purity 
(CD3−CD16/56+) with RosetteSep Human NK Cell Enrichment Cocktail (STEMCELL 
Technologies, Vancouver, BC, Canada) following manufacturer’s instructions. In brief, 
PBMCs were mixed at 1:100 ratio with red blood cells (RBCs) obtained from the same 
sample. To the PBMCs:RBCs mixture, Human NK Cell Enrichment Cocktail was added 
at 1 µl/106 PBMCs. The solution was mixed well and incubated at room temperature for 
20 minutes with gentle mixing every five minutes. After adding PBS with 2% fetal 
bovine serum (FBS) to the PBMCs:RBCs mix, the solution was layered on top of Ficoll-
Paque and centrifuged at 400g for 20 minutes. The NK cells were recovered from top 
of the Ficoll-Paque layer.  
The NK cells were cultured in RPMI 1640 (Cellgro/Mediatech, Manassas, VA) 
supplemented with 10% FBS (HyClone, Logan, UT), 2 mM l-glutamine 
(Gibco/Invitrogen, Carlsbad, CA), and 1% penicillin/streptomycin (Cellgro/Mediatech). 
This media is hereinafter referred to as NK cell media.  
3.2.4 Antibodies 
 
Murine anti-human CD3, CD56, and isotype control mAbs were obtained from 
BD Biosciences (Bedford, MA). 
3.2.5 Ex vivo expansion of human NK cells 
 
NK cells were expanded as previously described with few modifications (176). 
Briefly, PBMCs or purified NK cells were co-cultured with irradiated (100 cGy) K562 
artificial antigen presenting cells (aAPCs), genetically modified to express membrane 
bound cytokines, at 1:2 (PBMCs/NK:aAPCs) ratio and 50 U/ml recombinant human IL-2 
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in a T-75 flask (Corning, Corning, NY) at 106 cells/ml. The K562s expressing 
membrane bound cytokines were generated as previously described (134). Culture was 
refreshed with new media containing 50 U/ml IL-2 every three to four days. In 
expansions extended beyond one week, a portion of the expanded cells was carried 
forward by recursive stimulation with K562s expressing membrane bound cytokine and 
50 U/ml IL-2. In the expansions started with purified NK cells, fold expansion of NK 
cells was calculated by dividing the number of viable NK cells at the end of a weeklong 
expansion with the number of viable NK cells at the start of expansion. In the 
expansions started with PBMCs, fold expansion of NK cells was calculated by dividing 
the number of NK cells in the PBMCs at the end of weeklong expansion by the number 
of NK cells in the PBMCs at the start of expansion. Number of NK cells in the PBMCs 
were calculated by estimating the percentage of CD3- CD56+ cells by flow-cytometric 
analysis. Inferred fold NK cell expansion was calculated from the resulting cultures as if 
all the cells were carried forward in the expansion (134). 
3.2.6 Cell Count and Cell Viability 
 
Cells were counted using hemocytometer. Cell viability was determined by 
Trypan blue exclusion method. Briefly, cells were stained with trypan blue and number 
of cells stained blue and total number of cells were counted using hemocytometer. 
Percentage viability was calculated using the formula [((Total number of cells-number 
of blue cells)/Total number of cells) *100].  
3.2.7 Flow-Cytometry Analysis 
 
Flow cytometry buffer, PBS with 2mM EDTA and 0.1% sodium azide, was used 
for blocking, staining, washing and resuspending the cells. Before staining with 
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antibodies, the cells were blocked with 50% FBS for 30 minutes at 4C. Blocked cells 
were stained with appropriate fluorochrome conjugated antibodies for 30 minutes at 
4C, washed twice and resuspended in flow cytometry buffer. Data was acquired using 
a FACSCalibur cytometer (Becton Dickinson, Franklin Lakes, NJ), and was analyzed 
using FlowJo Version 9.2 software (FlowJo, Ashland, OR, USA).  
3.2.8 Pharmacological inhibition of STAT3 in NK cells 
 
S3I-201 (Calbiochem, Gibbstown, NJ), a small molecule STAT3 inhibitor, 
reconstituted in DMSO was used to block STAT3 signaling. Purified NK cells were 
incubated for an hour with or without S3I-201 before stimulating them with aAPCs and 
IL-2. Cells were pre-treated with the drug every time media was refreshed. Control cells 
were treated with the solvent, DMSO. 
3.2.9 Proliferation Assessment By CFSE Dilution  
 
Proliferation of NK cells was assessed by the 5,6-carboxyfluorescein diacetate 
succinimidyl ester (CFSE) dilution method (283). Briefly, freshly purified NK cells, 
resuspended in pre-warmed PBS containing 0.1% BSA at 106 cells/ml, were stained 
with 2 μM CFSE (Molecular Probes, Eugene, OR) by incubating them at 37oC for 10 
minutes. At the end of incubation period, staining was quenched by adding cold NK cell 
media 5 times the volume of the staining solution and by incubating them on ice for 5 
minutes. Cells were pelleted and washed three times with NK cell media. CFSE stained 
cells were expanded as described earlier. At the end of one week of expansion CFSE 
staining was measured by flow-cytometry.  
 
 134 
 
3.2.10 Apoptosis Assessment 
 
   Apoptotic NK cells were identified using apoptosis detection kit from BD 
Pharmingen (Franklin Lake, NJ) following manufacturer’s protocol with few 
modifications.  Briefly, NK cells were washed twice with cold PBS and then 
resuspended in 1X binding buffer at a density of 106 cells/ml. 100 μl of cell suspension 
(105 cells) was transferred to a 5 ml flow cytometry tube. 3 μl of Phycoerythrin (PE) 
conjugated Annexin V was added to the tube and mixed by gentle vortexing. The cells 
were incubated in dark for 15 minutes at room temperature. After incubation, cells were 
washed twice with 1X binding buffer and then resuspended in 400 μl 1X binding buffer 
containing 5 μl 7-Amino-Actinomycin (7-AAD). The cells were incubated in dark for 10 
minutes at room temperature. PE-Annexin V and 7-AAD staining were analyzed by 
flow-cytometry. 
3.2.11 Statistical Analysis 
 
 Statistical analysis was performed for the indicated statistical tests using 
GraphPad Prism for Macintosh, version 5.0a. P values <.05 were considered 
significant. 
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3.3 RESULTS 
 
Ex vivo NK cell expansion platform, developed in our lab, demonstrated robust 
expansion of human NK cells activated with K562 cells genetically modified to present 
membrane bound IL-21 (mbIL21) (134). As IL-21 pre-dominantly signals through 
STAT3 activation (104, 135), I hypothesized that STAT3 activation may play a role in 
the induction of proliferation of human NK cells. I used pharmacological and genetic 
models to test my hypothesis. 
3.3.1 Pharmacological Inhibition of STAT3 
3.3.1.1 STAT3 inhibitor S3I-201 reduces mbIL21 stimulated expansion of 
human NK cells  
 
I employed pharmacological approach to block STAT3 with a small molecule 
inhibitor S3I-201. It binds SH2 domain of STAT3 to block dimerization and thereby 
inhibits DNA binding and transcriptional activity of STAT3 (203). Human NK cells 
purified from peripheral blood mononuclear cells (PBMCs) were expanded by 
stimulation with mbIL21 for one week in the presence and absence S3I-201. At the end 
of the week, viable cells were counted by differentiating viable cells from non-viable 
cells by staining the cells with trypan blue. The number of NK cells was significantly 
higher in the cultures without STAT3 inhibitor (Figure 15).  
3.3.1.2 STAT3 inhibition decreases proliferation and survival of human        
     NK cells stimulated with mbIL21 
 
Expansion of cell number is the net result of two processes; increase in cell 
number due to proliferation and decrease in cell number due to cell death. I evaluated 
the effect of pharmacological inhibition of STAT3 on proliferation of NK cells using 
CFSE dilution assay. CFSE, a cell permeable fluorescent dye, reacts covalently with 
amine containing intracellular molecules thereby fluorescently labeling the cell. CFSE 
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fluorescence per cell is progressively halved after each cell division (284). Thus, more 
the number of cell divisions a cell undergoes, lesser the fluorescence intensity the 
daughter cells end up with. Flow-cytometric analysis revealed significantly higher CFSE 
fluorescence in S3I-201 treated NK cells than in control cells at the end of one week of 
expansion with mbIL21 indicating fewer cell divisions in S3I-201 treated NK cells 
compared to control cells (Figure 16b). This observation suggested that 
pharmacological blocking of STAT3 inhibits mbIL21 stimulated proliferation of human 
NK cells. I also evaluated the effect of STAT3 inhibition on the survival of NK cells by 
assessing viability and apoptosis. Viability of cells was evaluated by staining the cells 
with 7-AAD, a cell membrane impermeable fluorescent compound with strong affinity 
for DNA that stains non-viable cells with compromised cell membranes. Apoptotic cells 
were detected by staining the cells with fluorescent tagged Annexin V, a protein that 
binds phosphotidylserine that is exposed on the surface of apoptotic cells (285). Both, 
7-AAD and Annexin V, stainings were measured by flow-cytometry. Percentage of 
viable cells was found to decrease (Figure 16d) and percentage of apoptotic cells was 
found to increase (Figure 16e) in S3I-201 treated NK cells indicating that 
pharmacological inhibition of STAT3 negatively affects survival of mbIL21 activated 
human NK cells. 
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Figure 15. Pharmacological inhibition of STAT3 decreases mbIL21 stimulated 
expansion of human NK cells. Purified NK cells were incubated for an hour with or 
without small molecule STAT3 inhibitor S3I-201 before stimulating them with irradiated 
K562 artificial antigen presenting cells (aAPCs), genetically modified to express 
membrane bound IL-21 (mbIL21), at 1:2 (NK:K562) ratio and 50 U/ml recombinant 
human IL-2. Control cells were treated with the solvent, DMSO. Culture was refreshed 
with new media containing 50 U/ml IL-2 every three to four days. Cells were pre-treated 
with the drug every time media was refreshed. At the end of one week of expansion, 
viable cells were counted by trypan blue exclusion method. Fold expansion of NK cells 
was calculated by dividing the number of viable NK cells at the end of a weeklong 
expansion with the number of viable NK cells at the start of expansion. P value 
indicated is for two-tailed paired Student’s t test. 
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 Figure 16. Pharmacological inhibition of STAT3 decreases proliferation and 
survival of mbIL21 stimulated human NK cells. Significantly higher CFSE 
fluorescence in S3I-201 treated NK cells than in control cells at the end of one 
week of expansion with mbIL21, indicating fewer cell divisions in S3I-201 treated 
NK cells compared to control cells. Lower percentage of viable cells and higher 
percentage of apoptotic cells in S3I-201 treated NK cells at the end of one week 
of expansion with mbIL21, indicating reduced survival. Purified NK cells, stained 
with CFSE, were incubated for an hour with or without small molecule STAT3 inhibitor 
S3I-201, before stimulating them with irradiated K562 artificial antigen presenting cells 
(aAPCs), genetically modified to express membrane bound IL-21 (mbIL21), at 1:2 
(NK:K562) ratio and 50 U/ml recombinant human IL-2. Control cells were treated with 
the solvent, DMSO. Culture was refreshed with new media containing 50 U/ml IL-2 
every three to four days. Cells were pre-treated with the drug every time media was 
refreshed. At the end of one week of expansion mean fluorescence intensity (MFI) of 
CFSE was measured by flow cytometry (a) Representative flow-charts showing live NK 
cells gated on the basis of forward and side scatter and CFSE staining of this gated 
population for control and S3I-201 treated cells (b) CFSE MFI in control and S3I-201 
treated cells (c) At the end of one week of expansion viability and apoptosis of the 
entire population (100%) were assessed by flow-cytometric analysis of 7AAD and 
Annexin V  staining (d) Cells stained negative for both, 7AAD and Annexin V were 
considered viable. Percentage of viable cells at the end of one week expansion is 
shown (e) Cells stained with just Annexin V were considered apoptotic. Percentage of 
apoptotic cells at the end of one week expansion is shown. P values indicated are for 
two-tailed paired Student’s t test. 
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3.3.1.3 STAT3 inhibitor S3I-201 reduces mbIL15-15Rα stimulated expansion of 
human NK cells  
 
 To evaluate whether inhibition of STAT3 has any bearing on the expansion of 
NK cells stimulated with a cytokine, which does not pre-dominantly activate STAT3, I 
assessed the effect of S3I-201 on NK cells expanded with K562s genetically modified 
to present membrane bound IL-15 in complex with its receptor α (mbIL15-15Rα), the 
way IL15 is trans-presented to NK cells physiologically (286). IL-15 is a potent inducer 
of proliferation of mouse and human NK cells (58, 287, 288) and though it activates 
multiple STATs including STAT3 in NK cells (220), its pro-proliferative effect is mainly 
attributed to STAT5 signaling at least in mouse (162). NK cell expansion, measured by 
counting viable NK cells at the end of one week of activation with mbIL15-15Rα, 
showed significant reduction in the expansion of S3I-201 treated NK cells compared to 
control (Figure 17). Thus, pharmacological blocking of STAT3 not only inhibited 
expansion of NK cells stimulated with cytokine such as IL21, which pre- dominantly 
activates STAT3, but also of NK cells stimulated with cytokines such as IL15, which 
pre- dominantly activates STAT other than STAT3. 
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Figure 17. Pharmacological inhibition of STAT3 decreases mbIL15-15Rα 
stimulated expansion of human NK cells. Purified NK cells were incubated for an 
hour with or without small molecule STAT3 inhibitor S3I-201 before stimulating them 
with irradiated K562 artificial antigen presenting cells (aAPCs), genetically modified to 
express membrane bound IL-15 in complex with its receptor α (mbIL15-15Rα), at 1:2 
(NK:K562) ratio and 50 U/ml recombinant human IL-2. Control cells were treated with 
the solvent, DMSO. Culture was refreshed with new media containing 50 U/ml IL-2 
every three to four days. Cells were pre-treated with the drug every time media was 
refreshed. At the end of one week of expansion, viable cells were counted by trypan 
blue exclusion method. Fold expansion of NK cells was calculated by dividing the 
number of viable NK cells at the end of a weeklong expansion with the number of 
viable NK cells at the start of expansion. P value indicated is for two-tailed paired 
Student’s t test. 
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3.3.2 Impaired Expansion of Job Syndrome Patients’ NK Cells 
 
 Availability of NK cells from Job syndrome patients carrying dominant negative 
STAT3 mutations (Table 2) offered me an opportunity to test my hypothesis in a 
physiologically relevant genetic model. I expanded NK cells from Job syndrome 
patients’ PBMCs by stimulating them with membrane bound cytokine presenting K562 
cells. The cells were expanded over a three-week period by carrying forward a portion 
of expanded cells from the previous week. Fold expansion of NK cells from Job 
syndrome patients was found to be lower than NK cells from normal donors. Impaired 
expansion of Job syndrome patients’ NK cells was observed in mbIL21 (Figure 18) as 
well as in mbIL15-15Rα based expansion platforms (Figure 19). The fold expansion at 
the end of first and second week was lower in Job syndrome patients’ NK cells than in 
NK cells from normal donors, but the difference was not statistically significant (Figure 
18a and b for mbIL21 expanded cells and Figure 19a and b for mbIL15-15Rα 
expanded cells). A statistically significant difference in fold expansion was observed at 
the end of third week (Figure 18c for mbIL21 and Figure 19c for mbIL15-15Rα). 
Inferred fold expansion showed a widening difference between Job syndrome patient’s 
NK cells and normal donor’s NK cells over the three-week expansion period (Figure 
18d for mbIL21 and Figure 19d for mbIL15-15Rα). Thus, consistent with the results 
obtained with pharmacological inhibition of STAT3, genetic deficiency of STAT3 also 
impaired expansion of NK cells activated with mbIL21 as well as mbIL15-15Rα. 
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Figure 18. Impaired expansion of Job syndrome patients’ NK cells stimulated 
with mbIL21. The absolute fold expansion at the end of first and second week 
was lower in Job syndrome patients’ NK cells than in NK cells from normal 
donors, but the difference was not statistically significant. A statistically 
significant difference in fold expansion was observed at the end of third week. 
Inferred fold expansion showed a widening difference between Job syndrome 
patient’s NK cells and normal donor’s NK cells over the three week expansion 
period. PBMCs were stimulated with irradiated K562 artificial antigen presenting cells 
(aAPCs), genetically modified to express membrane bound IL-21 (mbIL21), at 1:2 
(PBMC:K562) ratio and 50 U/ml recombinant human IL-2. Culture was refreshed with 
new media containing 50 U/ml IL-2 every three to four days. Beyond one week, a 
portion of the expanded cells was carried forward by recursive stimulation with mbIL21 
and 50 U/ml IL-2. At the end of one week of expansion, viable cells were counted by 
trypan blue exclusion method. Fold expansion of NK cells was calculated by dividing 
the number of NK cells in the PBMCs at the end of weeklong expansion by the number 
of NK cells in the PBMCs at the start of expansion. Number of NK cells in the PBMCs 
were calculated by estimating the percentage of CD3- CD56+ cells by flow-cytometric 
analysis. Inferred fold NK cell expansion was calculated from the resulting cultures as if 
all the cells were carried forward in the expansion. (a) Fold expansion at the end of first 
week (b) Fold expansion at the end of second week (c) Fold expansion at the end of 
third week (d) Inferred fold expansion over the three week expansion period.  
In each graph values for individual donor are shown along with the mean for the group. 
P value indicated is for two-tailed Student’s t test.     
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Figure 19. Impaired expansion of Job syndrome patients’ NK cells stimulated 
with mbIL15-15Rα. The absolute fold expansion at the end of first and second 
week was lower in Job syndrome patients’ NK cells than in NK cells from normal 
donors, but the difference was not statistically significant. A statistically 
significant difference in fold expansion was observed at the end of third week. 
Inferred fold expansion showed a widening difference between Job syndrome 
patient’s NK cells and normal donor’s NK cells over the three week expansion 
period. PBMCs were stimulated with irradiated K562 artificial antigen presenting cells 
(aAPCs), genetically modified to express membrane bound IL-15 in complex with its 
receptor α (mbIL15-15Rα), at 1:2 (PBMC:K562) ratio and 50 U/ml recombinant human 
IL-2. Culture was refreshed with new media containing 50 U/ml IL-2 every three to four 
days. Beyond one week, a portion of the expanded cells was carried forward by 
recursive stimulation with mbIL21 and 50 U/ml IL-2. At the end of one week of 
expansion, viable cells were counted by trypan blue exclusion method. Fold expansion 
of NK cells was calculated by dividing the number of NK cells in the PBMCs at the end 
of weeklong expansion by the number of NK cells in the PBMCs at the start of 
expansion. Number of NK cells in the PBMCs were calculated by estimating the 
percentage of CD3- CD56+ cells by flow-cytometric analysis. Inferred fold NK cell 
expansion was calculated from the resulting cultures as if all the cells were carried 
forward in the expansion. (a) Fold expansion at the end of first week (b) Fold expansion 
at the end of second week (c) Fold expansion at the end of third week (d) Inferred fold 
expansion over the three week expansion period. In each graph values for individual 
donor are shown along with the mean for the group. P value indicated is for two-tailed 
Student’s t test. 
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3.3.3 Lower percentage of NK cells in the peripheral Blood of Job 
Syndrome Patients  
 
 To investigate whether genetic defect in STAT3 has any bearing on the number 
of NK cells in the peripheral blood of Job syndrome patients, I evaluated the 
percentage of NK cells, defined as CD3- CD56+, in the lymphocyte population. NK cells 
comprise around 2-18% of peripheral blood lymphocytes in human (8), which was 
reflected in the range of percentages of NK cells observed in normal donors (Figure 
20c). Even though majority of Job syndrome patients had NK cell percentages within 
the normal range, they were mostly at the lower end of the scale. The difference in the 
percentage of NK cells between normal and Job syndrome donors was statistically 
significant (Figure 20c). 
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Figure 20.  Lower percentage of NK cells in the PBMCs of Job syndrome 
patients. PBMCs isolated from normal and Job syndrome donors were analyzed by 
flow-cytometry. NK cells were identified as CD3-CD56+. Representative flow-chart 
showing percentage of CD3-CD56+ cells is shown for (a) normal and (b) Job syndrome 
donor. (C) Percentage of NK cells in the PBMCs is shown in graphical form.  
In the graph values for individual donor are shown along with the mean for the group. 
P value indicated is for two-tailed Student’s t test. 
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3.4 DISCUSSION  
 
 In this investigation, employing pharmacological blocking of STAT3, I showed 
that inhibition of STAT3 impairs human NK cells expansion stimulated with membrane 
bound cytokines, IL-21 and IL-15. I validated this finding in NK cells from Job syndrome 
patients carrying dominant negative STAT3 mutations. Both, pharmacological and 
genetic evidence underscored the importance of STAT3 in human NK cell expansion. 
 IL-21, a cytokine belonging to common γ chain family, has mitogenic effect on 
lymphocytes (59, 135, 289). IL-21 by itself cannot induce proliferation, but does so as a 
co-stimulator with other cytokines and mitotic factors (59, 135). Activation of JAK-STAT 
signaling pathway is central to the IL-21 mediated signals in immune cells. It activates 
multiple forms of STATs including STAT1, STAT3, STAT5a, and STAT5b. Out of these 
STATs, STAT3 is most strongly activated (135). In mouse T cells and human B cells, 
the mitogenic signals of IL-21 are mediated through activation of STAT1 and STAT3 
(135, 153).     
Like in B and T cells, IL-21 acts as a mitogen in NK cells. In mouse and human 
NK cells, IL-21 promotes proliferation in combination with either IL-2 or IL-15 (80, 290). 
We utilized the mitogenic property of IL-21 signaling to develop a human NK cell 
expansion platform in which cells are stimulated with K562s genetically modified to 
present membrane bound IL-21 (mbIL21) and soluble IL-2 (134). This expansion 
system supported log-phase growth in NK cell numbers over a six week period and 
resulted in significantly greater fold expansion than expansion of NK cells stimulated 
with K562s genetically modified to present membrane bound IL-15 (mbIL15) and 
soluble IL-2 (134). In NK cells, IL-21 activates STAT1, STAT3, STAT4, and STAT5, 
and out of all STATs, activates STAT3 predominantly (80, 92, 171). However, not much 
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is known about the role of individual STATs in IL-21 mediated pro-proliferative signals 
in NK cells. Very few studies have investigated the signaling mechanisms involved in 
IL-21 induced proliferation in NK cells.  
In this study, using small molecule inhibitor S3I-201, I showed that 
pharmacological blocking of STAT3 inhibits proliferation of human NK cells stimulated 
with mbIL21. These results validated an earlier report, which suggested that mbIL21 
induced expansion of human NK cells is mediated through STAT3 activation (202). 
However, the evidence presented in this particular study is not very conclusive due to 
the type of STAT3 inhibitor used. Wang et al. (202) used a small molecule inhibitor JSI-
124 to block STAT3. Even though, JSI-124 is used as a STAT3 specific inhibitor (224, 
225), along with STAT3, it also inhibits activation of JAK2 and JAK3 and thus actually it 
is a JAK-STAT inhibitor (226, 227). JSI-124 also blocks activation of STAT5 (228). As 
IL-21 activates STAT5 in NK cells (80, 92) and STAT5 deficiency is known to impair NK 
cell proliferation and survival (162, 208), the effect of JSI-124 could have been 
mediated through STAT5 inhibition. Compared to JSI-124, S3I-201 is a STAT3 specific 
inhibitor as it preferentially inhibits STAT3 DNA binding activity over that of other 
STATs with a two-fold higher potency (203). Along with proliferation, IL-21 has also 
been shown to support survival of human NK cells (81, 223). However, the signaling 
mechanism involved in the transmission of pro-survival signals was not known. In this 
investigation, along with the inhibition of proliferation, blockage of STAT3 also 
increased apoptosis of NK cells activated with mbIL21 thereby highlighting the critical 
role of activated STAT3 in the pro-proliferative as well as pro-survival signals mediated 
by IL-21. STAT3 is a pro-survival transcription factor as it activates expression of anti-
apoptotic genes such as Bcl-2, Bcl-XL (291), and survivin (282) and down-regulates 
expression of pro-apoptotic genes such as BCL2L11 (Bim) (225). IL-21 has also been 
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shown to promote survival of NK cells through the up-regulation of expression of anti-
apoptotic proteins Bcl-2 and Bcl-XL (223). The evidence presented in the current study 
suggests involvement of STAT3 in IL-21 mediated activation of expression of Bcl-2 and 
Bcl-XL.  
 Pharmacological blocking of STAT3 not only inhibited expansion of NK cells 
stimulated with mbIL21, which pre- dominantly activates STAT3, but also of NK cells 
stimulated with mbIL15-15Rα, which pre- dominantly activates STAT5 and activates 
STAT3 only marginally (292). In vivo IL-15 is trans presented to NK ceIls by accessory 
cells such as dendritic cells, which express IL-15 in complex with the α subunit of its 
receptor on their membranes. The IL15-IL15Rα complex mediates signals in NK cells 
by interacting with β and γ subunits of IL-15 receptor expressed on the NK cell 
membrane (293). IL-15 induced proliferation and survival of NK cells are considered to 
be mediated mainly through the activation of STAT5 (162, 208). Along with STAT5, IL-
15 also activates STAT3, albeit marginally (171). However, evidence presented in the 
current study suggests that STAT3 plays a major role, disproportionate to its activation, 
in IL-15 induced proliferation of NK cells. A recent study also implied involvement of 
STAT3 activation in the proliferation of mouse NK cells stimulated with IL-2 (294), a 
cytokine, which also activates STAT5 pre-dominantly, and STAT3 marginally in NK 
cells (80) and whose proliferative effects were considered to be mediated through 
STAT5 activation (162).  
 Even though, the concentration (25 μM) of the pharmacological inhibitor, S3I-
201, used in the present study was well below its IC50 for STATs other than STAT3, a 
non-specific effect cannot be entirely ruled out due to the sequence similarity between 
SH2 domain of STAT3, the binding target of S3I-201, and SH2 domains of other 
STATs, particularly STAT1 (295). To validate the results obtained using 
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pharmacological inhibitor and to obtain unequivocal evidence in support of the role of 
STAT3 in NK cell expansion, I expanded NK cells from Job syndrome patients’ carrying 
dominant negative STAT3 mutations. Both, mbIL21 and mbIL15-15Rα stimulation 
induced significant expansion of Job syndrome patients’ NK cells, but the expansion 
was significantly impaired compared to NK cell from normal donors. These results were 
consistent with the results obtained with pharmacological inhibition. Thus, both 
pharmacological and genetic evidence signify requirement of STAT3 in NK cell 
expansion.  
 Steady-state number of NK cells in vivo is maintained through homeostatic 
proliferation (263, 264). To evaluate whether impaired expansion of Job syndrome 
patients’ NK cell observed ex vivo has any bearing on NK cells in vivo, I assessed 
percentage of NK cells in the lymphocyte population of the peripheral blood. NK cells 
comprise around 2-18% of peripheral blood lymphocytes in human (8). Even though 
the percentages of NK cells in Job syndrome patients were within the normal range, 
they were at the lower end of the spectrum. The low NK percentage may result from a 
deficiency in either differentiation, proliferation or survival or a combination of these 
processes. Therefore, the low NK percentage cannot be attributed to just impaired 
proliferation unless all the aforementioned processes are studied.  
3.5 CONCLUSION 
 
 In this investigation, using pharmacological and genetic models, I showed that 
inhibition of STAT3 significantly reduces expansion of human NK cells stimulated not 
only with IL-21 that predominantly activates STAT3, but also the expansion stimulated 
with IL-15, which predominantly activates STAT5 and activates STAT3 only marginally. 
Thus, STAT3 signaling is critical for human NK cell expansion ex vivo. In mbIL-21 
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stimulated NK cell expansion, STAT3 signaling is critical for proliferation and survival. 
Even though fold expansion of Job syndrome patients’ NK cells was significantly 
reduced compared to NK cells from normal donors, Job syndrome patients’ NK cells 
expanded considerably in response to cytokine stimulation, suggesting adoptive NK 
immunotherapy potential in Job syndrome patients. This treatment option is promising 
in the light of the finding of low percentage of NK cells in the peripheral blood of Job 
syndrome patients.  
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4.1 FUTURE DIRECTIONS 
 
 In this investigation, I evaluated the role of STAT3 in the functions of human NK 
cells. Findings of this study established role of STAT3 signaling in human NK cell 
cytolytic activity and expansion. However, much work remains to be done to 
understand the role of STAT3 in NK cell biology in its entirety.  
 In this study, to investigate the underlying causes of impaired cytotoxicity of 
STAT3 deficient NK cells, I explored function of STAT3 in NK receptor expression and 
subcellular cytolytic processes, both of which were found to be affected in STAT3 
deficient NK cells. However, other factors that also have bearing on cytolytic function 
were not probed. Conjugate formation between NK and target cells, the very first step 
that sets the stage for the cytolytic encounter and expression of perforin and granzyme, 
the cytolytic molecules that effect the lysis (158), need to be assessed in STAT3 
deficient cells. NK cells also mediate cytolysis through CD16, an Fc receptor, which 
upon binding to the antibody attached to a target cell activates degranulation (8). I did 
not assess antibody dependent cellular cytotoxicity in STAT3 deficient NK cells. Even 
though CD16 expression level, measured in the present study, was unchanged in 
STAT3 deficient cells, effect of STAT3 deficiency on signaling pathways triggered by 
CD16 cannot be ruled out.  
In addition to cytolysis of infected and malignant cells, NK cells also mediate 
their functions through other means. In order to understand role of STAT3 in NK cell 
functions, it is critical to assess all NK cell effector functions in STAT3 deficient cells. 
NK cells are equipped with apoptosis inducing ligand FASL and TRAIL, which play 
important role in immunosurveillance of malignant cells, particularly in liver (296). Along 
with cytolytic capability, NK cells also exert their effect through secretion of cytokines 
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and chemokines in response to stimulation by target cells and cytokines secreted by 
accessory cells (10). NK cell generated cytokines include IFN-γ, TNF-α, granulocyte 
macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor 
(G-CSF), interleukin (IL)-10 and IL-3, while chemokines such as CCL2, CCL3, CCL4, 
CCL5, XCL1, and CXCL8 are also secreted by NK cells (2). Compared to leukocytes 
from normal donors, leukocytes from Job syndrome donors have been reported to 
secrete higher levels of IFN-γ and TNF-α in response to lipopolysaccharide and IL-12 
stimulation, indicating deregulation (130). In NK92 cells, an NK cell line, IL-2 stimulated 
IL-10 secretion requires STAT3 activation (222). As NK cells are the major source of 
cytokines, particularly IFN-γ, it would be of interest to assess cytokine secretion in 
STAT3 deficient NK cells in response to stimulation by cytokines and activating 
receptors. Assessment of expression of FASL, TRAIL, cytokines and chemokines in 
Job syndrome patients’ NK cells will provide important insights into the regulation of NK 
function by STAT3.   
 NK cells from Job syndrome patients are an excellent genetic tool to study the 
role of STAT3 in NK cell function. However, Job syndrome is a rare immunodeficiency 
and hence availability of cells from Job syndrome patients is a major limiting factor. 
This constraint warrants procurement of alternative genetic model that is easily 
accessible. In the present investigation, I used siRNA mediated STAT3 knock-down in 
primary human NK cells to validate the results I obtained with Job syndrome patients’ 
NK cells. But, the former genetic model does not exactly mimic the latter. siRNA 
mediated STAT3 knock-down generates acute STAT3 deficiency, while Job syndrome 
patients’ NK cells have chronic STAT3 deficiency right from their inception. This 
difference may account for the differences observed between the two in the present 
investigation. A genetic model closely mimicking Job syndrome patients’ NK cells 
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would require presence of the dominant negative STAT3 allele in NK cells throughout 
the development process, which entails transfection of dominant negative STAT3 in 
hematopoietic stem cells. Even then, the model will be far from perfect, as the cells 
would still have, unlike Job syndrome patients’ cells, two normal copies of STAT3 gene 
and one copy of dominant negative STAT3. A mouse carrying dominant negative Job 
syndrome STAT3 gene has been generated (297), however, due to the differences 
between mouse and human NK cells, as discussed earlier, not everything learned in 
mouse can be extrapolated to humans. This is especially true in case of role of STAT3 
in NK cells, as STAT3 deficiency in these two species has not generated uniform 
phenotypes. 
 In this investigation, I also studied proliferation of Job syndrome patients’ NK 
cells and human NK cells treated with STAT3 inhibitor, both of which showed impaired 
proliferation. However, the molecular mechanisms involved were not investigated. 
STAT3 is a pro-proliferative and pro-survival transcription factor. Whole genome 
transcriptome analysis and gene transcription analysis by microarray of STAT3 
deficient NK cells will help identify direct and indirect target genes of STAT3 involved in 
human NK cell proliferation and survival. A protein expression analysis by reverse 
phase protein array (RPPA) will further validate these targets at the functional level. 
 Constitutively active STAT3 and over activation of STAT3 are oncogenic. STAT3 
is a therapeutic target in many cancers and various strategies to block STAT3 
activation are under clinical consideration. In the light of the finding of my investigation 
that STAT3 deficiency causes impairment of NK cell cytolytic function, I was interested 
in determining the effect of pharmacological inhibition of STAT3 on NK cell cytolytic 
activity. In vitro cytotoxicity assays showed that treatment with small molecule STAT3 
inhibitor S3I-201 suppresses cytolytic activity of human NK cells. This finding bears 
 162 
 
importance because NK cells are the first line of defense against malignant cells. To 
determine whether impairment of NK cytolytic function is a likely adverse effect of 
STAT3 blocking in cancer treatment, cytotoxicity of NK cells from patients in clinical 
trials receiving STAT3 inhibitors should be assessed. Such an assessment will also 
help determine the compatibility of adoptive NK cell therapy, an emerging 
immunotherapy approach for cancer treatment, with the pharmacological blocking of 
STAT3, should these two treatment options be used in combination.  
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